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ASSESSING, MODIFYING, AND COMBINING DATA FIELDS FROM THE 
VIRGINIA OFFICE OF THE CHIEF MEDICAL EX4MIPTER (OCME) DATASET AND 
THE VIRGINIA DEPARTMENT OF FORENSIC SCIENCE (DFS) DATASETS IN 
ORDER TO COMPARE CONCENTRATIONS OF SELECTED DRUGS 
By Amy Elizabeth Henin 
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Associate Professor and Interim Chair 
Department of Biostatistics 
The Medical Examiner of Virginia (ME) dataset and the Virginia Department of 
Forensic Science Driving Under the Influence of Drugs (DUI) datasets were used to 
determine whether people have the potential to develop tolerances to diphenhydramine, 
cocaine, oxycodone, hydrocodone, methadone, and morphine. These datasets included the 
years 2000-2004 and were used to compare the concentrations of these six drugs between 
people who died from a drug-related cause of death (of the drug of interest) and people 
who were pulled over for driving under the influence. Three drug pattern groups were 
xiv 
created to divide each of the six drug-specific datasets in order to compare concentrations 
between individuals with the drug alone, the drug and ethanol, or a poly pharmacy of drugs 
(multiple drugs). An ANOVA model was used to determine if there was an interaction 
effect between the source dataset (ME or DUI) and the drug pattern groups. For 
diphenhydramine and cocaine, an interaction was statistically significant, but for the other 
drugs, it was not significant. The other four drug-specific datasets showed that the DUI 
and ME were statistically significantly different from each other, and all of those datasets 
except for methadone showed that there was a statistically significant difference between at 
least two drug pattern groups. Showing that all of these datasets showed differences 
between the ME and DUI datasets did not provide sufficieilt evidence to suggest the 
development of tolerances to each of the six drugs. One exception was with methadone 
because there were 14 individuals that had what is defined as a "clinical 'lethal' blood 
concentration". These individuals provide some evidence for the possibility of developing 
tolerances. 
The main outcomes of this study include suggesting changes to make to the ME 
datasets and the DUI datasets with regard to the way data is kept and collected. Several 
problems with the fields of these datasets arose before beginning the analysis and had to be 
corrected. Some of the changes suggested are currently being considered at the Virginia 
Office of the Chief Medical Examiner as they are beginning to restructure their database. 
CHAPTER 1 
Introduction 
1.1 Introduction to Datasets 
The datasets analyzed and presented in this thesis were provided by the Virginia 
Department of Forensic Science (DFS) and the Virginia Office of the Chief Medical 
Exanliner (OCME). The Medical Examiner (ME) dataset came from the OCME and 
included data on all persons from the years 2000-2004 who received a toxicological screen 
as a result of an autopsy throughout the Commonwealth of Virginia. The Driving Under 
the Influence of drugs (DUI) datasets came from the DFS and contained the demographic 
and drug data on all persons suspected of, stopped for, and given a blood test for DUI 
during the years 2000-2004. 
1.2 Initial Questions of Interest 
One of the original goals for this project was to compare concentrations of 
tetrahydrocannabinol (THC) between the ME and DUI datasets and among different drug 
drug patterns groups in the DUI dataset in order to have information available for the 
Virginia General Assembly for crafting legislation dealing with THC and driving. THC is 
the main active ingredient in marijuana, and currently, there are no laws in Virginia that 
address concentration limits for marijuana or THC. The General Assembly of Virginia 
uses information similar to the information in these datasets to create and amend current 
laws regarding drugs and legal limits. 
Other goals for this project were to identify concentrations of THC that impair or 
intoxicate individuals, to see how ethanol combined with THC affects individuals, and to 
look at drug combinations of THC and other identifiable drugs to see if the effects are 
additive. 
1.3 Problems with Initial Questions and the New Questions 
Upon receiving the ME and D-UI datasets, problems were encountered that did not 
allow the investigation of the questions regarding THC. Because THC is not considered 
lethal, there were no cases in the ME dataset that had THC data; therefore, the ME data 
was not helpfil in answering questions regarding THC. 
In the DUI dataset, there was no information about why the individual was stopped 
for DUI, so it was not possible to determine whether certain individuals were more or less 
intoxicated than others. This was problematic when trying to collect information about 
THC for the General Assembly that characterized the degree of intoxication; therefore, the 
current information contained in the DUI dataset was insufficient for assisting legislation 
or in the development of laws regarding concentrations of THC. 
Since .the datasets did not have enough information to answer the questions 
regarding THC, other questions were posed for this project. These questions included 
comparing concentrations between the ME and DUI datasets and comparing concentrations 
between created drug pattern groups for diphenhydramine, cocaine, oxycodone, 
hydrocodone, methadone, and morphine. Answering these questions would be a first step 
in determining if individuals in the DUI dataset had developed tolerances to any of these 
drugs. These questions are answered in the following chapters. 
1.4 Introduction to Subsequent Chapters 
This chapter has described the motivation behind this thesis as well as a brief 
introduction to the datasets and the questions of interest. Chapter 2 gives a description of 
the datasets, the problems encountered with them, and the solutions to these problems. 
The analysis is detailed in Chapter 3 where there is a general introduction, a methods 
section, and results sections for each of the six drugs of interest. Chapter 4 is a summary 
chapter that includes recommendations to the DFS and OCME on how to better collect the 
data for their database and suggestions for future projects using these datasets. Throughout 
this thesis, there will be sections that seem to repeat what has already been stated, but the 
repeated material was deemed necessary for clarity. 
Chapter 2 
Sources of the Datasets and Preparation for Analysis 
2.1 Sources 
2.1.1 Medical Examiner Dataset 
The Medical Examiner (ME) dataset is a subset of the database kept by the Office 
of the Chief Medical Examiner for the Commonwealth of Virginia. This dataset was 
provided, with permission, by Dr. Joseph J. Saady and the Office of the Chief Medical 
Examiner (OCME). The OCME collects data and maintains the ME database for the 
Commonwealth of Virginia. Located in Richmond, Virginia, the OCME is the central 
office for the medical examiner system throughout the Commonwealth. All autopsy 
information from any medical examiner in Virginia is entered into the ME database. 
Currently, there are no laws that mandate the OCME keep and maintain the ME 
database, but annual reports concerning fatalities linked with family violence, children, and 
motor vehicles are required by the Virginia General Assembly. The Virginia General 
Assembly requires that the Chief Medical Examiner (and committee) "provide ongoing 
surveillance of fatal family violence occurrences and promulgate an annual report based on 
4 
accumulated data"'. Information on children's death is also required to be annually 
reported to the Virginia General Assembly by the Chief Medical Examiner [and 
committee12. These reports should include information on "(i) violent and unnatural child 
deaths, (ii) sudden child deaths occurring within the first 18 months of life, and (iii) those 
fatalities for which the cause or manner of death was not determined with reasonable 
medical ~e r t a in t~ , "~ .  The reports concerning deaths of children will be public records, 
provided there is no identifying information2. The annual reports concerning fatalities 
involving family violence and deaths of children are to be supplied to the Governor and the 
General Assembly. All medical examiners must also make monthly reports to the 
Commissioner regarding deaths due to motor vehicle accidents3. The OCME also uses the 
ME database and the information it contains for other research projects in addition to the 
mandatory annual reports. 
The ME dataset that was used for this project included demographic, drug, and 
death information on all persons receiving a toxicological screen as a result of an autopsy, 
in Virginia, during the years 2000-2004. The cases in this dataset were limited to those 
persons who received a toxicological screen during autopsy because the purpose of this 
study is to look at drug concentrations. Persons not receiving toxicological screens would 
not have any drug information in their records. The ME dataset received for this project 
consisted of 2642 individuals and 6026 records. In the original dataset, an individual had a 
record for each of the drugs found during the autopsy. This dataset was reformatted to 
include only one observation per case number, and this record combined all information 
from the multiple observations for each case. The process used to reformat the data is 
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described in Section 2.2. Once the data was reformatted, any person not receiving a 
toxicological screen was removed, and the final ME dataset had 2623 observations - one 
per case number. 
Each record in the ME dataset contained the following information: case number, 
age, gender, fatality (general cause of death), cause of death (detailed description of cause 
of death), manner of death (e.g. suicide, homicide, natural, undetermined), place of injury 
and place of death (regional information), premise of death (location information such as 
home, water, hospital, etc.), drugs found during autopsy, concentrations of those drugs, and 
the tissue where the drug(s) was detected. Some of these variable fields required major 
restructuring for use in analysis, e.g. f a t a l i t y ,  premise o f  d e a t h ,  and c a u s e  
o f  d e a t h .  The reorganization of these fields is described in Section 2.2.1. Other fields 
were used in the analysis in their present condition (with no corrections or restructuring), 
and some fields were corrected and then used only for descriptive purposes. The initial 
dataset was received as a Microsoft Excel @ file and was imported into JMP @ for initial 
inspection of distributions and frequencies of the different fields. Once a general view of 
the dataset was established, the data was imported into SAS @ for preparation and analysis. 
2.1.2 Driving Under the Influence Dataset 
The Driving Under the Influence of drugs (DUI) dataset used for this project 
originally was received in two separate datasets that are both collected and maintained by 
the Virginia Department of Forensic Science (DFS). The first of these datasets contained 
demographic information, and the second contained drug information. These datasets were 
supplied, with permission, by Dr. Joseph J. Saady and the DFS. The data contained in 
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these datasets are typically used to generate frequency reports to the Virginia General 
Assembly to help amend and create laws concerning the legal limits of drugs with respect 
to driving. Previous uses of these datasets have included descriptive reports of 
demographic information (age, race, gender, etc.) and locality reports of people suspected 
of DUI in Virginia, when this information was available. 'This information is used to draw 
conclusions about drivers who are using drugs and the areas where driving while 
intoxicated is a problem. 
At this time, there are no laws concerning the collection or maintenance of these 
two datasets, but statistical reports from the DUI data are used by the Virginia General 
Assembly and sometimes results in laws concerning legal and illegal concentrations of 
drugs while driving. In the Code of Virginia, blood concentrations of the following 
substances have been deemed illegal, "(a) 0.02 milligrams of cocaine per liter of blood, (b) 
0.1 milligrams of methamphetamine per liter of blood, (c) 0.01 milligrams of 
phencyclidine per liter of blood, or (d) 0.1 milligrams of 3,4- 
methylenedioxymethamphetamine per liter of blood,'*. It is also "unlawful to drive or 
operate any motor vehicle, engine or train if a blood alcohol concentration is 0.08 percent 
or more by weight by volume or 0.08 grams or more per 210 liters of breath as indicated 
by a chen~ical test administered,". By collecting the information contained in the DUI 
dataset, the DFS can ascertain more information about other drugs and the concentrations 
that impair drivers throughout the state of Virginia. 
Both the demographic and drug datasets of the DUI data used for this project 
spanned the years 2000-2004. The demographic dataset contained the descriptive 
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information for all persons suspected of, stopped for, and given a blood test for DUI. This 
dataset included case numbers, age, race, gender, location of where the subject was 
detained, and the type of court. The drug dataset contained all drug information, including 
the case numbers, the drugs found in the blood test, the amount of the drug found, and 
whether the drug was detected at a concentration "less than", "greater than", "not 
detected", "quantitated", etc. for the amount that was reported. The drugs detected in the 
blood test were screened in a precise order specified by the tier system that is described in 
Section 2.2.5. The guidelines for the tier system are shown in Appendix A. 
A driver can be stopped for suspicion of DUI more than one time during the four- 
year period encompassed in these datasets. In order to avoid repeating information in the 
datasets (including the same driver more than once), a random sample of case numbers 
were sent to the DFS to look for individuals who might appear in the dataset more than 
once. This potential problem is addressed in Section 2.2.4. By definition, being stopped 
by a police officer for suspicion of DUI does not mean that the driver was convicted of 
DUI. 
The demographic and drug datasets were combined together, based on the case 
numbers, to form one DUI dataset. The DUI demographic dataset originally included 
12,365 individuals, but only 1 1,819 were unique case numbers. This problem is addressed 
in Section 2.2.2. The DUI drug dataset contained 48,907 observations, but in this dataset, 
an identifiable individual could have as many observations as the number of drugs tested 
for during the blood test, whether or not these drugs were detected. The multiple 
observations problem was not addressed until the demographic and drug DUI datasets 
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were combined. When the two datasets were joined together, the pooled dataset contained 
55,148 observations with all demographic and drug information in one dataset. This 
dataset was then reformatted to include only one observation per case number. The 
process used to reformat this dataset is described in detail in Section 2.2. There were 
11,926 individuals in the new dataset, and each individuai's record contained all 
information from the previous multiple observations. This DUI dataset with 11,926 unique 
individuals was then merged with the 2623 unique individuals in the ME dataset for use in 
the analysis of the specific drugs and their concentrations. 
2.2 Problems 
2.2.1 Problems with Free Text Fields 
A field is defined as "a named subdivision of a record containing a specifically- 
defined piece of information within a systemw5. A fiee text field is a field with data 
"containing no formal or predefined structure other than the normal use of grammar and 
punctuation"5. Generally, free text fields should be avoided in the development of 
databases because of the unlimited number of possible responses. "The data typed into the 
computer is often entered in a hurry. The language includes abbreviations, jargon, 
misspelled words, and incorrect grammar,"6. These multiple responses usually need to be 
combined to form general categories for use in analysis. For example, these non-uniform 
responses could include misspellings, different punctuation, dissimilar orderings of words, 
and the use of similar or detailed explanations. Although free text fields are valid and 
sometimes usable, the fiee text fields in this project required major reorganizing to make 
new fields that were functional for analysis. 
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Two of the free text fields in the ME dataset, fatality and premise of 
death, were restructured for use in analysis. This reconstruction consisted of the creation 
of a new field that combined several response levels of the original free text field. An 
example of this alteration was to the field fat a 1 i ty,  which contained information 
regarding a general cause of death. Originally, the field contained 23 levels such as 
"asphyxia: aspirationlcafk coronary", "asphyxia: mechanical/positional", and "asphyxia: 
plastic bag". All three of these levels were joined to form "asphyxia" in the new variable 
field, fa talnew. The field fa tali ty initially consisted of 23 levels that were reduced 
to 14 levels in f atalnew, including the new categories "asphyxia", "CO poisoning", 
"vehicle", and "drug poisoning" and some of the original categories. The new variable 
included the levels "alcohol/drug withdrawal", "asphyxia", "beating/blows/blunt 
instrument", "burnslfire", "carbon monoxide poisoning", "cutting instrument/stab", 
"drowning", "drug poisoning", "explosion", "falVpush", "gun: handgun", "lethal 
injection", "undetermined", and "vehicle". 
A similar alteration was made to premise of death, which contained location 
information regarding the death of an individual. The initial field contained 45 responses 
such as "street: adjacent", "street: alley", street: bridge", "street: ditch", "street: driveway", 
"street: highway", "street: interstate", "street: nonspecified" "street: parking", and "street: 
sidewalk". These 10 levels were combined to form a new category "street" in a new field, 
premisenew. The 45 initial levels of premise of death were reduced to 28 levels 
in premi senew by creating four new categories: "street", "water", "home", and 
"hospital", and keeping some of the original categories from premise of death. The 
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four new categories combined 2 1 of the original levels from pr emi se o f death. An 
example of how SAS 8 was used to decrease the number of levels is seen in the following 
code. 
if fatality = 'ASPHYXIA: ASPIRATION/CAFE CORONARY' I 
fatality = 'ASPHYXIA: MECHANICAL/POSITIONAL' I fatality = 
'ASPHYXIA: PLASTIC BAG' then fatklnew = 'Asphyxia'; 
With regard to grammatical differences, the only field in the ME dataset that 
displayed this problem was cause of death. The original field cause of death 
had 1724 responses for 2642 individuals, and many of these levels were different only 
because of misspelled words, different punctuation, synonyms for the same words, or 
listing the same drugs in a different order. Some examples of misspelled words in the 
cause of death field were "intoxiciation", "intoxicatikon", "poinsoning", 
"poisoining", "herion", and "cintributing". Misspellings were found by visually searching 
through a frequency table of the cause of death field and looking for observations 
that were similar to other observations with the only difference being a misspelling. 
Once these misspelled words were identified, SAS 8 was used to scan the cause 
of death field for the misspelled word, and if it was found, it was replaced with the 
correct spelling. An example of how misspelled words were corrected is seen in the 
following code where the misspelled word "intoxiciation" is replaced with the correct 
spelling "intoxication". Not all misspelled words were corrected because there were too 
many misspellings to detect them all by scrolling through the frequency tables. 
Approximately 100 grammar problems were found and corrected, and 3003 changes were 
made to the cause of death field for the 2642 cases in the ME dataset. 
index = find(cause-of-death, 'INTOXICIATION', ' i t ) ;  
if index ne 0 then temp = substrn(cause~of~death,l,index-1) I  I  
'INTOXICATION' I  I  
substrn(cause~of~death,index+l3,length(cause~of~death) 1 ;  
else temp = cause-of-death; 
cause-of-death = temp; 
Some observations for cause of death were only different in the punctuation. 
These punctuation differences included having double spaces between words, periods at 
the end of some cases, spaces between commas, and using "&", "and" "d/t", "d/t to" or 
"due to" inconsistently. In all of these cases, one example was chosen as the standard 
form, and the others were modified to match the standard form of the punctuation. An 
example of .the grammatical fix is seen in the following SAS 8 code. 
index = find(cause-of-death, 'DUE TO', 'i'); 
if index ne 0 then temp = substrn(cause-of-death,l,index-1) 1 )  
'D/T' I  I  
substrn(cause~of~death,index+6,length(cause~of~death) ) ;  
else temp = cause-of-death; 
cause-of-death = temp; 
index = find(cause-of-death, 'D/T TO', 'it); 
if index ne 0 then temp = substrn(cause~of~death,l,index-1) ( 1  
'D/T' 1 )  
substrn(cause~of~death,index+6,length(cause~of~death) 1 ;  
else temp = cause-of-death; 
cause-of-death = temp; 
Using synonyms for some words also posed a problem in the cause of death 
field. "A synonym is created when two different names are used for the same information 
(attribute). If an attribute resides in more than one entity [record], insure that all entities 
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[records] use the same attribute name,"7. For example, "overdose", "poisoning", 
"toxicity", and "intoxication" all have the sanle meaning in c a u s e  of d e a t h ,  but 
different medical examiners used these words interchangeably in their description for 
c a u s e  of d e a t h .  "Using more than one name for the same attribute causes many 
problems,"7. In this example, all variations of "overdose", "poisoning", "toxicity", and 
"intoxication" were changed to "poisoning" in order to provide consistency within this 
field. 
Yet another problem with this free text field was different orderings of words. The 
field c a u s e  of death contained a detailed description of the cause of death including 
the drugs tha.t were attributable to death and the specific cause such as asphyxia, poisoning, 
lethal injection, drowning, etc. In several instances, a detailed cause of death was the same 
as another with the only difference being the ordering of the drugs. For example, one cause 
of death was "acute ethanol and opiate poisoning", and another cause of death was "acute 
opiate and ethanol poisoning". These two causes of death are the same for purposes of 
analysis, but they appear as two different responses. 
Originally, one of the main variable fields of interest for analysis, c a u s e  of 
d e a t h  contained a large number of non-uniform levels, and only parts of it were 
corrected. "Typographical errors are not trivial matters. A user can have little confidence 
in a database in which many typographical errors o~cur ,"~.  Because there were so many 
errors in c a u s e  of d e a t h ,  it was not the only field used to help choose the individuals 
from the ME dataset to include in analysis. Other fields were used to determine the cases 
where an individual died from an actual drug overdose. These fields included f a t a l n e w  
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and drug l e v e l ,  which was renamed to amount in a process described in Section 
2.2.6. Those cases where the person died of a drug overdose were the ones of interest from 
the ME dataset to include in analysis. The DUI datasets did not have problems with free 
text fields, but they did have problems with demographic information and missing data. 
2.2.2 Problems with Demographic Fields 
A demographic variable (or field) is "a varying characteristic that is a vital or social 
statistic of an individual, sample group, or population, for example, age, sex, 
socioeconomic status, racial origin, edu~ation,"~. The DUI demographic dataset contained 
demographic information on drivers who were stopped by police for suspicion of "driving 
under the.influenceW of drugs and received a blood test. When a suspect is stopped for 
driving under the influence, he or she "may be required to perform field sobriety tests, and 
the police officer usually asks them to blow into a Breathalyzer device to detect alcoh01"'~. 
If the police officer thinks the driver is impaired and the Breathalyzer device shows no 
ethanol or not enough to explain the impairment, then the driver is taken by the police 
officer to a location where a blood sample is ~ollected'~.  
Because demographic information does not change for a particular person, a case 
number in the demographic dataset should appear only one time; however, some case 
numbers were listed multiple times within this dataset. Upon investigation, it was 
discovered that any change in a record was accomplished by appending an updated record 
to the end of the database instead of correcting the existing entry. By appending these 
"new," updated records instead of replacing them, a case number could appear more than 
once in the dataset, one for every time the record was entered. To rectify this problem, the 
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last record added to the database for each case was assumed to have the most current 
information, and any previous records for the same case number were removed from the 
dataset. 
Some of the demographic information in the DUI dataset was identified as being 
invalid due to laws concerning driver's license age. To possess a driver's license 
(including a driving permit) in the United States, a person must be at least fourteen years of 
age. The minimum driving age is usually 16, but this age varies by state1 l .  Farm permits 
or school permits can be issued to drivers under 16 (but not younger than 14) in special 
circumstances in some states12. Using age 14 as the cutoff age for possessing a driver's 
license (or permit), there were some cases where the ages were too young to be legally 
driving, i,e. ages 0, 8, and 13. Eleven case numbers with ages less than 14 were sent to the 
DFS for verification. The ages were determined to be a clerical error, but a correct age 
could not be established. Because the correct age could not be found, the ages for these 
cases were set to missing. The problem of missing demographic information is discussed 
in the next section, but because of the magnitude of this problem, adding the 11 missing 
ages (due to clerical errors) did not pose any major problems for the dataset. These 11 
cases were kept in the dataset (with missing ages) to keep the maximum number of 
observations possible for analysis. 
Problems were also identified with the field race. Race can be determined by 
many methods, including self-report or observation by another party. In the ME dataset, 
race was not recorded, but a racial description was reported in the DUI demographic 
dataset. The race field in the DUI dataset was usually determined by the police officer. 
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"Some jurisdictions may require that the officer check the DMV [Department of Motor 
Vehicles] record, but mostly the officer decides,"13. In this dataset, race is not reported in a 
standard way because it was either self-reported by the individual (from the DMV record) 
or observed by the police officer; therefore, the information in the race field is prone to 
error. 
2.2.3 Problem with Missing Data 
A nearly universal problem with datasets or databases is missing observations, and 
this problem was especially apparent in the DUI datasets. The missing data problem 
appeared when the DUI demographic and drug datasets were combined to form one da.taset 
with all DUI information. The DUI demographic dataset contained case number,  
r a c e ,  g e n d e r ,  a g e ,  c o u r t  type d e s c r i p t i o n ,  and c o u r t  name. The DUI 
drug dataset contained c a s e  number, d r u g ,  amount,  and p r e s e n c e .  The datasets 
were joined by matching the case numbers in each dataset to create one dataset with both 
demographic and drug information. 
Numerous case numbers appeared in the demographic dataset that did not appear in 
the drug dataset and vice versa. When the case numbers were matched, if a case number 
did not appear in the demographic dataset, then there was no demographic information to 
attach to the drug information, producing instances of missing demographic data. This 
missing information posed a problem because roughly half of the number of observations 
had missing values for a g e ;  therefore, age could not be used to accurately characterize 
the DUI dataset. About 100 observations were missing all demographic data. On the other 
hand, if a case number appeared in the demographic dataset and not in the drug dataset, 
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then there was no corresponding drug information for that case number when the two 
datasets were combined. Approximately 6000 of the 1 1,926 cases had missing drug data, 
which created a smaller pool of observations to select individuals for the analyses. 
Because of the high percentage of missing demographic information for a g e ,  the 11 ages 
that were set to missing (mentioned in the previous section) did not notably increase the 
amount of missing demographic data. 
The ME dataset had some missing data, but a far lower percentage of the 
information was missing in this dataset. For example, g e n d e r  had only one missing 
observation. There was not much missing data in the ME dataset, and consequently, it was 
not considered problematic for .the analysis. 
2.2.4 Problem with Independence Assumption 
"Independence of observations refers to the notion that the value of one datum is 
unrelated to any other datum. In other words, knowing the value of one observation gives 
you no information about the value of any ~ ther , " '~ .  Having an individual appear in the 
dataset more than once would violate the assumption of independence and cause problems 
in the analysis of the datasets. If any individual had been stopped for suspicion of driving 
under the influence more than once, then he or she appeared in th.e dataset under two 
different case numbers. Because an individual could be stopped for suspicion of DUI more 
than once over the course of four years and thus, appear in the dataset more than once, a 
random sample of 10% (1 192) of the case numbers from the combined DUI dataset was 
sent to the DFS to cross-reference the case numbers with last names, looking for people 
who had been stopped more than once. The purpose for doing this cross-reference was to 
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estimate the number of individuals with multiple traffic stops and the impact (if any) on the 
independence assumption. 
The results of this cross-reference test were inconclusive. The dataset "does not 
capture the proper data to ensure the query would produce good  result^"'^. Because a 
unique identifier, such as social security number, was not collected in this dataset, the 
search could only be by name, gender, race, and date of birth". Birthdates and names are 
not unique identifiers (neither are race are gender), so that combination is reliable to 
determine if people appear in the DUI dataset more than once. No combination of those 
four variables would guarantee unique individuals. From the list of case numbers provided 
to the DFS, "the names do not match between submission 1 and 2, submission 1 might 
have J. Smith with DOB of 6/12/1956 and Submission 2 might have John Smith without at 
DOB, so there is no reliable way to get this data [meaning the reoccurrence of an 
individual in the data set^"'^. 
2.2.5 Problem with Data Completeness (Underestimation) 
Drugs listed in the DUI drug dataset were found using a tier system designed by 
Dr. Joseph J. Saady and the DFS (Appendix A). Because the DFS adopted this tier system 
to rapidly respond to DUI requests and maintain quality and validity within the program 
and to save time and money for the Commonwealth, some of the drug information in the 
DUI dataset is underestimated. Underestimation is "an estimation that is too low"I6 or "an 
estimate that is less than the true or actual ~alue," '~ .  
The tier system was designed so that once a drug, or group of drugs, was found at a 
concentration high enough for probable conviction of DUI, no other testing was done to 
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detect other drugs. The first drug tested was always ethanol, and if ethanol was found at 
the cutoff concentration (0.09 %), then the blood was not tested for the presence of other 
substances. Thus, there was a potential for all drugs other than ethanol to be 
underestimated. If the concentration of ethanol was not sent or high enough for probable 
conviction, then tests were done for a second group of drugs (Level I1 drugs). Level I1 
drugs include, but are not limited to, Amphetamines, Barbiturates, Cannabinoids, 
Benzodiazepines, and Opiates. If no Level I1 drugs are found at a concentration high 
enough for probable conviction, then the blood is tested for Level I11 substances, such as 
Antihistimines, Antidepressants/Antipsychotics, hypnotics, muscle relaxants, and 
ketamine. If no Level I11 drugs are found at an illegal concentration, the blood is no longer 
tested and .the drug information is likely not sufficient evidence for conviction. 
This tier system presents an underestimation problem for the DUI dataset because 
the number of drugs found is clearly less than the "true or actual"16 number of drugs that 
were present in an individual at the time of the traffic stop. Underestimation is not a 
problem for ethanol because all blood samples were tested for ethanol. Using the tier 
system's testing protocol causes Level I1 and Level I11 drugs to be underestimated, but due 
to the design of the tier system, Level I11 drugs will be more severely underestimated than 
the Level I1 drugs. 
By using the tier system, the effect of underestimation on the DUI dataset results in 
several problems. First, the number of drugs that were found in the DUI dataset and the 
number of individuals using these drugs are both measures that are underestimated. The 
concentration levels are possibly underestimated as well in this dataset because while the 
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range of concentrations could span the entire range of drugs possibly found in blood, it is 
more likely that if more drugs were detected in more cases then the ranges of the drugs 
would expand. 
A second problem with underestimation occurs with ,the reported concentration. 
When detecting a drug, the tier system's testing protocol (Appendix A) specifies lower and 
higher reporting limits for each drug (or group of drugs). The guidelines for the testing 
protocol instruct the laboratory to stop testing for a drug if the upper limit is reached. If 
the lower reporting limit for a drug is detected, then the lower reporting limit amount is 
recorded in .the amount field. "Less than" is recorded in the p r e s e n c e  field to report 
that the drug was detected below the lower reporting limit for that drug. On the other 
hand, if an upper limit for a drug is reached, then the upper limit amount is recorded in 
amount.  "Greater than" is recorded in p r e s e n c e .  When either of these situations takes 
places, an adjustment had to be made to the concentration amount to accurately reflect the 
amount of drug in a person's system. For concentrations that have a "less than" value for 
p r e s e n c e ,  the concentration is considered to be one half of the concentration reported, 
and for concentrations with a "greater than" value for p r e s e n c e ,  15% of the amount 
reported is added to the concentration. This rule was determined by Dr. Saady in order to 
use the most accurate concentrations. The details of this adjustment are discussed in the 
last paragraph of Section 2.2.6. 
2.2.6 Problem with Converting Character Fields to Numeric Fields 
The ME dataset was joined with the DUI datasets by concatenating the two 
datasets. "Concatenating is combining two or more data sets one after the other into a 
single data set. The number of observations in the new data set is the sum of the number 
of observations in the original data sets, and the order is all the observations from the first 
data set followed by all observations from the second data set and so on,"'7. Problems 
with concatenating datasets occur when some fields appear in one dataset but not in the 
others and when some fields have different characteristics, attributes, or formats in the 
datasets. In order to concatenate the datasets, it must be determined what information 
should be assembled and collected from each of the source datasets to have in the final 
combined dataset. After determining what information to keep from each dataset, a format 
needs to be determined for the final dataset. Since all datasets being concatenated must fit 
into the chosen final format, any number of the fields from these datasets needs to be 
modified, including field names, types, and contents. Any extra information from either 
dataset is removed before concatenating the two sets. 
In the ME dataset, the original variable field drug level contained a 
concentration amount and the units of measurement for each drug found. Thus, drug 
level was a character field. A character field can contain any series of letters, numbers, 
and special characters1*. The corresponding variable field amount in the combined DUI 
dataset was a numeric field, "containing only numbers, including numbers in E-notation, 
and sometimes a decimal point or minus sign,"'* because it contained only the 
concentration amount with no associated unit of measurement. Because amount (from 
the DUI dataset) was a numeric field and drug level (from the ME dataset) was a 
character field, drug level was converted to a numeric field in order to combine the 
two datasets. This conversion created the character to numeric problem discussed next. 
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To facilitate the conversion from character to numeric, new fields were created to 
contain the numeric part "concentration" of drug level and the character part "units of 
measurement" of drug level from the ME dataset. The concentration field of drug 
level (from the ME dataset) was named amount to match the name of the field in the 
DUI dataset, and unit was the field created for the unit of measurement. 
Some of the case numbers in the ME dataset did not have a unit of measurement 
associated with the concentration, so a standard unit was fixed to each concentration. This 
standard unit of measurement was determined by the specific drug and the tissue where the 
drug was detected. Table 1 shows the tissues and the corresponding units of measurement. 
Certain cases in the ME dataset did not have a specific concentration and contained only 
"present" for drug level. These cases were not used in analysis for that drug because 
an exact concentration amount could not be determined. 
Table 1: Tissues and the Corresponding Unit of Measurement 
Drug 
Ethanol 
All (except ethanol) 
All (except ethanol) 
All (except ethanol) 
All (except ethanol) 
All (except ethanol) 
All (except ethanol) 
All (except ethanol) 
Tissue 
All 
Bile 
Blood 
Brain 
Gastric 
Liver 
Urine 
Vitreous 
Unit of Measurement 
Grams % (gI1 OOmL) 
mgkg 
mg/L 
mgk2 
mg/L 
mg/kg 
mg/L 
mg/L 
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In the DUI dataset, amount was kept as numeric, and an additional field was 
created for the unit of measurement. In a blood test, the unit of measurement for all drugs 
is "rng/L" with the exception of ethanol, which is measured in "grams percent"'g. This 
standard unit of measurement was added to the created field unit for all observations in 
the DUI dataset. 
Another field in the DUI dataset was presence, and this field characterized 
amount as "less than" or "greater than" the concentration reported, as "quantitated" at 
that concentration, or "not detected". If presence was labeled as "less than", the 
amount was estimated to be one half of the value reported, which was usually the lower 
limit of detection. If presence was labeled as "greater than", then amount was 
calculated to be 15% higher than the reported concentration, which was usually the upper 
limit of detection. If presence was "not detected", then those cases were not used for 
the analysis of the particular drug. "Quantitated" values for presence were used as the 
values were reported. The field presence was only found in the DUI dataset. For the 
ME dataset, presence was always set to missing, and amount was assumed to be 
"quantitated." 
2.3 Creation of New Fields (Compatibility for Concatenating) 
Many new fields were created to use during analysis. These fields were created by 
grouping levels of the original variable fields, splitting existing fields into separate fields, 
or using information from one variable field in order to create multiple fields to divide the 
information into a more usable format. 
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The ME dataset was originally designed so that a case number could appear more 
than once in the dataset, with the maximum number of observations per case number equal 
to the number of drugs found during an autopsy. The original DUI drug dataset was 
designed in the same manner as the ME dataset, with the possibility of more than one 
observation per case number, and the maximum observations per case number equal to the 
number of drugs tested in the blood sample. When the two DUI datasets were merged 
together, the demographic information for a case number was replicated for the number of 
observations for that case in the DUI drug dataset. Both the ME and the combined DUI 
datasets had the possibility for multiple observations per case. For analysis, it was needed 
to combine the multiple observations for each case into a single observation that contained 
all of the pertinent information for each individual from the many observations. 
Converting these datasets from multiple observations per case number into a 
dataset that had only one observation per case nuniber involved the creation of 695 new 
variable fields to create a field for each of the 139 drugs, their concentrations, their 
presences, and their unit of measurement. Five arrays, each consisting of 139 fields (one 
for each of the 139 drugs found in either dataset), were created to sift through the multiple 
observations to combine all of the information into one observation for each case number. 
The first array, names, contained the names of all 139 drugs and was used to compare to 
the field d r u g  to check whether or not a drug was listed (found) for a particular case 
number. The next array, d r u g s ,  contained 139 fields which either contained a "1" if the 
drug was listed for a case number or "." if the drug was not listed. The array amounts  
contained a numeric value for the concentration level, and levels contained a unit of 
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measurement for each drug found. Each of these two arrays, amoun t s  and l e v e l s ,  
contained 139 fields to match each of the 139 drugs. The last array, p r e s s ,  contained the 
information from the DUI field presence. Since p r e s e n c e  was not in the ME dataset, 
when the two datasets were combined, press was set to missing for any observation that 
came from the ME dataset. The field names in all of the arrays (except d r u g s )  were 
distinguished by the name of the drug followed by an underscore and then a letter that 
differentiated the variable fields between each array. The field names in d r u g s  did not 
have an underscore or letter; they were merely the drugs themselves. For example, the 
fields in drugs include names like "acetaminophen," "ethanol," and "gamma- 
hydroxybutyrate." In the other arrays, the fields included names such as 
"acetaminophen-n" for names,  "acetaminophen - c" for amounts ,  "acetaminophenq" 
for p r e s s ,  and "acetaminophen_l" for levels. The SAS 0 code that illustrates this 
process follows the next paragraph. 
SAS @ was then used to create a single observation from the multiple observations 
by using a loop that retained the case number. If the subsequent observation and the 
previous observation had the same case number then the information for those records 
were combined. The arrays mentioned previously allowed for the new record (a single 
entry per case number) to contain information about whether a drug was tested (drugs) ,  
the concentration (amounts) ,  the unit of measurement ( 1  eve 1 s), and the presence 
( p r e s s )  for each drug. The following SAS 0 code shows how the DUI dataset was 
transformed from a dataset with multiple observations per case number to a dataset with 
only one observation per case number. The SAS 0 code for the ME dataset differs slightly 
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due to the different variable fields in the dataset. The full SAS 09 code can be seen in 
Appendix D. 
if first.case-number then do; 
do i = 1 to 139 by 1; 
drugsIi1 = .; 
amounts{i} = .; 
levels{i) = "; 
press{i} = ' I ;  
number-of-drugs = 0; 
end; 
end ; 
do i =1 to 139 by 1; 
if drug=upcase(names{i)) then do; 
drugs{i}=l; 
amounts{i}=amount; 
levels{i} = unit; 
press{i} = presence; 
number-of-drugs = number-of-drugs+l; 
end ; 
end; 
if 1ast.case-number then output; 
Other fields were also created for this project. As mentioned earlier, the variable 
fields f atalnew and premisenew were both created in the ME dataset to correct the 
original fatality and premise of death fields. The field fa talnew was created 
to assist in subsetting the data into separate drug datasets for analysis. Premi senew was 
created to have location information for the cause of death that could be used in the 
analysis. The two datasets (ME and DUI) contained some of the same information in 
fields with different names, so new fields were created to aid in combining the two 
datasets. For example, in the ME dataset, the information regarding a person's gender was 
in a field called sex, and in the DUI dataset the field was called gender. A new field 
27 
g e n d e r  was created in the ME dataset and set equal to the values from sex. The field 
sex was then dropped from the ME dataset. 
As mentioned in Section 2.2.6, d r u g  level (ME dataset) was separated into two 
separate fields. The numeric piece of information (the part containing the concentration) 
became amount ,  which was the same in the DUI dataset. The field u n i t  was created for 
both datasets, but the values for each dataset were different. The details creating the field 
u n i t  for each of the datasets was discussed in Section 2.2.6 with the problem of 
converting character fields to numeric fields. Another variable field, d a t a b a s e ,  was 
created in each of the datasets (ME and DUI). The database field contained character 
information regarding the original dataset affiliation and was used as an identifier of the 
source dataset after the ME and DUI datasets were combined. 
2.4 Final Numbers 
2.4.1 ME Dataset 
The ME dataset initially contained 6026 records, 2642 unique case numbers, and 
15 variable fields in a Microsoft Excel @ file. These fields contained information on age, 
race, gender, fatality, cause of death, premise of death, place of injury and place of death, 
drugs detected during an autopsy, drug concentration, and tissue where the drug was 
detected. After encountering numerous problems with the fields in the ME dataset, some 
of the fields were corrected for use in analysis. 
The fields, f a  t a l i  t y  and p r e m i s e  o f  d e a t h ,  were restructured by 
combining multiple levels of the original free text fields. Creating new fields, such as 
f a t a l n e w  and p r e m i  senew combined many of the original levels (responses) into a 
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smaller number of levels in each of the two fields. Examples of combining the levels were 
discussed in Section 2.2.1 as well as other free text problems. 
The new field f atalnew was used as a filter for the ME dataset to remove those 
persons who did not die from "drug poisoning". The purpose of premi senew was for 
descriptive information on the location for the cause of death. 
Other free text problems encountered in the cause of death field consisted of 
many types of grammatical errors including misspelled words, different punctuation, 
different orderings of words, and synonyms for specific words. Once these grammatical 
problems were addressed, cause of death was used as another filter to create the 
specific drug datasets for use in analysis. Approximately 100 grammatical errors were 
corrected in the cause of death field. Section 2.2.1 described the details of the free 
text problems encountered and the respective fixes to these problems. 
Some new fields were created in order to match variable field names between the 
two datasets because some fields were designed as character fields for one dataset and as 
numeric for another dataset. This problem was addressed in Section 2.2.6. An additional 
695 fields were created to keep track of the 139 listed drugs and their information 
including names, whether a drug was detected during an autopsy, the concentrations of the 
drugs, units of measurement, and information regarding the "presence" of the drugs 
(Section 2.3). The 139 "presence" variable fields were created to use the information 
regarding lower and upper recording limits from the tier system from the DUI dataset. The 
array consisting of the 139 names of drugs was only used to compare the listed drug with 
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the drug field in each of the two datasets to see whether it was detected in an individual. 
Once the comparison was made, these 139 fields were deleted from the filial dataset. 
Some specific names of drugs in the ME dataset were renamed to match the names 
of the same drug in the DUI dataset. An example of this correction was 
"methylenedioxyamphetamine" which was changed to "mda". Not all of these drugs were 
used for analysis, but they were changed in the dataset for possible future use. Nineteen 
records in the ME dataset were removed from the dataset because the cases did not receive 
a toxicological screen as a result of an autopsy. 
After all of these corrections and amendments were made, the final ME dataset 
consisted of 2623 records, 2623 unique individuals, and 577 variables. 
2.4.2 DUI Dataset 
The DUI dataset originally consisted of two datasets - one with demographic data 
and one with drug data. The DUI demographic dataset contained 12,365 records, but the 
records were not 12,365 unique individuals. In the demographic dataset, 11,819 case 
numbers were distinctive. Information in the DUI demographic dataset included case 
number, age, gender, race, court type, and court name (location of jurisdiction). The DUI 
drug dataset consisted of 48,907 records, and in this dataset, a case could have multiple 
observations up to the number of drugs tested for in the blood sample. The variable fields 
in the drug dataset included case number, drugs detected during blood test, concentration 
of drug, and presence of the drug. 
The 1 1,8 19 unique case numbers from the DUI demographic dataset were matched 
with the case numbers in the DUI drug dataset to combine the two datasets into one dataset 
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with all possible information. Some of the case numbers appeared in one or ,the other of 
the two datasets (demographic and drug), but not in both. When this happened, sections of 
data in the combined dataset were missing. A section of case numbers had drug 
information with no demographic information and vice versa. This resulted in a problem 
with missing data (Section 2.2.3). Having missing drug data was more common than 
having missing demographic data, but both situations occurred when the two datasets were 
combined. Once the two DUI datasets were combined into one dataset, the resulting 
dataset had 55,148 records. 
Other problems needed to be addressed in order to combine the collective DUI 
dataset with the ME dataset. These problems included creating new variable fields (both 
datasets) (Section 2.3 and 2.4.1), addressing problems with underestimation and 
independence (DUI only) (Sections 2.2.5 and 2.2.4), and converting character fields to 
numeric fields (ME only) (Section 2.2.6). After these problems were addressed and 
amendments were made, the DUI dataset needed to be reformatted to include only one 
observation per person. (When the demographic and drug datasets were combined, the 
drug dataset contained multiple observations per case, and the demographic information 
was duplicated to match the nuniber of observations in the drug dataset for each record.) 
By reformatting the DUI dataset, each case number appeared only one time, and each of 
these records contained all the data for each drug tested and detected. This final dataset 
had 1 1,926 records and 577 variable fields. Close to half of the records (-6000) had 
missing drug information, and about other 100 records had completely missing 
demographic information. 
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2.4.3 Combined Dataset 
With both the DUI and ME datasets in formats compatible with each other, the two 
datasets could be joined together for ease of analysis. The joint dataset that included all 
2623 ME records and 11,926 DUI records, and had 14,549 records total. This dataset 
included all individuals from the source datasets, including some individuals from the ME 
dataset who did not die from "drug poisoning". Using the variable field fa talnew as a 
filter, 70 persons having a cause of death other than "drug poisoning" were 
eliminated from the dataset. The final dataset consisted of 14,479 total records and 577 
variable fields from either the DUI or the ME dataset. These records compose the base 
dataset from which all of the smaller .drug datasets were generated. 
CHAPTER 3 
Analysis of the Drug-Specific Datasets 
3.0 The Analysis of the Combined Dataset 
This chapter begins with an introduction of the combined dataset used for the 
analyses and the process that was used to select the smaller, drug-specific datasets. A short 
description of the combined dataset, including the number of observations from each of the 
contributing datasets (ME and DUI), and the variable fields in the final dataset are 
presented in Section 3.1. The remainder of this section (Section 3.1) describes how the six 
datasets (one for each drug of interest) were created. The methods section (Section 3.2) 
details the process used to break down each of the six datasets into categories to compare 
the concentrations of the drug between the two source datasets (ME and DUI) and between 
each of the three drug pattern groups. After specifying the process used to divide each 
dataset into the drug pattern groups, Section 3.2 describes the statistical methods that were 
used for each of the six datasets. Section 3.3 contains the results of the analyses of the six 
drug-specific datasets. This section is composed of six parts - one for each of the drug- 
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specific dataset. Section 3.4 summarizes the results from all six analyses and gives general 
conclusions of all analyses. 
3.1 Introduction 
The original ME and DUI datasets were combined into a final dataset that was 
subsequently divided into six smaller datasets (one for each drug of interest). The final 
dataset contained 14,479 individuals and 577 variable fields. (There were a couple of 
additional fields added to the drug datasets for transformation purposes and combining of 
the drug pattern groups.) The variable fields in the final dataset included case number, 
a g e , r a c e  d e s c r i p t i o n , c o u r t  n a m e , c o u r t  type d e s c r i p t i o n ,  
c u r r e n t  d a t e , c a u s e  o f  d e a t h , m a n n e r  o f  death,date o f  i n j u r y ,  
date o f  d e a t h , p l a c e  o f  i n j u r y , p l a c e  o f  d e a t h , f a t a l n e w ,  
pr emi s enew, g e n d e r ,  d a t a b a s e ,  c o u n  t(used to determine how many corrections 
were made to the c a u s e  o f  d e a t h  field), bac (listed the tissue where the drug was 
detected), 139 variable fields that indicate the name of the drug, 139 fields that give the 
concentrations of each of the drugs, 139 fields with the unit of measurement, 139 fields that 
give information on presence of the drug, number o f  drugs (a counter field that 
specifies the number of drugs that were detected in someone's system), i n d e x  f a t a l  
(denoting whether or not the c a u s e  o f  d e a t h  field was attributable to a drug 
poisoning), and g r o u p  (indicates whether the individual had the only the drug of interest, 
the drug and ethanol, or the drug and any other combination of drugs). The variable field 
g r o u p  is discussed in more detail in Section 3.2. (A table with all of these variable fields 
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and a description is seen in Appendix E.) Out of the 14,479 cases in the final dataset, 2553 
came from the ME dataset and 1 1,926 came from the DUI datasets. 
As mentioned in Chapter 1, there were six drugs of interest for this project. These 
drugs were diphenhydramine, cocaine, oxycodone, hydrocodone, methadone, and 
morphine. A separate dataset was created for each of the six drugs; each dataset was a 
subset of the final combined dataset where the subset contained all persons with the drug 
of interest. These six datasets were used to assess differences in concentrations of the drug 
of interest between the ME and DUI datasets and between the three drug pattern groups. 
Initially, the ME dataset contained cases that included other tissues such as liver, brain, 
urine, etc. These tissues were sampled when a blood sample was not available2'. Because 
of differences in the unit of measurements between various tissue sources, only those 
samples taken in blood were used to compare concentrations since all individuals in the 
DUI dataset received blood tests. (Because blood was the oly tissue sampled for in the 
DUI dataset, any individual from the DUI dataset who tested positive for the drug of 
interest was included in the respective drug dataset.) 
3.2 Methods 
Each dataset was created by excluding individuals from the final combined dataset 
that did not have a positive screen for the specific drug for the analysis. First, individuals 
who did not receive a toxicological screen as a result of an autopsy were excluded from the 
ME dataset prior to combining the ME and DUI datasets. For the ME dataset, a second 
inclusion criterion was that individuals must have died from a drug-related death due to the 
drug of interest (f atalnew must have "drug poisoning" as the factor). Third, individuals 
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who did not have the specific drug of interest in their system were excluded (i.e., the 
concentration was zero, missing, or "not detected"). Finally, some individuals were 
excluded based on clinical judgment. "It was a clinical decision. If a particular drug level 
was too low, it was determined to be an incidental finding and not a cause of death, and the 
case was excluder2'. This clinical decision was only for cases in the ME dataset. A 
detailed flow chart of the filtering system used to create the six smaller datasets is seen in 
Appendix B. 
Following the creation of the six drug-specific datasets, the cases were divided into 
three drug pattern groups; the groupings were determined using clinical criteria. "The 
groups were chosen based on practicality. We definitely wanted to have the drug alone 
because it is informative and previous studies have been done with the drug alone. Ethanol 
is the most abused drug and there are many circumstances of ethanol and a drug. Because 
ethanol is so prevalent, that was the reason for the second group. The "poly pharmacy" 
drug pattern group was chosen because there was no other option Using this 
criteria, a new field, g roup ,  was created to distinguish between the different drug pattern 
groups. The first category in g r o u p  consisted of those individuals who had only the drug 
of interest detected in their system. In the DUI dataset, all individuals were initially tested 
for ethanol, so for an individual from the DUI dataset to be in Group 1, the concentration 
for ethanol (and all other drugs) had to be "0 mg/L" or "missing" in the blood sample. 
(Section 2.2.5 details the tier system and the process for which drugs were screened in the 
DUI dataset). Group 2 contained individuals who had both the specific drug and ethanol in 
their system. Finally, Group 3 contained any other combination with the drug of interest 
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and thus, was considered a poly pharmacy group. All three of the created drug pattern 
groups were mutually exclusive, i.e., if an individual was in one of these drug pattern 
groups, then the same individual could not be in another drug pattern group (within the 
same drug dataset). It is important to note the possibility that individuals may appear in 
multiple drug-specific subgroups because of the nature of the poly pharmacy group (Group 
The analysis of the data began with a normal quantile plot constructed for each drug 
pattern group and each source dataset to assess if the blood concentration data followed an 
approximately normal distribution. Because the blood concentration data is bounded at 
zero and because of the likelihood of unusually high concentrations (especially in the ME 
dataset), it was anticipated that the blood concentration data would be positively skewed. 
If the blood concentrations were skewed positively then the drug concentration data were 
log-transformed in an attempt to transform the data to be approximately normal. The 
means of the log concentrations of all drugs for each of the drug pattern groups were 
calculated with the equivalent untransformed concentration amount. The log-transformed 
data was reported in "log (mg/L)" units, and the untransformed data was reported in 
"mg/L" units. For ease in interpretation of the concentrations, the untransformed (original 
metric) data in lieu of the log-transformed data is given whenever an amount is reported. 
Using a statistical "rule of thumb," the minimum number needed to calculate a 
confidence interval, is 12. "The width of a confidence interval, involving estimation of 
variability and sample size, decreases rapidly until 12 observations are reached and then 
decreases less rapidly"22. In certain cases, samples sizes as small as 11 were accepted 
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based upon clinical judgment. Otherwise, if a drug pattern group had less than 12, an 
adjustment had to be made to the drug pattern groups. The options for adjustments were to 
combine the drug pattern group with a different drug pattern group or to omit that category 
from the analysis of that drug, so the number of drug pattern groups was either three (the 
number created) or two (if two drug pattern groups were combined or one was left out of 
the analysis). 
A quantile box plot is a plot that summarizes the distribution of points for a specific 
factor level. The two ends of the box display the 25th and 75th quartiles. The space 
between these two ends is known as the interquartile range, and the line that crosses the 
middle of the box is the median (or 5oth percentile). Each box has lines that extend from 
each end of the box, called whiskers, that mark the furthest points in either direction23. 
Quantile box plots of the concentrations were produced for each of the drug pattern groups 
and each source dataset for both the log-transformed and untransfonned data. The box 
plots were used to visually inspect for overlaps between the source datasets, within each 
drug pattern group. The box plots seen in the following sections show the concentrations 
before and after the log transformation. Each pair of box plots (transformed and 
untransfonned) is displayed on the same scale, and some of the box plots show expanded 
versions for the DUI dataset. When the DUI datasets were put on the same scale as the ME 
datasets, the plots of the DUI data appeared condensed, and thus, it is frequently difficult to 
see the details of the plots. 
A two-factor analysis of variance (ANOVA) model was fit to each of the six 
datasets in order to detect statistical differences between the mean blood concentration for 
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the two source datasets (ME and DUI) and for the three drug pattern groups. For this 
model, the dependent variable field (y) is always the log blood concentration of the drug of 
interest (due to the non normality of the untransformed concentrations) and the independent 
fields are database (P) and group (a). An additional term was also added to allow for 
an interaction (a p) between database and group. The two-factor ANOVA model is 
given, 
Yiik =~u+ai +Pi +(aP),j +gii, 
where y;k is the log of the drug concentration from the ith drug pattern group (i = 1,2, 3), 
the jth source dataset (j = 1,2), and the kth observation. The grand mean of the log 
concentrations is p, ai is the effect due to the ith drug pattern group (1 = drug only, 2 = drug 
and ethanol, 3 = drug with any other drug combination), P, is the effect due to the jth source 
dataset (1 = ME, 2 = DUI), is the interaction effect between the ith level of a and the 
jth level of p, and is the random error associated with y;,k. The assumptions for the two- 
factor ANOVA model are that the errors (Cijk) are independent and identifcally distributed 
with a normal distribution ( E ~ , ~  - N(0,02)). 
When fitting the two-factor ANOVA, an interaction term was considered significant 
at a = 0.10, and thus, it was retained in the model; otherwise, the interaction was removed 
from the model, and the model was rerun. The alpha was set at 0.10 for testing the 
interaction in order to mitigate the possibility of inappropriately removing the interaction 
term (a Type I1 error). In this case that the interaction term was removed from the model, 
the comparison of the two source datasets and the comparison of the three drug pattern 
groups is a straight-forward test of the main effects. A Tukeyys multiple comparison 
39 
procedure was used to assess the nature of differences between the three levels of the drug 
pattern groups while controlling the overall alpha level. 
If the p-value associated with the interaction was less than 0.10, then the 
comparison of the source datasets and the drug pattern groups were made within the 
interaction term. In other words, because of the presence of the interaction, the comparison 
of the source datasets must be made within each of the drug pattern groups. Similarly, the 
comparison of the drug pattern groups must be made within each of the source datasets. 
Again, a Tukey's multiple comparison procedure was used to determine individual 
differences while controlling the overall alpha level. Tukey's multiple comparison 
procedure makes all possible pairwise comparisons to detect any differences. The results 
of the ANOVA models and the Tukey tests are discussed in each of the sections respective 
to the drug of interest. 
Residual by predicted plots and normal quantile plots of the residuals for all six 
drug datasets are seen in Appendix C. The residual by predicted plots are inspected to see 
if the residuals are randomly scattered above and below the horizontal line at zero and that 
there is not systematic pattern to the residuals; this is a check of the common variance 
assumption and of the model adequacy. The normal quantile plots of the residuals are used 
to verify the normality assumption of the residuals for the ANOVA model. 
3.3 Results 
The results section is divided into six subsections - one for each of the drug- 
specific datasets. Each section contains a short description of the dataset, a table with the 
number of observations per drug pattern group and per source dataset, and a table of 
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demographic information for each drug pattern group divided by dataset (ME and DUI). 
The normal quantile plots before and after the log transformations for each drug pattern 
group and source dataset are displayed as well as the pairs of box plots; these box plots 
show the effect of using the log-transformed concentrations and the untransformed 
concentrations for the ME and the DUI datasets and the levels in the group field. The 
results of the analyses will vary depending on the drug of interest. 
3.3.1 Diphenhydramine (Level 111) 
"Diphenhydramine is an antihistamine, used to treat allergies, motion sickness, 
allergic reactions, insomnia, cough, nausea, and phenothiazine drug-induced abnormal 
muscle movement,"24 Diphenhydramine is commonly known by its trade name, Benadryl 
@, and is frequently used by cancer patients, people with allergies or nausea, or by people 
who have Parkinson's disease24. "Diphenhydramine (DPH)-related deaths in adults are 
extremely rare, and detailed autopsy studies are rarer however, there were some 
cases in the ME dataset with a cause of death attributable to diphenhydramine. 
Using the filters mentioned in Section 3.2, the diphenhydramine dataset generated 
from the final dataset consisted of 2 13 cases. Of these 21 3 individuals, 102 came from the 
ME dataset and 1 11 came from the DUI dataset. Table 2 breaks down .the 2 13 observations 
by drug pattern group and by dataset (ME or DUI). Because there were only two 
individuals in Group 2 for the ME dataset, Groups 2 and 3 were combined for the analysis 
of diphenhydramine. The combined group (Groups 2 and 3) consisted of 89 individuals 
from the ME dataset and 85 individuals from the DUI dataset for a total of 174 
observations in Group 2. Table 3 shows the categorization of the demographics for the two 
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source datasets and the two new drug pattern groups. These two drug pattern groups are 
Group 1 (diphenhydramine only) and the new group (diphenhydramine with any 
combination of drug - including ethanol) that combined Group 2 and Group 3. In this 
table, the field age is displayed as a range of the youngest and the oldest, while the 
gender and race rows give frequencies of the individuals that fit into each of those 
categories. The percentages shown in this table are the percentage of ,the category (cell) in 
the source dataset. 
Table 2: Number of Observations for Categories in the Diphenhydramine Dataset 
Table 3: Demographics on the Diphenhydramine Dataset 
Group 
1 
(diphenhydramine only) 
2 
(diphenhydramine and ethanol) 
3 
(any other combination with 
diphenhydramine) 
Total 
ME 
13 
2 
87 
102 
DUI 
26 
3 1 
54 
11 1 
Race 
Gender 
Age (in years) 
DUI Source Dataset 
Drug Pattern 
Group 
White 
Black 
Other 
Missing 
Male 
Female 
Missing 
Range 
13 (1 1.7%) 
3 (2.7%) 
0 
10 (9%) 
11 (9.9%) 
5 (4.5%) 
10(9%) 
18-60 
Combined 
(2&3) 
54 (48.6%) 
3 (2.7 %) 
0 
28 (25.2%) 
35 (31.5%) 
23 (20.7%) 
27(24.3%) 
20-69 
ME 
1 
-- 
-- 
-- 
13 (12.7%) 
7 (6.9%) 
6 (5.9%) 
0 
18-66 
Combined 
(2&3) 
-- 
-- 
-- 
89 (87.3%) 
32 (31.3%) 
57 (55.9%) 
0 
14-87 
The normal quantile plots for the drug pattern groups and the source datasets for 
diphenhydrarnine revealed a non-normal distribution for most of the categories. This type 
non-normality is typically corrected by a log transformation, so a log transformation was 
employed on the concentration of diphenhydrarnine. The normal quantile plots (before and 
after log transformation) are seen in Figures 1,2,3, and 4. From these figures, the log 
transformation appears to work very well; thus, the ANOVA was run on the log- 
transformed concentration for diphenhydrarnine. The first normal quantile plot for each of 
these figures shows the data for diphenhydranline concentration before the log 
transformation. 
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Figure 1: Normal quantile plots for DUI Group 1 (diphenhydramine only) before and after log 
transformation 
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Figure 2: Normal quantile plots for DUI Groups 2 & 3 (diphenhydramine with any drug - including 
ethanol) before and after log transformation 
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Figure 3: Normal quantile plots for ME Group 1 (diphenhydramine only) before and after log 
transformation 
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Figure 4: Normal quantile plots for ME Groups 2 & 3 (diphenhydramine with any drug - including 
ethanol) before and after log transformation 
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The box plots seen in Figure 5 are the set of box plots for the concentriition of 
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diphenhydramiae for Group 1 for log-transformed and untransfornied data. Each of the 
two sets of these box plots has been plotted on the same scale to simplify visual 
comparison. Figure 6 shows an expanded box plot for DUI Group 1 (untransformed data). 
Figure 7 shows the pair of box plots for the combined group - Groups 2 & 3 - for the ME 
and DUI datasets. The box plots in Figures 5 and 7 show the concentrations of the log of 
diphenhydramine concentration (left side) for each of the drug pattern groups in each of the 
source datasets, and the untransformed data (right side). Figure 8 shows an expanded box 
plot for the combined drug pattern group for DUI where the y-axis is modified to 
accommodate the inspection of the distribution. 
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For ME Group 1, the mean (with log transformation) is 1.53 log (mg/L) units (* 
0.413 standard errors) which is equivalent to 4.62 mg/L, and the mean of DUI Group 1 is - 
2.406 log (mg/L) units (* 0.292 standard errors) [0.09 mg/L]. The range of the 
concentrations for the ME Group 1 was -0.942 log (mglL) units to 3.784 log (mg/L) units 
[0.39 mg/L to 44 mg/L], and the range for the DUI dataset for Group 1 was -4.605 log 
(mg/L) units to 0.742 log (mg/L) units [0.01 mg/L to 2.1 mg/L]. (These means and 
standard errors are from the log-transformed concentrations and from untransforming those 
means; they will not necessarily match the raw means and standard errors seen in the table 
with the results of the Tukey tests.) There does seem to be some overlap between the two 
datasets in Group 1, but this is not enough evidence to tell whether or not there is a 
significant difference between the two datasets. 
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Figure 5: Box plots of Group 1 (diphenhydramine only) for DUI and ME - log transformed and 
untransformed data 
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Figure 6: Expanded box plot for DUI Group 1 (diphenhydramine only) - untransformed data 
Figure 7 shows the pair of box plots for log-transformed and untransformed data for 
Groups 2 & 3 combined. The mean of the concentration for the ME combined drug pattern 
group is -0.05 log (mg/L) units (* 0.158 standard errors) [0.95 mg/L] and the ragge is from 
-0.2 19 log (mg/L) units [0.04 mg/L] to 3.784 log mg/L [44.0 mgIL]. The mean of 
concentration for diphenhydramine for the DUI combined drug pattern group is -3.006 log 
(mg/L) units (k 0.162 standard errors) [0.05 mg/L] and the range is from -4.605 log (mg/L) 
units [0.01 mg/L] to 0.262 log (mg/L) units [1.3 mg/L]. The low ends of each of these 
ranges are close, so there is a definite overlap, but the high end of the ME range is much 
larger than that of the DUI range. 
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Figure 7: Box plots for Groups 2 & 3 (diphenhydramine with any drug - including ethanol) for DUI 
and ME - log transformed and untransformed data 
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Figure 8: Expanded box plot for DUI Groups 2 & 3 (diphenhydramine with any drug - including 
ethanol) - untransformed data 
When the ANOVA model was fit to the diphenhydramine data it was determined 
that the interaction between the group and database fields was significant at the pre- 
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determined a = 0.10 level (p-value = 0.0793); therefore, it was kept in the model, and 
assessment of the differences in the blood concentrations between the drug pattern groups 
and the source datasets was within the interaction. The plot of the means in Figure 9 
shows the interaction of the two fields group and database. From Figure 9, it can be 
seen that concentration of diphenhydramine between the ME and DUI datasets in Group 1 
is a larger difference than ,the difference between the ME and DUI datasets in the 
combined drug pattern group. 
Plot of the Means 
Log-transformed concentration of diphenhydramine 
-4 
diphenhydrarnine only 
Drug Pattern Group 
poly pharmacy 
Figure 9: Plot of the means for log-transformed diphenhydramine - interaction 
By interpreting the assessment of the differences in the blood concentrations between the 
drug pattern groups and the source datasets through the interaction, Tukey's test for 
multiple comparisons revealed that the ME and DUI dataset are statistically significantly 
different from each other both in Group 1 and the combined drug pattern group. Within the 
ME dataset, both drug pattern groups are different from each other, but in the DUI dataset, 
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Group 1 and the combined drug pattern group (Groups 2 & 3) are not different from each 
other. These results of the Tukey's test are summarized in Table 4 where levels not 
connected by the same letter are statistically significantly different from each other. Table 
4 also shows the means and standard errors for the untransformed concentration of 
diphenhydramine. 
Table 4: Levels of drug pattern groups and source datasets for diphenhydramine from Tukey's test 
The residual by predicted plot for diphenhydramine is seen in Appendix C and does 
not show any pattern between the residuals and the predicted values from the model. It 
also seems that the assumption of constant variance is met because all four categories 
appear to have roughly the same span on this plot. A normal quantile plot of the residuals 
(Appendix C) was also inspected for deviations from normality, but for the 
diphenhydramine dataset, the residuals followed an approximately normal distribution. 
A clinical range of 8-3 1 mg/L of diphenhydramine is considered a fatal blood 
concentration for an i nd iv id~a l~~ .  Using this limit, there were no individuals in the DUI 
dataset with a "lethal" amount of diphenhydramine in their system, and thus, there is no 
evidence to suggest a development of tolerance to diphenhydramine. The high end of the 
fatal blood concentration for diphenhydramine was 3 1 mglL, but there were four cases in 
the ME dataset that had a concentration of 3 1 mg/L or higher, with the highest being 44 
Group 
ME, Group 1 
ME, Combined Group 
DUI, Group 1 
DUI, Combined Group 
Letter 
A 
B 
C 
C 
Mean(Std. Error) 
11.56(3.82) 
3.58(0.77) 
0.37(0.112) 
0.1 15(0.025) 
5 0 
mglL. All four of these cases listed "suicide" a.s a manner  of d e a t h ,  but they might 
still be of clinical interest for a case study. Two of these four individuals had only 
diphenhydramine detected, one had diphenhydramine and ethanol, and the last had a poly 
pharmacy of drugs in their system. 
3.3.2 Cocaine (Level 11) 
"Cocaine is a stimulant of the central nervous system and an appetite suppressant, 
crea.ting what has been described as a euphoric sense of happiness and increased energy,"27. 
Cocaine is most often used as a "recreational drug", but it is sometimes used as a topical 
anesthetic for certain types of One of the problems with determining 
information concerning cocaine in deaths is that "since cocaine in blood rapidly hydrolyzes 
to benzoylecgonine, cocaine concentrations determined in postmortem blood may not 
reflect the presence or true concentration of cocaine in the body at the time of death,"28. 
The main metabolite of cocaine is benzoylecgonine, and this metabolite has a longer half- 
life than cocaine, so the metabolite provides additional information when doing a drug test 
that searches for cocaine. The DUI drug tests were all administered via a blood sample, so 
using the ME concentrations from brain or tissues other than blood were not an appropriate 
comparator to the DUI blood concentrations; therefore, only the blood concentrations from 
the ME dataset were used in the comparison. 
Using the same inclusion and exclusion criteria mentioned in Section 3.2, the final 
cocaine dataset contained 691 cases and 577 variable fields. Of the 691 observations, 359 
came from the ME dataset and 332 from the DUI dataset. Detecting benzoylecgonine in a 
person's system could lead to the cause of death being "cocaine poisoning" (for an ME 
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case) or showing that the individual had taken cocaine prior to being stopped for DUI. If 
an individual had benzoylecgonine detected and not cocaine, then he or she was excluded 
from the cocaine dataset because a concentration amount of cocaine could not be 
established. This means that even if an individual had taken cocaine (as evidenced by the 
presence of benzoylecgonine), if no cocaine was determined from the blood sample, then 
this individual was excluded from the cocaine dataset. 
Table 5 details the number of observations for the three drug pattern groups and the 
two datasets (ME and DUI) for the 691 observations. The next table, Table 6, shows the 
breakdown of r a c e ,  gender ,  and age for the two source datasets and the three drug 
pattern groups. The information in Table 6 shows the frequencies for each of the 
categories except in the field age,  which is displayed as a range from youngest to oldest. 
The demographic information shown in Table 6 is only displayed for descriptive purposes, 
and it is not used in the analysis. Because all six categories met the minimum number of 
observations requirement, no drug pattern groups were combined or removed for the 
analysis of the cocaine dataset. 
Table 5: Number of Observations for Categories in the Cocaine Dataset 
Group 
1 
(cocaine only) 
2 
(cocaine and ethanol) 
3 
(any other combination with 
cocaine) 
Total 
ME 
129 
15 
215 
359 
DUI 
122 
146 
64 
332 
52 
Table 6: Demographics on the Cocaine Dataset 
The majority of the normal quantile plots for the drug pattern groups showed non- 
normal distribution~. Figures 10, 11, and 12 show the normal quantile plots for the three 
drug pattern groups for the DUI dataset before and after the log transformation. For the 
ME dataset drug pattern groups, Figures 13, 14, and 15 show the normal quantile plots for 
both the untransformed and log-transformed data. Using the log transformation for the 
concentration of cocaine, the data appears to be approximately normally distributed. This 
log transformation was used for the ANOVA model that was used for analysis of the 
cocaine dataset. 
Race 
Gender 
Age (in 
years) 
Source Dataset 
Drug Paitern Group 
White 
Black 
Other 
Missing 
Male 
Female 
Missing 
Range 
ME 
1 
-- 
-- 
-- 
129 
(35.9%) 
101 
(28.1%) 
28 
(7.8%) 
0 
16-68 
DUI 
1 
50 
(15.1%) 
25 
(7.5%) 
0 
47 
(14.2%) 
54 
(16.3%) 
22 
(6.6%) 
46 
(13.9%) 
19-53 
2 
-- 
-- 
-- 
15 
(4.2%) 
14 
(3.9%) 
1 
(0.3%) 
0 
19-46 
3 
-- 
-- 
-- 
215 
(59.9%) 
152 
(42.3%) 
63 
(17.5%) 
O 
19-64 
2 
50 
(15.1%) 
38 
(1 1.4%) 
1 (.3%) 
57 ) (17.2% 
69 
(20.8%) 
20 
(6%) 
5 7 
(17.2%) 
16-64 
3 
3 1 
(9.3%) 
13 
(3.9%) 
0 
20 (6%) 
3 5 
(10.5%) 
9 
(2.7%) 
20 
(6%) 
17-55 
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Figure 10: Normal quantile plots for DUI Group 1 (cocaine only) before and after log transformation 
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Figure 11: Normal quantile plots for DUI Group 2 (cocaine and ethanol) before and after log 
transformation 
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Figure 12: Normal quantile plots for DUI Group 3 (cocaine with any other combination of drug) 
before and after log transformation 
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Figure 13: Normal quantile plots for ME Group 1 (cocaine only) before and after log transformation 
ME 
Group 2 
Cocaine 
ME 
Group 2 
Cocaine 
6- . - .  . - . . .  * 
.01 .05.10 .25 .50 .75 .90.95 .99 
5- 
4- 
3 - 
2 - 
1 - 
0-, 
I I I I I 
-3 -2 -1 0 1 2 3 
Normal Quantile Plot 
Log transformed 
2 -~ 
1 - 
0- 
-1 - 
-2 - 
-3 - 
-4 - 
I I I I I 
-3 -2 -1 0 1 2 3 
I Normal Quantile Plot I 
Figure 14: Normal quantile plots for ME Group 2 (cocaine and ethanol) before and after log 
transformation 
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Figure 15: Normal quantile plots for ME Group 3 (cocaine with any other combination of drug) before 
and after log transformation 
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Box plots were created to compare the concentration of cocaine between the three 
drug pattern groups and between the two source datasets. The box plots shown in the 
following figures are of the log-transformed data and the untransformed data for each 
dataset (ME and DUI) and each drug pattern group. Figure 16 shows the comparisons 
between the two datasets for Group 1 (cocaine alone) for both the log-transformed and 
untransformed concentration amounts, and Figure 17 shows an expanded version of the 
untransformed data for DUI Group 1. When the log-transformed data was used, there was 
no need to expand any of the box plots, but when the untransformed data was used and the 
scales for the ME and DUI datasets were set to the same scale, the DUI box plot of the 
untransformed data needed to be expanded to view the details of the plot. The mean for 
the ME dataset for Group 1 is -1.333 log (mg/L) units (f 0.1 1 1 standard errors) [0.264 
mg/L] with the range from -4.605 log (mg/L) units [0.01 mg/L] to 3.689 log (mg/L) units 
[40.0 mg/L]. The mean for DUI Group 1 is -3.135 log (mg/L) units (f 0.1 14 standard 
errors) [0.04 mg/L] with a range of -5.298 log (mg/L) units E0.005 mg/L] to -0.942 log 
(mg/L) units [0.39 mg/L]. For Group 1, the majority of the DUI cases fit into the ME 
range, showing some sort of overlap. 
DUI ME DUI ME 
Group 1 Group 1 Group 1 Group 1 
Cocaine Cocaine Cocaine Cocaine 
Log transformed 
-2 
-3 
-4 
-5 
Log transformed 
-1 
-2 
-3 
-4 
-5 
Figure 16: Box plots for Group 1 (cocaine only) for DUI and ME - 
untransformed data 
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Figure 17: Expanded box plot for DUI Group 1 (cocaine only) - untransformed data 
In the next figure, Figure 18, the two pairs of box plots for Group 2 of the cocaine dataset 
are shown; Figure 19 shows the expanded box plot for the DUI untraasformed data. The 
range for the DUI dataset is larger than it was in Group 1, but the overlap between the ME 
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and DUI datasets is still there. For the ME dataset Group 2, the mean is -1.783 log (mg/L) 
units (* 0.324 standard errors) [0.17 mg/L], and the DUI mean for Group 2 is -3.68 log 
(mg/L) units (k 0.104 standard errors) [0.025 mg/L]. The range for the ME dataset for 
Group 2 is from -3.507 log (mg/L) units [0.03 mg/L] to 1.686 log (mg/L) units [5.40 
mg/L], and the range for DUI Group 2 is from -5.298 log (mg/L) units [0.005 mg/L] to - 
1.204 log (mg1L) units [0.3 mg/L]. These ranges have some overlap, but the range for this 
drug pattern group in the DUI dataset was smaller than that for the ME dataset. 
DUI 
Group 2 
Cocaine 
Log transformed 
-3 
-4 
-5 
ME 
Group 2 
Cocaine 
Log transformed 
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Figure 18: Box plots for Group 2 (cocaine and ethanol) for DUI and ME - log-transformed and 
untransformed data 
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Figure 19: Expanded box plot for DUI Group 2 (cocaine and ethanol) - untransformed data 
The last figures for the cocaine dataset show the box plots for the log-transformed and 
untransformed concentrations for Group 3. Figure 20 shows that the range for DUI Group 
3 can be completely encompassed within the range for ME Group 3. Figure 21 shows an 
expanded box plot for DUI Group 3 of the untransformed data. The means for the ME and 
DUI dataset are -2.812 log (mg/L) units (* 0.086 standard errors) [0.06 mg/L] and -3.723 
log (mg/L) units (* 0.157 standard errors) [0.024 mg/L] respectively. The range for Group 
3 in the DUI dataset is from -5.298 log (mg/L) units [0.005 mg/L] to -1.273 log (mg/L) 
units [0.28 mg/L], while the range for Group 3 in the ME dataset is from -7.264 log (mg/L) 
units [0.0007 mg/L] to 1.435 log (mg/L) units [4.2 mg/L]. (These means and ranges are 
determined from the log-transformed concentrations of cocaine and by untransforming 
these means; they will not necessarily match the means for the untransformed 
concentrations that are seen in the table with the Tukey results.) 
DUI ME 
Group 3 Group 3 
Cocaine Cocaine 
Log transformed 
-3 
-4 
-5 
-6 
-7 
-8 
Log transformed 
-3 
-4 
-5 
-6 
-7 
-8 
DUI 
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Cocaine 
ME 
Group 3 
Cocaine 
Figure 20: Box plots for Group 3 (cocaine with any other combination of drug) for DUI and ME - log- 
transformed and untransformed data 
DUI 
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Figure 21: Expanded box plot for DUI Group 3 (cocaine with any other combination of drug) - 
untransforrned data 
Based only on the box plots, it seems that there might be a difference between the 
two source datasets for some drug pattern groups, but perhaps, not all, and that perhaps the 
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drug pattern groups are different from each other, within the same dataset. An ANOVA 
model was fit to the log-transformed data to see if these conjectures were correct. 
When the ANOVA model was fit to the cocaine dataset, it was determined that the 
interaction between group and database was significant (p-value = 0.0004). Since this 
interaction was significant, assessments of the differences in the blood concentrations 
between drug pattern groups and source datasets were tested through the interaction. The 
plot of the means for the cocaine dataset is seen in Figure 22, and it shows that the 
difference in concentrations between the source datasets (ME and DUI) for Group 3 is 
different than the difference in concentrations between the source datasets for Groups 1 and 
2. Table 7 shows the results of the Tukey's test with different letters signifying statistical 
significant differences between the different levels; categories that do not share the same 
letter are statistically significantly different from each other. This table shows that ME 
Group 1 and ME Group 2 are different from all of the drug pattern groups in the DUI 
dataset, but ME Group 3 is not different from DUI Group 1. Within the ME dataset, 
Groups 1 and 2 are not different from each other, but both are different from ME Group 3. 
For the DUI dataset, Groups 2 and 3 are not different from each other, but both are 
different from Group 1. Table 7 also shows the raw means and standard errors 
(untransformed concentrations) for cocaine; the units for these means and standard errors 
are mg/L. 
Plot of the Means 
Log-transformed concentration of cocaine 
-1 .o 
-4.5 
cocaine only cocaine and ethanol poly pharmacy 
Drug Pattern Groups 
Figure 22: Plot of the means for log-transformed cocaine - interaction 
Table 7: Levels of drug pattern groups and source datasets for cocaine from Tukey's test 
The residual by predicted plot for the cocaine dataset is seen in Appendix C, and 
this plot shows no obvious pattern of the residuals with the predicted values from the 
model. Because there is no pattern of the residuals and there does not seem to be a problem 
with constant variance, then the modeling assumptions are verified. The constant variance 
assumption is met because for each of the combinations, the variance appears to be the 
same. The adequacy of the model is verifed through the fact that there not a systematic 
pattern of residuals and the normal quantile plot. The normal quantile plot of the residuals 
Group 
ME, Group 1 
ME, Group 2 
ME, Group 3 
DUI, Group 1 
DUI, Group 2 
DUI, Group 3 
Letter 
A 
A 
B 
B 
C 
C 
Mean(Std. Error) 
1.7 l(0.403) 
0.528(0.35) 
0.149(0.028) 
0.071(0.007) 
0.039(0.003) 
0.038(0.005) 
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for the ANOVA model, also seen in Appendix C, shows an approximately normal 
distribution because the data points fall along the diagonal, so the normality assumption in 
not violatedin the fitted model. 
Using 0.9 - 21 mg/L as the clinically defined, fatal blood concentration for 
cocainez6, no cases in the DUI dataset fell within this range, but there was one case in the 
ME dataset that exceeded the upper end of the range (21 mg/L) by having 40 mg/L. This 
case was a single drug overdose and might be of interest in a case study. 
3.3.3 Oxycodone (Level 11) 
Oxycodone, commonly known as OxyContin @, Percocet @, or Percodan @ is a 
"central nervous system depressant that appears to work through stimulating the opioid 
receptors found in the central nervous system that activate responses ranging from 
analgesia to respiratory depression to euphoria,"29. According to an article from 
www.streetdruns.org, "people who take the drug repeatedly can develop a tolerance or 
resistance to the drug's effects,"29. 
The dataset created for oxycodone consisted of 487 individuals and 577 fields. This 
dataset was created using the same criteria as the previous datasets and excluded those 
individuals who did not die from an oxycodone-related drug death, those individuals not 
receiving a toxicological screen as a result of an autopsy, and those individuals in .the DUI 
dataset that did not register any level of concentration for oxycodone. From the ME 
dataset, 263 individuals were included, and from the DUI dataset, 224 individuals were 
included. Table 8 shows the number of observations that appear in each drug pattern group 
(oxycodone only, oxycodone and ethanol, and oxycodone with any other combination of 
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drug) for each of the source datasets, and Table 9 shows the demographic descriptions for 
each of these drug pattern groups. In Table 8, the category for oxycodone and ethanol 
(Group 2) from the ME dataset had only 11 observations. The general rule of thumb for a 
minimum number of observations was 12", but the clinical decision was to leave the drug 
pattern groups as is, without combining Group 2 with any of the other drug pattern groups. 
One interesting fact to notice in Table 9 is that in ME Group 1 (oxycodone only), there was 
an individual with an age of zero; this might be an interesting individual to use for a case 
study, once the age is verified. 
Table 8: Number of Observations for Categories in the Oxycodone Dataset 
Table 9: Demographics on theoxycodone Dataset 
Group 
1 
(oxycodone only) 
2 
(oxycodone and ethanol) 
3 
(any other combination with 
oxycodone) 
Total 
ME 
5 3 
11 
199 
263 
DUI 
3 1 
68 
125 
224 
Race 
Gender 
Age (in years) 
Source Dataset 
Drug Pattern Group 
White 
Black 
Other 
Missing 
Male 
Female 
Missing 
Range 
ME 
1 
-- 
-- 
-- 
53 
(20.1%) 
40 
(15.2%) 
13 
(4.9%) 
0 
0-57 
DUI 
1 
18 
(8%) 
1 
(0.4%) 
0 
12 
(5.4%) 
11 
(4.9%) 
8 
(3.5%) 
12 
(5.4%) 
20-57 
2 
-- 
-- 
-- 
11 
(4.2%) 
1 I 
(4.2%) 
O 
0 
20-46 
3 
-- 
-- 
-- 
199 
(75.7%) 
120 
(45.6%) 
79 
(30.1%) 
O 
19-73 
2 
46 
(20.6%) 
3 
(1.3%) 
0 
19 
(8.5%) 
3 6 
(16.1%) 
13 
(5.8%) 
19 
(8.5%) 
17-59 
3 
77 
(34.4%) 
3 
(1.3%) 
0 
45 
(20.1%) 
5 8 
(25.9%) 
22 
(9.8%) 
45 
(20.1%) , 
18-68 
The normal quantile plots for the concentration of oxycodone showed data that 
did not appear normally distributed, so a log transformation was done on the 
concentration of oxycodone. The normal quantile plots, before and after the log 
transformation, are seen in Figures 23, 24,25,26, 27, and 28. The first three figures 
show the normal quantile plots for the DUI dataset for Groups 1,2, and 3, with the 
untransformed data on the left, and the log-transformed data on the right. Figures 26,27, 
and 28 show the normal quantile plots for the ME dataset. As these figures show, the 
normal quantile plots for the log-transformed concentration appear approximately 
normally distributed, while the normal quantile plots for the untransformed data show 
data that is not normally distributed. 
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Figure 23: Normal quantile plots for DUI Group 1 (oxycodone only) before and after log 
transformation 
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Figure 24: Normal quantile plots for DUI Group 2 (oxycodone and ethanol) before and after log 
transformation 
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Figure 25: Normal quantile plots for DUI Group 3 (oxycodone with any other combination of drug) 
before and after log transformation 
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Figure 26: Normal quantile plots for ME Group 1 (oxycodone only) before and after log 
transformation 
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Figure 27: Normal quantile plots for ME Group 2 (oxycodone and ethanol) before and after log 
transformation 
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Figure 28: Normal quantile plots for ME Group 3 (oxycodone with any other combination of drug) 
before and after log transformation 
The following figures show two pairs of box plots for the three drug pattern groups 
before and after the log transformation of cocaine. Figure 29 shows the pair of box plots 
for Group 1, and Figure 30 shows the expanded box plot for the DUI dataset for Group 1. 
DUI ME DUI ME 
Group 1 Group 1 Group 1 Group 1 
Oxycodone Oxycodone Oxycodone Ox ycodone 
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Figure 29: Box plots for Group 1 (oxycodone only) for DUI and ME - log-transformed and 
untransformed data 
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Figure 30: Expanded box plot for DUI Group 1 (oxycodone only) - untransformed data 
The mean of DUI Group 1 is -1.85 log (mg/L) units (h 0.13 1 standard errors) [O. 16 mg/L], 
ranging fkom -3.507 log (mg/L) units [0.03 mg/L] to -0.598 log (mg/L) units [0.55 mg/L]. 
The mean of ME Group 1 is -0.71 85 log (mg/L) units (* 0.0974 standard errors) [0.49 
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mg/L] with a range from -2.813 log (mg/L) units [0.06 mg/L] to 0.693 log (mg/L) units 
[2.0 mg/L]. The majority of the cases in the DUI dataset for Group 1 fit inside the range 
determined by ME Group 1. The box plots seen in Figure 3 1 show Group 2 for the ME 
and DUI datasets with and without the log transformation; Figure 3 2  shows the box plot 
for untransfonned DUI Group 2 on an expanded scale. 
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Figure 31: Box plots for Group 2 (oxycodone and ethanol) for DUI and ME - log-transformed and 
untransformed data 
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Figure 32: Expanded box plot for DUI Group 2 (oxycodone and ethanol) - untransformed data 
For Group 2, the means for the DUI and ME datasets are -2.638 log (mg/L) units (k 0.1 18 
standard errors) [0.07 mg/L] and - 1 -02 log (mg/L) units (* 0.226 standard errors) [0.36 
mg/L], respectively. The range for the DUI dataset for this drug pattern group is from - 
5.298 log (mg/L) units [0.005 mg/L] to -0.916 log (mg/L) units [0.4 mg/L], while the ME 
dataset for Group 2 ranges from -1.833 log (mg/L) units [0.16 mg/L] to 0.833 log (mg/L) 
units [2.3 mg/L]. There seems to be some overlapping between the two datasets (ME and 
DUI) for Group 2. 
The box plots for Group 3 for the oxycodone dataset are seen in Figures 33 and 34, 
with Figure 34 showing an expanded box plot for the untransformed data for DUI Group 3. 
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Figure 33: Box plots for Group 3 (oxycodone with any other combination of drug) for DUI and ME - 
log-transformed and untransformed data 
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Figure 34: Expanded box plot for DUI Group 3 (oxycodone with any other combination of drug) - 
untransformed data 
For DUI Group 3, the mean is -2.782 log (mg/L) units (* 0.102 standard errors) [0.06 
rng/L] and the mean for ME Group 3 is - 1.366 log (mg/L) units (k 0.087 standard errors) 
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[0.255 mg/L]. The range for DUI Group 3 is -5.298 log (mg/L) units [0.005 mg/L] to - 
0.163 log (mg/L) units [0.85 mg/L]. The range for ME Group 3 is from -4.605 log (mg/L) 
units [0.01 mg/L] to 2.079 log (mg/L) units [8.0 mg/L]. As ,the ranges show, there is a 
much larger spread of the oxycodone concentration for the ME dataset than for the DUI 
dataset. Note that the box plots of the log-transformed data do not always show the 
differences in the concentrations as well as the box plots of the untransfonned 
concentration amounts. (All of these means and ranges are determined by the log 
transformed concentrations of oxycodone and by untransforming these values; they are not 
necessarily the same values as the untransformed means and standard errors as the ones 
seen in the table that displays .the results of Tukey's test.) 
After the box plots were created to visually inspect for obvious differences between 
the ME and DUI datasets, an ANOVA model was fit to the log-transformed concentration. 
The interaction term between group and database was not significant (p-value = 
0.4625), so it was removed from the model. The new model contained only the two 
independent variables, and both of these were significant (p-values were both less than 
0.0001); therefore, there is a statistically significant difference between the two datasets 
(ME and DUI), and there is also a statistically significant difference between at least two of 
the three drug pattern groups. The plots of the means for each of the independent fields are 
seen in Figures 35 and 36. Because there are only two source datasets, the statistically 
significant difference is between the ME and DUI datasets. The drug concentrations from 
the ME dataset are significantly higher than the drug concentrations from the DUI dataset 
(see Figure 36). With respect to the three levels in the drug pattern groups, the ANOVA 
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indicates that there is a significant difference between the levels, but it does not specify 
which levels are different from each other. A Tukey's test was done to determine which 
differences between the means of the drug pattern groups are statistically significantly 
different. Table 10 shows the results of the Tukey's test where levels with different letter 
labels are statistically significantly different, and thus, levels that are not connected by the 
same letter are significantly different from each other (regardless of the source dataset). 
Referring to Table 10, Groups 2 and 3 are not different from each other, but both are 
different from Group 1, and from the plot of the means in Figure 35, it seems that Group 1 
has a higher concentration of oxycodone than Groups 2 and 3. Table 10 also displays the 
means and standard errors of the untransformed, or raw, concentrations of oxycodone. The 
means and standard errors reported in Table 10 are in mg/L units. 
Plot of the Means 
Log-transformed concentration of oxycodone 
-1 .o 
-2.2 
oxydone  only oxydone  and ethanol pdy pharmacy 
Drug Pattern Group 
Figure 35: Plot of the means for "group" field for log-transformed oxycodone 
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Figure 36: Plot of the means for "database" field for log-transformed oxycodone 
Table 10: Levels of drug pattern groups for oxycodone from Tukey's test 
The residual by predicted plot for oxycodone is seen in Appendix C and shows that 
there does not seen1 to be any systematic pattern between the predicted values and the 
residuals. The residuals also appear to follow the constant variance assumption since there 
seems to be roughly the same span of residuals in each of the categories. A normal 
quantile plot of the residuals was also constructed for the ANOVA model (see Appendix 
C), and it did not reveal any non-normality of the residuals. 
There is not a specified clinical limit that indicates a lethal amount of oxycodone, 
so there was not an amount or range to compare the concentrations of oxycodone to for 
Mean(Std. Error) 
0.465(0.045) 
0.163(0.03 1) 
0.373(0.044) 
Group 
Group 1 
Group 2 
Group 3 
~ e t t e r  
A 
B 
B 
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either dataset. Since the datasets were determined to be different when it came to 
oxycodone concentration, the DUI dataset and the ME dataset did not have enough 
evidence to suggest development of tolerance to oxycodone. 
3.3.4 Hydrocodone (Level 11) 
Hydrocodone is marketed as Vicodin @, Lorcet 09, Lortab 0, and many other trade 
names. This drug is used as "an orally active narcotic analgesic and antitus~ive,"~~. 
Hydrocodone can be "habit forming and can lead to physical and psychological 
addi~t ion"~~.  Mixing alcohol with hydrocodone can also cause other health problems30. 
The hydrocodone dataset consisted of 542 individuals and 577 variable fields, 
including 200 cases from the ME dataset and 342 cases from the DUI dataset. The dataset 
for hydrocodone was created using the same criteria as the other datasets, and includes all 
individuals from the ME dataset who died from a hydrocodone-related drug death and all 
DUI individuals that had hydrocodone detected in their system. Table 11 shows the 
number of individuals in each of the drug pattern groups and each source dataset. As Table 
11 shows, Group 2 for the ME dataset contained only six individuals, so Groups 2 and 3 
were combined for analysis. The combined drug pattern group consisted of 166 individuals 
from the ME dataset and 3 15 from the DUI dataset for a total of 48 1 observations. Table 
12 shows the demographic breakdown for Group 1 and the combined drug pattern group 
(Groups 2 & 3) for the ME and DUI datasets for the hydrocodone. 
Table 11: Number of Observations for Categories in the Hydrocodone Dataset 
- - 
Table 12: Demographics on the Hydrocodone Dataset 
Group 
1 
(hydrocodone only) 
2 
(hydrocodone and ethanol) 
3 
(any other combination with 
hydrocodone) 
Total 
The normal quantile plots for the four categories shown in the tables, showed non- 
normal distribution~ for the drug pattern groups and datasets, so a log transformation was 
used for the hydrocodone concentration. The normal quantile plots for all categories are 
seen in the following figures with the untransformed data and the log-transformed data for 
the concentration of hydrocodone. As Figures 37,38,39, and 40 show, the log- 
transfornied data followed an approximately normal distribution for all drug pattern groups 
and datasets, while the untransformed data did not follow an approximately normal 
distribution. 
ME 
34 
6 
160 
200 
Race 
Gender 
Age (in years) 
DUI 
27 
121 
194 
342 
Source Dataset 
Drug Pattern Group 
White 
Black 
Other 
Missing 
Male 
Female 
Missing 
Range 
ME 
1 
-- 
-- 
-- 
34 (17%) 
18(9%) 
16 (8%) 
0 
19-77 
DUI 
Combined 
(2&3) 
-- 
-- 
-- 
166 (83%) 
104(52%) 
62 (31%) 
0 
17-73 
19 (5.6%) 
1 (0.3%) 
0 
7 (2%) 
16(4.7%) 
4 (1.2%) 
7 (2%) 
18-46 
Combined 
(2&3) 
205 (59.9%) 
6 (1.8%) 
0 
104 (30.4%) 
136(39.8%) 
75 (21.9%) 
104 (30.4%) 
17-68 
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Figure 37: Normal quantile plots for DUI Group 1 (hydrocodone only) before and after log 
transformation 
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Figure 38: Normal quantile plots for DUI Groups 2 & 3 (hydrocodone with any drug - including 
ethanol) before and after log transformation 
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Figure 39: Normal quantile plots for ME Group 1 (hydrocodone only) before and after log 
transformation 
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Figure 40: Normal quantile plots for ME Groups 2 & 3 (hydrocodone with any drug - including 
ethanol) before and after log transformation 
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The box plots comparing the log-transformed concentrations and the untransforrned 
concentrations for the source datasets for each of the drug pattern groups are seen in the 
following figures. Figure 41 shows the box plots for Group 1, and Figure 42 shows the box 
plots for the combined drug pattern group (Groups 2 and 3). Figure 43 shows an expanded 
version of .the untransformed DUI box plot for the combined drug pattern group, but there 
is not an expanded DUI box plot for Group 1 because Figure 41 shows the details with no 
need to expand the scale. 
DUI ME DUI ME 
Group 1 Group 1 Group 1 Group 1 
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Figure 41: BOX plots for Group 1 (hydrocodone only) for DUI and ME - log-transformed and 
untransformed data 
The mean for Group 1 for the ME dataset is -1.565 log (mg/L) units (A 0.1 19 standard 
errors) [0.2 1 mg/L], and the mean for Group 1 for the DUI dataset is -3.172 log (mg/L) 
units (f 0.195 standard errors) [0.04 mglL]. The range for the ME dataset for Group 1 
spans from -3.219 log (mglL) units [0.04 mg/L] to -0.51 1 log (mg/L) units 10.6 mg/L], 
while the range for the DUI dataset for this drug pattern group is from -4.605 log (mg/L) 
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units [0.01 mg/L] to -0.968 log (mg/L) units 10.38 mg/L]. Group 1 for the ME dataset 
spans a larger region than the DUI dataset, but the two datasets seem to follow a similar 
pattern for Group 1. 
DUI 
Groups 2 & 3 
Hydrocodone 
Log transformed 
-4 
-5 
-6 
ME 
Groups 2 & 3 
Hydrocodone 
Log transformed 
-3 
-4 
-5 
-6 
DUI 
Groups 2 & 3 
Hydrocodone 
ME 
Groups 2 & 3 
Hydrocodone 
Figure 42: Box plots for Groups 2 & 3 (hydrocodone with any drug - including ethanol) for DUI and 
ME - log-transformed and untransformed data 
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Figure 43: Expanded box plot for DUI Groups 2 & 3 (hydrocodone with any drug - including ethanol) 
- untransformed data 
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For the drug pattern group that combined Groups 2 & 3, the mean for the ME 
dataset was -2.317 log (mg/L) units (h 0.087 standard errors) [0.10 mg/L], and the mean for 
the DUI dataset was -3.63 log (mg/L) units (* 0.045 standard errors) [0.027 mg/L]. The 
range for the ME dataset was from -5.843 log (mg/L) units [0.0029 mgIL] to -0.693 log 
(mg/L) units [2.0 mg/L]; the range for the DUI dataset is from -5.298 log (mg1L) units 
[0.005 mg/L] to -1.609 log (mg/L) units [0.2 mg/L]. It is interesting to note that the range 
for DUI combined drug pattern group is completely contained in the range for the ME 
dataset. (All of these means and ranges are determined by using the log-transformed 
concentrations of hydrocodone and by untransforming these values; they will not always be 
the same as the raw means reported with the results of the ANOVA model. 
An ANOVA model was fit to the hydrocodone dataset. The interaction between 
group and database was not statistically significant (p-value = 0.2475), so it was 
removed from the model. With only the independent fields left in the model, both were 
determined to be statistically significant (p-values each less than 0.0001). Since both fields 
were statistically significant, then the ME dataset and the DUI datasets were determined to 
be statistically significantly different from each other within the hydrocodone dataset. 
Group 1 was also determined to be statistically different from the combined drug pattern 
group (Groups 2 & 3). The plots of the means for each of the variable fields are shown in 
Figures 44 and 45. The concentration of hydrocodone is statistically significantly higher 
for the ME dataset (mean = 0.196 k 0.01 8 standard errors) than for the DUI dataset (mean 
= 0.039 5 0.002 standard errors), and the concentration is statistically significantly higher 
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in Group 1 (mean = 0.1 73 * 0.02 standard errors) than it is in the combined drug pattern 
group (Groups 2 & 3) (mean = 0.087 k 0.008 standard errors). 
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Figure 44: Plot of the means for "database" field for log-transformed hydrocodone 
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Figure 45: Plot of the means for "group" field for log-transformed hydrocodone 
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Once the model was fitted to the data, a residual by predicted plot was constructed 
(Appendix C). This plot showed that the constant variance assumption was met, and since 
there did not seem to be overall systematic pattern, the model was adequate for the data. 
The residuals for this model were also plotted in a normal quantile plot to check for 
normality (Appendix C), and the residuals appeared to be approximately normal. 
Because the ME and DUI datasets are statistically different with respect to 
hydrocodone, there is not sufficient evidence to suggest tolerances to hydrocodone. There 
is not a defined clinical concentration of hydrocodone that is considered fatal. 
3.3.5 Methadone (Level 111) 
"German scientists synthesized methadone during World War I1 because of a 
shortage of m~r~h ine , "~ ' .  The trade name for methadone is Dolophine @, and it is "used as 
,932 '6 an analgesic and in the treatment of narcotic addiction . Ironically, methadone used to 
control narcotic addiction is frequently encountered on the illicit market and has been 
associated with a number of overdose deathsw3'. 
The methadone dataset contained 522 observations and 577 variable fields. 
Consisting of 407 individuals from the ME dataset and 1 15 from the DUI dataset, the 
methadone dataset followed the same inclusion and exclusion rules that the previous 
datasets have mentioned. Three drug pattern groups were created: methadone only, 
methadone and alcohol, and methadone with any other combination of drugs. The 
following two tables show the frequency of observations for each category and the 
demographics of each of the categories. The number of observations in each drug pattern 
group and each source dataset is shown in Table 13, and Table 14 shows the itemization of 
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the three drug pattern groups and the two source datasets with respect to the demographic 
variable fields r a c e ,  g e n d e r ,  and age. 
Table 13: Number of Observations for Categories in the Methadone Dataset 
Table 14: Demographics on the Methadone Dataset 
Group 
1 
(methadone only) 
2 
(methadone and ethanol) 
3 
(any other combination with 
methadone) 
Total 
Race 
ME 
142 
20 
245 
407 
Because all of the drug pattern groups contained at least 12 cases, none of them 
were combined, and the analysis was done using all three drug pattern groups. The normal 
quantile plots of the drug pattern groups and the source datasets showed non-normal 
distributions, so a log transformation was done on the concentration of methadone for the 
DUI 
14 
27 
74 
115 
Gender 
Age (in years) 
Source Dataset 
Drug Pattern 
Group 
White 
Black 
Other 
Missing 
Male 
Female 
Missing 
Range 
ME 
1 
-- 
-- 
-- 
142 
(34.9%) 
97 
(23.8%) 
45 
(1 1.1%) 
0 
18-59 
DUI 
1 
7 
(6.1%) 
O 
0 
7 
(6.1%) 
4 
(3.5%) 
3 
(2.6%) 
7 
(6.1%) 
18-44 
2 
-- 
-- 
-- 
20 
(4.9%) 
17 
(4.2%) 
3 
(0.7%) 
O 
18-45 
3 
-- 
-- 
-- 
245 
(60.2%) 
153 
(37.6%) 
91 
(22.4%) 
1 
(0.2%) 
17-71 
2 
13 
(1 1.3%) 
1 
(0.9%) 
O 
13 
(11.3%) 
9 
(7.8%) 
5 
(4.3%) 
13 
(11.3%) 
22-48 
3 
45 
(39.1%) 
2 
(1.7%) 
1 
(0.9%) 
26 
(22.6%) 
3 1 
(27%) 
18 
(15.7%) 
25 
(21.7%) 
18-64 
analysis. The normal quantile plots for each of the datasets and drug pattern groups are 
displayed in the following figures. Figures 46 through 48 show the normal quantile plots 
for all of the DUI drug pattern groups with both the untransformed and the log-transformed 
data. Figures 49 through 5 1 show the normal quantile plots for the ME drug pattern 
groups. The normal quantile plots of the log-transformed data show an approximately 
normal distribution, and this transformed data was used for the ANOVA model. 
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Figure 46: Normal quantile plots for DUI Group 1 (methadone only) before and after log 
transformation 
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Figure 47: Normal quantile plots for DUI Group 2 (methadone and ethanol) before and after log 
transformation 
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Figure 48: Normal quantile plots for DUI Group 3 (methadone with any other combination of drug) 
before and after log transformation 
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Figure 49: Normal quantile plots for ME Group 1 (methadone only) before and after log 
transformation 
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Figure 50: Normal quantile plots for ME Group 2 (methadone and ethanol) before and after log 
transformation 
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Figure 51: Normal quantile plots for ME Group 3 (methadone with any other combination of drug) 
before and after log transformation 
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The next sets of figures show the box plots (log-transformed and untransformed) 
Normal Quantile Plot 
comparing the ME and DUI datasets for each of the three drug pattern groups. Figure 52 
displays two pairs of box plots for Group 1 (methadone only) for the log-transformed data 
(left side) and the untransformed data (right side), and Figure 53 shows an expanded box 
plot of the untransformed DUI Group 1 data. The expanded box plot is displayed to show 
the details of the untransformed DUI data. Figures 54 and 55 show .the box plots for Group 
2 (methadone and ethanol). 
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Figure 52: Box plots for Group 1 (methadone only) for DUI and ME - log-transformed and 
untransformed data 
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Figure 53: Expanded box plot for DUI Group 1 (methadone only) - untransformed data 
The means for Group 1 of the methadone dataset are -0.678 log (mg/L) units (* 
0.068 standard errors) [0.51 mg/L] for the ME dataset and -2.157 log (mg/L) units (* 0.353 
standard errors) [0.116 mg/L] for the DUI dataset. The range for Group 1 for the ME 
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dataset is from -5.776 log (mg/L) units [0.003 mg/L] to 1.686 log (mg/L) units [5.4 mg/L], 
and the range for Group 1 for the DUI dataset is from -4.605 log (mg/L) units [0.01 m a ]  
to -0.386 log (mg/L) units [0.68 mg/L]. As these ranges show, the entire range of the DUI 
dataset fits within the boundaries defined by the ME range; however, the lower boundary 
for the DUI dataset is higher than the lower boundary for the ME dataset. It might be of 
clinical interest to inspect the ME case that has a methadone-related death with a 
concentration of methadone equal to 0.0003 mg/L because it seems .that the concentration 
is not a "lethal" dose. 
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Figure 54: Box plots for Group 2 (methadone and ethanol) for DUI and ME - log-transformed and 
untransformed data 
For Group 2, the mean for the ME dataset is -1.146 log (mg/L) units (* 0.159 
standard errors) [0.32 mg/L], while the mean for the DUI dataset is -2.088 log (mg/L) units 
(* 0.227 standard errors) [0.124 mg/L]. The span of the concentrations for methadone in 
the ME dataset ranges from -2.303 log (mg/L) units [0.1 mg/L] to 0.336 log (mg/L) units 
[1.4 mg/L]. For the DUI dataset for Group 2, the range is from -5.298 log (mg/L) units 
[0.005 mg/L] to -0.693 log (mg/L) units [0.5 mgIL]. In this drug pattern group, unlike 
Group 1, the range for the DUI dataset starts at a lower concentration than that of the ME 
dataset. 
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Figure 55: Box plots for Group 3 (methadone with any other combination of drug) for DUI and ME - 
log-transformed and untransformed data 
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Figure 56: Expanded box plot for DUI Group 3 (methadone with any other combination of drug) - 
untransformed data 
In Group 3, the means for the two datasets are -0.87 log (mg/L) units (A 0.056 
standard errors) [0.419 mg/L] for the ME dataset and -2.255 log (mg/L) units (* 0.152 
standard errors) [O. 105 mg/L] for the DUI dataset. The concentrations of methadone for 
Group 3 for the ME dataset ranges from -3.507 log (mg/L) units [0.03 mg/L] to 2.485 log 
(mg/L) units [12 mg/L], and the range for the DUI dataset is from -5.298 log (mg/L) units 
[0.005 mg/L] to 0.095 log (mg/L) units [1 . l  mg/L]. The span of the range for the DUI 
dataset for this particular drug pattern group is smaller and begins at a lower dose than the 
range for the ME dataset. (All of these means and ranges were determined from the log- 
transformed concentrations of methadone and by untransforming these means.) 
An ANOVA model was fit to the data to determine whether or not there was a 
statistically significant difference in concentrations of methadone between the two source 
datasets and between the three drug pattern groups. Once this model was fit, the 
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intera.ction term was determined to be not statistically significant (p-value = 0.3064), and 
thus, it was removed from the model. After removing the interaction term from the 
ANOVA model, the group variable field was also noted as not significant (p-value = 
0.1 1 17), and it was removed from the model as well. The only significant variable field 
left in the model was the source dataset, implying that the ME and DUI datasets are 
different from each other with regard to concentration of methadone. Figure 57 shows the 
plot of the means for the database field. From this plot, it can be seen that the ME 
dataset has a statistically significant higher mean for concentration of methadone (mean = 
0.664 mg/L * 0.052 standard errors) than the DUI dataset (mean = 0.202 mg/L h 0.01 9 
standard errors). (These means and standard errors are the untransformed concentrations 
for methadone and are given in mg/L units.) Because the ME and the DUI datasets are 
statistically significantly different from each other, there is not sufficient evidence to 
suggest tolerances to methadone. 
Plot of the Means 
Log-transformed concentrations of methadone 
-2.4 -I I 
dui me 
Source Dataset 
Figure 57: Plot of the means for "database" field for log-transformed methadone 
A residual by predicted plot was constructed (Appendix C) from the model with 
only the field for the source datasets. This plot verified the constant variance assumption 
and did not show any systematic pattern of the residuals with the predicted values that 
would imply any inadequacy with the model did not fit. A normal quantile plot of the 
residuals from this model was also constructed and can be seen in Appendix C. This plot 
shows that the assumption of normality for the residuals is met because the residuals 
follow the diagonal. 
The clinically determined fatal blood concentration for methadone ranges from 0.4 
to 1.8 m g , , ~ ~ ~ .  Using this as the guideline to determine whether there are any interesting 
DUI cases with high levels of methadone, 14 individuals (in the DUI dataset) were found 
to have a concentration of methadone that fell within the "lethal" concentration; this is 
visible on the box plots in Figures 53, 54, and 56 where data points for the DUI dataset fall 
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within this clinically defined range. These cases offer some evidence, regardless of the 
results of the analysis, that it is possible to develop a tolerance to methadone; these 14 
individuals have "lethal" doses of methadone in their systems and are still attempting to 
operate a motor vehicle. 
3.3.6 Morphine (Level 11) 
"Morphine is the naturally occumng substance in the opium poppy, Papaver 
Somniferous. It is a potent narcotic analgesic, and its primary clinical use is in the 
management of moderately severe and severe pain. After heroin, morphine has the greatest 
dependence liability of the narcotic analgesics in common use"33. It is thought that regular 
use of morphine can result in developing tolerances to the drug33. 
The morphine dataset consisted of the individuals testing positive for morphine and 
contained 742'cases and 577 variable fields. The morphine dataset was divided into the 
same three types of drug pattern groups as the other drugs: morphine only, morphine and 
ethanol, and morphine with any other combination of drugs. These drug pattern groups 
were used to compare the concentration of morphine between the ME and DUI datasets and 
among the three drug pattern groups. The number of observations in each of the three drug 
pattern groups is seen in Table 15. The ME dataset contributed 61 1 cases to the morphine 
dataset, while the DUI dataset contributed 13 1 cases. From the numbers in Table 15, it is 
obvious that none of the categories had less than 12 cases in them, so no drug pattern 
groups were combined or removed for analysis of the morphine dataset. The demographics 
of a g e ,  g e n d e r ,  and race, are broken down by drug pattern group and dataset in Table 
16. 
Table 15: Number of Observations for Categories in the Morphine Dataset 
Table 16: Demographics on the Morphine Dataset 
Group 
1 
(morphine only) 
2 
(morphine and ethanol) 
3 
(any other combination with 
morphme) 
Total 
The normal quantile plots for the concentrations of morphine by drug pattern group 
and by source dataset showed non-normal distributions, so a log transformation was used 
for the concentration of morphine. The normal quantile plots seen in the following figures 
show both the untransformed data and the log-transformed data. Figures 5 8 , 5 9 ,  and 60 
show the untransformed and log-transformed box plots for the DUI dataset for Groups 1,2, 
and 3. The box plots for the ME dataset are seen in Figures 61,62, and 63. 
ME 
143 
50 
418 
61 1 
DUI 
25 
3 5 
7 1 
131 
Race 
Source Dataset 
Drug Pattern 
Group 
White 
Black 
ME 
1 
-- 
-- 
-- 
DUI 
1 
15 
(1 1.5%) 
2 
(1.5%) 
0 
2 
-- 
-- 
-- 
3 
-- 
-- 
-- 
2 
16 
(12.2%) 
3 
(2.3%) 
0 
143 
(23.4%) 
3 
3 7 
(28.2%) 
9 
(6.9%) 
0 
Gender 
50 
(8.2%) 
47 
(7.7%) 
3 
(0.5%) 
0 
--- 
19-59 
0 
Age (in years) Range 20-76 
Male 
Female 
--
119 
(19.5%) 
24 
(3.9%) 
300 
(49.1%) 
118 
(19.3%) 
0 
15-69 18-54 18-49 16-59 
10 
(7.6%) 
7 
(5.3%) 
15 
(1 1.5%) 
4 
(3.1%) 
3 8 
(29%) 
8 
(6.1%) 
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Figure 58: Normal quantile plots for DUI Group 1 (morphine only) before and after log 
transformation 
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Figure 59: Normal quantile plots for DUI Group 2 (morphine and ethanol) before and after log 
transformation 
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Figure 60: Normal quantile plots for DUI Group 3 (morphine with any other combination of drug) 
before and after log transformation 
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Figure 61: Normal quantile plots for ME Group 1 (morphine only) before and after log transformation 
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Figure 62: Normal quantile plots for ME Group 2 (morphine and ethanol) before and after log 
transformation 
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Figure 63: Normal quantile plots for ME Group 3 (morphine with any other combination of drug) 
before and after log transformation 
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The next section of figures shows the pairs of box plots for each of three drug 
pattern groups and compares the ME and DUI datasets. The set of box plots for Group 1 
(morphine only) is seen in Figure 64. Figures 66 and 68 show the set of box plots for 
Group 2 and Group 3, for the DUI and ME datasets before and after the log 
transformation. For each of the three drug pattern groups, an expanded version of the 
untransformed DUI data is displayed to better view the details of the box plot. 
DUI 
Group 1 
Morphine 
Log transformed 
-2 
-3 
-4 
-5 - 
Group 1 
Morphine 
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-2 
-3 
-4 
-5 
DUI 
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Morphine 
ME 
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Morphine 
Figure 64: Box plots for Group 1 (morphine only) for DUI and ME - log-transformed and 
untransformed data 
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Morphine 
Ex~anded 
Figure 65: Expanded box plot for DUI Group 1 (morphine only) - untransformed data 
The mean for Group 1 for the ME dataset is -1.52 log (mg/L) units (k 0.089 
standard errors) [0.22 mg/L], and the mean for Group 1 for the DUI dataset is -3.01 log 
(mg/L) units (* 0.193 standard errors) [0.05 mg/L]. The range for the ME dataset for this 
group is from -4.605 log (mg/L) units [0.01 mg/L] to 1.435 log (mg/L) units [4.2 mg/L], 
while the range for the DUI dataset is from -4.605 log (mg/L) units [0.01 mg/L] to -0.616 
log (mg/L) units [0.54 mg/L]. Both datasets have the same lower boundary for the range, 
but the ME dataset spans a much larger region than the DUI dataset. 
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Figure 66: Box 
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ME 
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Figure 657: Expanded box plot for DUI Group 2 (morphine and ethanol) - untransformed data 
Group 2 has a mean of - 1.903 log (mg/L) units (f 0.109  standard errors) [O. 15 
mgIL] for the ME dataset and a mean of -3.492 log (mg/L) units (* 0.139 standard errors) 
[0.03 mg/L] for the DUI dataset. The range of .the ME da'taset is from -3.912 log (mg/L) 
104 
units [0.02 m a ]  to 0.182  log (mg/L) units [I .  1 2  mg/L], and the range for the DUI dataset 
is fiom -5.298 log (mg/L) units [0.005 mg/L] to -2.408 log (mg/L) units [0.09 mg/L]. The 
range for the DUI dataset starts at a lower concentration, but it also has a lower maximum 
log concentration than the ME dataset. 
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Figure 68: Box plots for Group 3 (morphine with any other combination of drug) for DUI and ME - 
log-transformed and untransformed data 
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Figure 69: Expanded box plot for DUI Group 3 (morphine with any other combination of drug) - 
untransformed data 
The means for Group 3 for the ME and DUI datasets are -2.047 log (mg/L) units (* 
0.05 standard errors) C0.129 mg/L] and -3.657 log (mg/L) units (* 0.11 8 standard errors) 
[0.026 mg/L], respectively. The range for the ME dataset for this group is from -6.075 log 
(mg/L) units [0.0023 mg/L] to 2.079 log (mg/L) units [8 mgIL]. The DUI dataset had a 
smaller range than the range for the ME dataset, and it was from -5.298 log (mg/L) units 
[0.005 mg/L] to 0 log (mg/L) units 11.0 mg/L]. (The means and ranges reported in the 
previous sections canie from the log-transformed concentrations for morphine and by 
untransforming these values; they are not necessarily the same as the means of the 
untransfonned concentrations of morphine seen in Table 17.) 
An ANOVA model was run on the log-transformed data for the concentration of 
morphine. Upon running the model, the interaction term was not determined to be 
significant (p-value = 0.897), so it was removed from the model. After the interaction term 
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was removed, the two independent fields, group and d a t a b a s e ,  were both determined 
to be significant (p-values both less than 0.0001); therefore, there is a statistically 
significant difference between the ME and DUI datasets and a statistically significant 
difference between at least two of the three drug pattern groups. The plots of the means for 
each of these variable fields are seen in Figures 70 and 71. In Figure 70, the plot shows 
that the concentration of morphine is statistically higher for the ME dataset than for the 
DUI dataset. Because the ME and DUI datasets have significantly different means, there is 
not sufficient evidence to suggest of development of tolerance to morphine. The ANOVA 
indicated that there was a significant difference between the levels of the drug pattern 
groups, but it does not specify which differences between the means of the drug pattern 
groups are statistically significantly different. A Tukey's test was done to test for all 
painvise differences, and the results of this test are seen in Table 17 wh.ere levels not 
connected by the same letter are significantly different. Group 1 is different from both 
Groups 2 and 3, but Groups 2 and 3 are not different from each other. (The values for the 
means seen in Table 17 are of the untransformed, or raw, concentrations of morphine, and 
they are reported in mg/L units.) 
Plot of the Means 
Log-transformed concentrations of morphine 
-3.6 
dui 
Source Dataset 
Figure 70: Plot of the means for "database" field for log-transformed morphine 
Plot of the Means 
Log-transformed concentration of morphine 
morphine only morphine and ethanol poiy pharmacy 
Drug Pattern Group 
Figure 71: Plot of the means for "group" field for log-transformed morphine 
Table 17: Levels of drug pattern groups for morphine from Tukey's test 
The residual by predicted plot shows that the constant variance assumption is met 
and that there does not show a systematic pattern. There also does not seem to be any 
inadequacy with the ANOVA model. A normal quantile plot of the residuals for the fitted 
model was also constructed (Appendix C). This plot showed no obvious problems with the 
norniality assumption as the residuals followed the diagonal in the plot. 
There is not an exact range of concentration for morphine that clinicians have 
determined "fatal", so there is no definite way to know if there are individuals in the DUI 
dataset that had a concentration of morphine that would be termed be "lethal". Since there 
was a difference in the drug pattern groups in the ANOVA model, it implies that the 
concentration of morphine varies depending on whether the individual had morphine only 
or morphine with any drug. (Groups 2 and 3 were not statistically significantly different 
from each other). Because the database field was significant, then there is a significant 
statistical difference between the ME and DUI datasets, with the ME dataset having a 
higher concentration of morphine. 
3.4 Conclusions 
Based on the evidence provided by the ANOVA models discussed in the previous 
sections, there is not sufficient evidence to suggest the development of tolerances to 
diphenhydramine, cocaine, oxycodone, hydrocodone, methadone, or morphine. The only 
Group 
Group 1 
Group 2 
Group 3 
~ e t t e r  
A 
B 
B 
Mean(Std. Error) 
0.322(0.034) 
0.134(0.018) 
0.207(0.022) 
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exception to this is in the methadone dataset, where 14 individuals from the DUI dataset 
had "lethal" concentrations of methadone (determined by clinical evidence). Because there 
is not sufficient evidence for the development of tolerances with the ANOVA models does 
not imply that tolerances cannot be developed for any of these drugs. The collection of and 
data contained in the ME and DUI datasets do not provide adequate information to fully 
answer the question of tolerance with respect to these drugs. One of the reasons that the 
DUI dataset does not provide adequate information is because of the underestimation bias 
due to the tier system. This is a downward bias that underestimates the number of drugs 
found in persons suspected of DUI, which may have been a cause as to why the source 
datasets were determined to be statistically significantly different. The analyses of these 
six drug-specific datasets did provide selected cases that might be of interest to analyze 
further for case studies. These cases included the fourteen individuals in the DUI dataset 
with "lethal" concentrations of methadone in their system, the infant with an oxycodone 
death, the case in the ME dataset with a concentration of hydrocodone of 0.0003 mg/L, and 
the individuals in the ME dataset with diphenhydrarnine and cocaine concentrations higher 
than the upper boundary of the clinical "fatal" blood concentration. All of these cases 
would be of further interest to study for specific case analyses. 
CHAPTER 4 
Recommendations and Future Work 
4.1 Summary of Project 
The datasets used for this project came from the Office of the Chief Medical 
Examiner (ME dataset) and the Department of Forensic Science (DUI datasets). The 
original goals for this project were to investigate concentrations of THC in order to provide 
information to the Virginia General Assembly for the purpose of enacting legislation 
similar to that for ethanol intoxication. This informa.tion was anticipated to pertain to THC 
concentration in drivers, to concentrations of THC that "intoxicate" individuals, how 
ethanol affects THC, and to see if combinations of multiple drugs have additive affects. 
Unfortunately, due to the form of the database, the data collection procedures, and the 
overall quality of .the data, this goal was unable to be achieved. Because the original goals 
could not be met, secondary objectives were set for this project. The new goals included 
comparing the concentrations of diphenhydramine, cocaine, oxycodone, hydrocodone, 
methadone, and morphine between the ME and DUI datasets and between three groups: 
drug only, drug and ethanol, or drug with any other combination of drug. The motivation 
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for this analysis was to investigate the possibility that some individuals in the DUI dataset 
have developed tolerances to some of these drugs to the point that the amount in their 
system approximates the amount that would be considered a lethal concentration for most 
individuals. 
The first part of this thesis includes a description of each of the datasets and the 
modifications made to use them in analysis. Attempts were made to identify and correct 
all prob1em.s with these datasets in order to address the research questions. These problems 
in the datasets included changing character fields to numeric fields, correcting grammatical 
errors, addressing the missing data and underestimation issues, and creating new variable 
fields needed for analysis. Multiplechanges had to be made to existing data fields in order 
to combine the data across the various datasets to allow the data analysis. 
Once these changes were made to the datasets, a two-factor ANOVA was done to 
look for differences between the ME and DUI datasets and between the drug pattern 
groups created to divide each drug dataset. It was stated a priori that if the source datasets 
were not significantly different or if the concentrations in DUI dataset tended to be higher 
than the cases in the ME dataset, then this would constitute evidence to suggest that 
individuals in the DUI dataset that have built up tolerances to the drugs. 
In the analyses of the six drug datasets, all of the datasets showed that the 
database field was significant, implying that the two datasets had statistically 
significant differences with respect to the drug concentration levels. Thus, there was no 
evidence to suggest that individuals in the DUI datasets had developed tolerances to any of 
.the six drugs. In. all of the datasets, except for morphine, the drug pattern group variable 
11 1 
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field wa.s significant, meaning that depending on whether an individual had the drug only, 
the drug and ethanol, or the drug with any other combination of drug, the concentration for 
that drug would vary. The analyses did not provide any evidence to support the original 
hypothesis, but they did pinpoint some individuals in the DUI and ME datasets that might 
be of further interest in a case study. 
The main outcome of the project was that the datasets were unable to establish 
evidence of tolerance. This does not mean that those stopped for DUI do not have a 
tolerance to the six drugs studied, just that the analysis did not show any evidence for it. 
Several reasons are possible for this result, including that the DUI dataset was collected 
based on a tier system, and thus, not all concentrations for all drug were recorded in the 
dataset. The tier system creates mean concentrations that are biased downward (number of 
drugs and concentrations of drugs were all underestimated). Suggestions and 
recommendations will be made in the next section (Section 4.2) on how to change the 
datasets and data collection procedures in order to possibly allow the question of tolerance 
to be answered with a future dataset. Some of these changes are already being 
implemented into the ME database, and others will be given the OCME to suggest other 
ways to improve their data quality. 
4.2 Recommendations for Change 
On average, one out of every eight death certificates in Virginia is sent back to the 
medical examiner because it is "~ninterpretable"~~. This is evidence of the problems in the 
ME dataset. Another reason that the ME dataset had problems is because of the number of 
people who enter the information into the database. At this time, there are no rules 
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concerning how the data is entered or who enters it. Most of the fields in this database are 
free text fields, which allows for any character, number, or symbol to be entered into this 
field. If .the database was reorganized so that it had drop-down menus instead of free text 
fields, many of the free-text problems would be eliminated. For example, in the cause 
of death field, instead of having a free text field where an unlimited number of 
characters or words can be entered, a menu that allows the data entry person to choose 
from "drug overdose", "lethal injection", "drowning", "fall", "gunshot wound", etc., would 
be more beneficial for analysis than the current design of the database. Eliminating free 
text fields would ensure that all entries into the database are standardized - a more usefbl 
form for analysis. The DUI datasetsdid not have many free text problems, but a drop- 
down menu for drugs or concentration amounts would be beneficial and a time-saving 
technique for future use of the dataset. 
The DUI dataset is currently designed to test blood samples using the tier system 
described in Chapter 2. Because of the tier system, all drugs except ethanol are 
underestimated in the DUI dataset. The tier system was designed to save time and money 
for the state laboratories that do the analysis of the blood samples, and once a drug is found 
at a concentration high enough for conviction, then no other drugs are tested. To avoid the 
underestimation problem in the future, a random sample of blood samples from DUI 
suspects could be tested for all possible drugs. Thus, the drug coiicentrations from those in 
the random sample would not be underestimated. This data could then be used to give a 
better idea of the number of people in Virginia that drive under the influence of drugs, and 
to have a fuller range of the drugs that are being used across the state. 
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The Commonwealth of Virginia sends all death certificate information to the 
National Center for Health Statistics where the death certificates are used to generate 
National Death Index (NDI) codes. Currently, the OCME does not automatically receive 
these death codes, unless they specifically request them for research purposes. One 
suggestion for the OCME is to request these codes regularly and incorporate them into the 
ME database so that when research projects are being done, no fiuther categorization on 
cause of death fields has to be done. Having the NDI codes would allow researchers 
to compare Virginia death statistics nationally or with specific states. 
Another recommendation for the ME database is to attempt to detect the drugs in a 
consistent manner, i.e. in the same tissues. Usually, if the drug was detected in a tissue 
other than blood, it was because a blood sample was not available or more information was 
needed regarding the nature of the dea.th (i.e. suicide vs. accident120. If a standard system 
existed for routinely testing drugs in specific tissues, then fewer cases would be lost when 
trying to compare datasets. If a drug was tested and detected in the brain tissue, but not in 
blood, then that individual was not included in the analysis for this project because it is 
extremely problematic to convert brain concentrations to blood concentrations for analysis. 
Another solution to this problem is to have a reference tool designed that allows drug 
concentrations from one tissue to be converted into an equivalent amount for the tissue 
desired. This solution would be difficult because the clinical evidence for finding 
equivalent concentrations is inconclusive. 
In the DUI dataset, the data collected does not provide the information needed to 
check for individuals appearing in the dataset more than once. To fix this problem, the 
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DUI dataset should collect and keep cross-referencing information to look for these 
individuals. This information could be a combination of driver's license number, social 
security number, date of birth, or full name. Keeping this information would help in 
analysis to verify the independence assumption. 
Some of the changes that have been suggested are currently being made to the ME 
dataset. The OCME is reorganizing their database to be more "user-friendly" (including 
using drop-down menus), and the Chief Medical Examiner, Dr. Marcella Fierro, sent a 
statewide message to medical examiners concerning the consistency of their reporting3'. 
"Furthermore, they are writing an SOP [Standard Operating Procedure] for the MEs to 
fo l l o~"~ '  because of what this project uncovered. 
4.3 Future Work 
There are many questions that were left unanswered at the end of this project, and 
they are all ideas for future work with the ME and DUI datasets. One proposal is to use 
the location information ( c o u r t  name or place o f  d e a t h )  to look at prevalence of 
drugs in certain regions of Virginia. This information could be displayed by means of a 
map with certain areas highlighted that show problem areas for specific drugs, displaying 
the number of drugs found in a certain area, or the ratio of the number of drugs found to 
the number of people (or children) in an area. 
Another suggestion for future work is to redo the analysis done in this thesis, but 
without using the tier system mentioned in Section 2.2.5. To have more accurate results, a 
random sample of DUI suspects is needed that tests the blood samples for all possible 
drugs. By doing this, the blood concentration data for the DUI dataset would not be 
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underestimated. An alternative way to do this analysis would be to answer the question 
"Are the two source datasets equivalent when it comes to the selected drugs?" This was 
perhaps a better way to do this study. 
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APPENDIX A 
Testing Protocol for Drugs in the DUI Dataset 
FEE SCHEDULE FOR APPROVED LABORATORY ANALYSES 
OF BLOOD FOR ALCOHOJ, AND DRUGS 
ALLOWED FEES 
Level I Alcohol Testing $50 
Level I1 Drug Screening $50 
Drug IdentificatiodQuantitation $75 I Drug Class * 
Level 111 Drug Screening $50 
Drug IdentificationQuantitation $75 I Drug Class * 
* Includes results for all drugs reported in a class 
ANALYTICAL SCHEME 
All analyses shall be for the unconiu~ated (free) form of drugs. 
1. Analyze all samples for ethanol (Alcohol screening may be performed, if desired, using immunoassay.) 
a. If ethanol is less than 0.09%, include it in the report, and go to 2. 
b. If ethanol is at or above 0.09%, stop; report results. 
2. Perform Level I1 Drug Screening: 
a. If no drug classes are detected, go to 4. 
b. If any drug is tentatively present at or above the reporting limit, go to 3. 
3. Perform Level I1 IdentificatiodQuantitation: 
a. If no drugs are present, or are identified as present but at a concentration below the reporting limit, go 
to 4. 
b. If drugs are identified as present at a concentration at or above the reporting limit, but below the stop 
analysis limit, include them in the report, and go to 4. 
c. If drugs are identified as present at a concentration at or above the stop analysis limit, stop; report 
results. 
4. Perform Level 111 Screening: 
a. If any drug is tentatively identified as present, go to 5. 
b. If no drugs are present, stop; report results. 
5. Perform Level I11 IdentificationtQuantitation: 
a. Report results. 
ANALYTICAL LIMITS 
Level I Alcohol Testing (Limits are in units of % by weight by volume) 
LIMIT LIMIT** 
Ethanol 
'* Do not proceed further in the analytical scheme when results at or above this concentration 
are obtained. 
Level I1 Drug Screening and IdentificationIQuantitation (Limits are in units of mg/L) 
I- SCREENING 
DRUG CLASS DRUG 
I 
Amphetamine 1 Amphetamine 
( Methylenedioxyamphetamine 
Barbiturate ( Amobarbital 
Cocaine1 
Benzoylecgonine 
Benzodiazepine 
Butabarbital 
Butalbital 
Pentobarbital 
Phenobarbital 
Secobarbital 
Cocaine 
Benzoylecgonine 
Cocaethylene 
Alprazolam 
Chlordiazepoxide 
Clonazepam 
Diazepam 
Lorazepam 
n-Desalky lflurazepam 
Nordiazepam 
Oxazepam I ~ e m a z e ~ a m  
Cannabinoid I Tetrahydrocannabinol 
Hydrocodone 
Morphine 
6-Acetylmorphme 
I Oxycodone 
** Do not proceed further in the analytical scheme when results 
REPORTING I STOP ANALYSIS 
LIMIT LIMIT ** 
0.01 0.1 
0.02 0.06 
t or above this concentration are 
obtained. 
Level I11 Drug Identification/Quantitation (Limits are in units of mg/L) 
DRUG CLASS 
Antih~stamine 
Antidepressant, 
Antipsychotic 
Hypnotic 
Muscle Relaxant 
Opiate/ 
Opiate-like 
Ketamine 
Phencyclidine 
DRUG 
Chlorphenirarnine 
Brompheniramine 
Dextromethorphan 
Diphenhydramine 
Promethazine 
Amitriptyline 
Buproprion 
Clomipramine 
Clozapine 
Desipramine 
Doxepin 
Haloperidol 
Imipramine 
Mirtazapine 
Nortriptyline 
Nordoxepin 
Trazodone 
Zolpidem 
Carisoprodol 
Meprobamate 
Methocarbamol 
Cyclobenzaprine 
Dlhydrocodeine 
Hydromorphone 
Oxyrnorphone 
Meperidine 
Methadone 
Pentazocine 
Propoxyphene 
Tramadol 
Ketamine 
Phencyclidine 
REPORTING 
LIMIT 
0.02 
0.02 
0.1 
0.02 
0.02 
0.05 
0.05 
0.05 
0.05 
0.05 
0.05 
0.02 
0.05 
0.02 
0.05 
0.05 
0.05 
0.02 
1 
1 
1 
0.02 
0.02 
0.02 
0.02 
0.02 
0.02 
0.02 
0.02 
0.02 
0.05 
0.01 
Appendix B 
Flow Chart of Exclusion Criteria 
ME Dataset (I? 
Toxicologicai Screen 
Done During Autopsy? 
L I 
DUI Drug Dataset 
I 
1 Cause of Death deals with Dn.  Poisoning? 
70 Excluded  ME Dataset 0 
Combined Dataset 
14,479 
Drug found in system and included based a clinical 
decision by Dr. Saady 
Appendix C 
Analyses of the Residuals 
Residual by Predicted Plot for diohenhvdramine 
Predicted 
I 
Figure 66c: Residual by predicted plot for diphenhydramine 
Normal Quantile Plot of Residuals - diphenhydramine 
-3 -2 -1 0 1 2 
Normal Quantile Plot 
-- 
Figure 67c: Normal quantile plot of residuals for diphenhydramine 
Residual by Predicted Plot for cocaine 
I 
I Predicted I 
Figure 68c: Residual by predicted plot for cocaine 
Normal Ouantile Plot of Residuals - cocaine 
I Normal Quantile Plot I 
Figure 69c: Normal quantile plot of residuals for cocaine 
Residual by Predicted Plot for oxycodone 
I 1 
Predicted 
Figure 70c: Residual by predicted plot for oxycodone 
Normal Quantile Plot of Residuals - oxycodone 
Normal Quantile Plot 
Figure 71c: Normal quantile plot of residuals for oxycodone 
Residual by Predicted Plot for hydrocodone 
I Predicted I 
Figure 72c: Residual by predicted plot for hydrocodone 
Normal Quantile Plot of Residuals - hydrocodone 
3- , . .  
I Normal Quantile Plot I 
Figure 73c: Normal quantile plot of residuals for hydrocodone 
Residual by Predicted Plot for methadone 
Predicted 
Figure 74c: Residual by predicted plot for methadone 
Normal Ouantile Plot of Residuals - methadone 
-3 -2 -1 0 1 2 
Normal Quantile Plot 
Figure 75c: Normal quantile plot of residuals for methadone 
Residual bv Predicted Plot for momhine 
-6 -5 -4 -3 -2 -1  0 1 2 
Predicted 
-- -- 
Figure 76c: Residual by predicted plot for morphine 
I Normal Quantile Plot 
Figure 77c: Normal quantile plot of residuals for morphine 
Appendix D 
SAS Code 
libname thesis 'C:\Documents and Settings\Owner\Desktopl; 
*ME DATABASE; 
*Import the JMP file - from the Excel file; 
PROC IMPORT OUT= thesis.ME1 
DATAFILE= "E:\Thesis Files\MEoriginal.jmpl' 
DBMS=JMP REPLACE; 
RUN; 
proc freq data = thesis.me1; 
tables fatality premise-of-death; 
run ; 
/*Combine asphyxia, poisoning, vehicular fatality groups and combine 
premise of death street, house, water, and hospital groups*/ 
data thesis.meclean1; 
set thesis.me1; 
attrib fatalnew format=$58.; 
attrib premisenew format=$19.; 
if fatality = 'ASPHYXIA: ASPIRATION/CAFE CORONARY' I fatality = 
'ASPHYXIA: MECHANICAL/POSITIONAL1 1 fatality = 
'ASPHYXIA: PLASTIC BAG' then fatalnew = 'Asphyxia'; 
else if fatality = 'POISONING: CARBON MONOXIDE (FAULTY HEATER)' I 
fatality = 'POISONING: CARBON MONOXIDE (FIRE SMOKE 
INHALATION) ' I fatality = 'POISONING: CARBON MONOXIDE 
(GENERATOR)' ( fatality = 'POISONING: CARBON MONOXIDE (MOTOR 
VEHICLE EXHAUST)' then fatalnew = 'CO poisoning'; 
else if fatality = 'POISONING: ALCOHOL-ETHANOL' I fatality = 
'POISONING: DRUGS, OTHER POISONS' I fatality = 
'POISONING: OTHER ALCOHOLS' then fatalnew = 
'Drug Poisoning'; 
else if fatality = 'VEHICULAR: AUTO/TRUCK (DRIVER)' I fatality = 
'VEHICULAR: AUTO/TRUCK (PASSENGER)' I 
fatality = 'VEHICULAR: AUTO/TRUCK (PEDESTRIAN)' 
then fatalnew = 'Vechicle'; 
else fatalnew = fatality; 
if premise-of-death = 'STREET: ADJACEN' I premise-of-death = 
'STREET: ALLEY' 1 premise-of-death = 'STREET: BRIDGE' I 
premise-of-death = 'STREET: DITCH' I premise-of-death = 
'STREET: DRIVEWA' I premise-of-death = 'STREET: HIGHWAY' I 
premise-of-death = 'STREET: INTERST' I premise-of-death = 
'STREET: NONSPEC' 1 premise-of-death = 'STREET: PARKING1 I 
premise-of-death = 'STREET: SIDEWAL' then premisenew = 
'Street' ;
else if premise-of-death = 'WATER: LAKE' ( premise-of-death = 
'WATER: OTHER' then premisenew = 'Water'; 
else if premise-of-death = 'HOME: APARTMENT' I premise-of-death = 
'HOME: GARAGE/SHf I premise-of-death = 'HOME: HOUSE/RES1 ( 
premise-of-death = 'HOME: NONSPECIF' I premise-of-death = 
'HOME: TRAILER' I premise-of-death = 'HOME: YARD/PORC1 
then premisenew = 'Home'; 
else if premise-of-death = 'HOSPITAL/INPATIf 1 
premise-of-death = 'HOSPITAL/MENTAL1 ( premise-of-death = 
'HOSPITAL/OUTPAT' then premisenew = 'Hospital'; 
else premisenew = premise-of-death; 
drop premise-of-death fatality; 
*Remove all double spaces and any periods at the end; 
index = find(cause-of-death, ' I ,  'il); 
new = substrn(cause-of-death, 1, index) I I 
substrn(cause-of-death, index+2, length(cause-of-death)); 
cause-of-death = new; 
new2 = cause-of-death; 
end = length(cause-of-death); 
str = substrn(new2,end); 
if str eq ' . '  then per = 1; 
else per = 0; 
if per = 1 then substr(new2, end) = "; 
cause-of-death = new2; 
drop index new new2 per str end; 
*Fixing drug names to match in both datasets; 
if drug-s- = "METHYLENEDIOXYAMPHETAMINE" then drug-s- = "MDA"; 
if drug-s- = "METHYLENEDIOXYMETHAMPHETAMINE" then drug-s- = 
" MDMA " ; 
if drug-s- = "BENZOYL ECGONINE" then drug-s- = "BENZOYLECGONINE"; 
if drug-s- = "DESOXYCHLORDIAZEPOXIDE" then drug-s- = 
" CHLORDIAZEPOXIDE" ; 
if drug-s- = "MONOACETYLMORPHINE" then drug-s- = "ACETYLMORPHINE"; 
if drug-s- = "BUPROPION (WELLBUTRIN)" then drug-s- = "BUPROPION"; 
attrib gender format = $4.; 
if sex = 'FEMALE' then gender = 'F'; 
else if sex = 'MALE' then gender = 'MI; 
else if sex = 'NULL' then gender = 'N'; 
else gender = "; 
*so that blood will come first alphabetically (or last - 
descending); 
if bac = 'BLOOD(P0ST) ' then bac = 'aBLOOD(P0ST) ' ;  
if bac = 'BLOOD(PRE) ' then bac = 'bBLOOD(PRE) ' ;  
if bac = 'BILE' then bac = 'cBILE'; 
if bac = 'LIVER' then bac = 'dLIVERf; 
if bac = 'URINE' then bac = 'eURINE1; 
if bac = 'GASTRIC' then bac = '£GASTRIC1; 
if bac = 'VITREOUS' then bac = 'gVITREOUS1; 
if bac = 'BRAIN' then bac = 'hBRAINt; 
drug = drug-s-; 
attrib database format = $3.; 
database = 'me'; 
attrib presence format = $31.; 
presence = "; 
*Count will keep track of the number of grammatical fixes 
for each observation; 
count = 0: 
drop sex drug-s-; 
run ; 
proc freq data=thesis.mecleanl; 
tables fatalnew premisenew; 
run ; 
/*match tissues to correct drug & fix cause of death misspellings 
and create units of measurement*/ 
data thesis.metissues; 
set thesis .mecleanl; 
if drug = 'ETHANOL' then unit = 'Grams%'; 
else if bac = 'aBLOOD(P0ST) ' I bac = '£GASTRIC1 I bac = 'gVITREOUS1 
I bac = 'bBLOOD(PRE)' I bac = 'eURINEt then unit = 'mg/L1; 
else if bac = 'dLIVER1 I bac = 'cBILE' I bac = 'hBRAIN1 then unit = 
'mg/kgq ;
else unit = "; 
index = find(cause-of-death, 'AMTRIPTYLINE', 'it); 
if index ne 0 then do; 
temp = substrn(cause~of~death,l,index-1) I I 
'AMITRIPTYLINE' I I 
substrn(cause~of~death,index+l2,length(cause~of~death) ) ;  
count = count + 1; 
end ; 
else temp = cause-of-death; 
cause-of-death = temp; 
index = find(cause-of-death, 'INTOXICIATION', 'i'); 
if index ne 0 then do; 
temp = substrn(cause~of~death,l,index-1) I I 
'INTOXICATION' I I 
substrn(cause~of~death,index+l3,length(cause~of~death) ) ;  
count = count + 1; 
end; 
else temp = cause-of-death; 
cause-of-death = temp; 
index = find(cause-of-death, 'INTOXICATIKON', 'i'); 
if index ne 0 then do; 
temp = substrn(cause-of-death,l,index-1) ( I  
'INTOXICATION' I  ( 
substrn(cause~of~death,index+l3,length(cause~of~death)); 
count = count + 1; 
end ; 
else temp = cause-of-death; 
cause-of-death = temp; 
index = find(cause-of-death, 'POINSONING', 'i'); 
if index ne 0 then do; 
temp = substrn(cause-of-death,l,index-1) I  I  
'POISONING' I  I  
substrn(cause~of~death,index+l0,length(cause~of~death)); 
count = count + 1; 
end ; 
else temp = cause-of-death; 
cause-of-death = temp; 
index = find(cause-of-death, 'POISIONING', 'i'); 
if index ne 0 then do; 
temp = substrn(cause-of-death,l,index-1) I  I  
'POISONING' 1 I  
substrn(cause~of~death,index+l0,length(cause~of~death) ) ;  
count = count + 1; 
end ; 
else temp = cause-of-death; 
cause-of-death = temp; 
index = find(cause-of-death, 'HOUSE FIRE', 'i'); 
if index ne 0 then do; 
temp = substrn(cause-of-death,l,index-1) ( 1  
'HOUSEFIRE' ( 1  
substrn(cause~of~death,index+l0,length(cause~of~death)); 
count = count + 1; 
end ; 
else temp = cause-of-death; 
cause-of-death = temp; 
index = find(cause-of-death, 'HERION', 'i'); 
if index ne 0 then do; 
temp = substrn(cause-of-death,l,index-1) I  I  
'HEROIN' 1 )  
substrn(cause~of~death,index+6,length(cause~of~death)); 
count = count + 1; 
end ; 
else temp = cause-of-death; 
cause-of-death = temp; 
index = find(cause-of-death, 'HERION', 'i'); 
if index ne 0 then do; 
temp = substrn(cause~of~death,l,index-1) I I 
'HEROIN' I I 
substrn(cause~of~death,index+6,length(cause~of~death)); 
count = count + 1; 
end ; 
else temp = cause-of-death; 
cause-of-death = temp; 
index = find(cause-of-death, 'HREOIN', 'i'); 
if index ne 0 then do; 
temp = substrn(cause~of~death,l,index-1) I I
'HEROIN' ( 1  
substrn(cause~of~death,index+6,length(cause~of~death) ) ;  
count = count + 1; 
end ; 
else temp = cause-of-death; 
cause-of-death = temp; 
index = find(cause-of-death, 'HEROIN, POISONING ' ,  'it); 
if index ne 0 then do; 
temp = substrn(cause~of~death,l,index-1) I I 
'HEROIN POISONING' 1 ( 
substrn(cause~of~death,index+l8,length(cause~of~death)); 
count = count + 1; 
end ; 
else temp = cause-of-death; 
cause-of-.-death = temp; 
index = find(cause-of-death, 'LIKELY ' ,  'i'); 
if index ne 0 then do; 
temp = substrn(cause~of~death,l,index-1) I I 
'LIKELY,' I I 
substrn(cause~of~death,index+7,length(cause~of~death)); 
count = count + 1; 
end ; 
else temp = cause-of-death; 
cause-of-death = temp; 
index = find(cause-of-death, 'AND', 'i'); 
if index ne 0 then do; 
temp = substrn(cause~of~death,l,index-1) I I 
' & '  I I 
substrn(cause~of~death,index+3,length(cause~of~death)); 
count = count + 1; 
end ; 
else temp = cause-of-death; 
cause-of-death = temp; 
*Occurs more than once - see comment below; 
index = find(cause-of-death, 'AND', 'i'); 
if index ne 0 then do; 
temp = substrn(cause~of~death,l,index-1) I I 
' & '  I  I  
substrn(cause~of~death,index+3,length(cause~of~death) ) ;  
count = count + 1; 
end ; 
else temp = cause-of-death; 
cause-of-death = temp; 
index = find(cause-of-death, 'DUE TO', 'i'); 
if index ne 0 then do; 
temp = substrn(cause~of~death,l,index-1) ( I  
'D/T' I  ( 
substrn(cause~of~death,index+6,length(cause~of~death) ) ;  
count = count + 1; 
end ; 
else temp = cause-of-death; 
cause-of-death = temp; 
*if 'DUE TO' occurred more than once, find only picks up the 
first time; 
index = find(cause-of-death, 'DUE TO', 'i'); 
if index ne 0 then do; 
temp = substrn(cause~of~death,l,index-1) I I  
'D/T8 I I  
substrn(cause~of~death,index+6,length(cause~of~death)); 
count = count + 1; 
end ; 
else temp = cause-of-death; 
cause-of-death = temp; 
index = find(cause-of-death, 'D/T TO', 'i'); 
if index ne 0 then do; 
temp = substrn.(cause~of~death,l,index-1) 1 )  
'D/T1 1 )  
substrn(cause~of~death,index+6,length(cause~of~death) 1 ;  
count = count + 1; 
end ; 
else temp = cause-of-death; 
cause-of-death = temp; 
index = find(cause-of-death, ' ,  & ' ,  'i'); 
if index ne 0 then do; 
temp = substrn(cause-of-death,l,index-1) I  I 
' & ' I 1  
substrn(cause~of~death,index+4,length(cause~of~death)); 
count = count + 1; 
end ; 
else temp = cause-of-death; 
cause-of-death = temp; 
*Delete all spaces after commas; 
index = find(cause-of-death, ' ,  ' ,  'i'); 
if index ne 0 then do; 
temp = substrn(cause-of-death,l,index-1) I  I  
' I '  I I  
substrn(cause~of~death,index+2,length(cause~of~death)); 
count = count + 1; 
end ; 
else temp = cause-of-death; 
cause-of-death = temp; 
index = find(cause-of-death, ' ,  I ,  'i'); 
if index ne 0 then do; 
temp = substrn(cause-of-death,l,index-1) I  I  
' 1 '  I I  
substrn(cause~of~death,index+2,length(cause~of~death)); 
count = count + 1; 
end ; 
else temp = cause-of-death; 
cause-of-death = temp; 
*Remove all periods and replace with commas; 
index = find(cause-of-death, I . ' ,  'if); 
if index ne 0 then do; 
temp = substrn(cause-of-death,l,index-1) 1 I  
' 1 '  I I  
substrn(cause~of~death,index+l,length(cause~of~death)); 
count = count + 1; 
end ; 
else temp = cause-of-death; 
cause-of.-death = temp; 
index = find(cause-of-death, ' ) I  ' ,  'i'); 
if index ne 0 then do; 
temp = substrn(cause-of-death,l,index-1) I  I  
' 1 '  I 1  
substrn(cause~of~death,index+2,length(cause~of~death~ 1 ;  
count = count + 1; 
end ; 
else temp = cause-of-death; 
cause-of-death = temp; 
index = find(cause-of-death, 'OLAANZAPINE', 'i'); 
if index ne 0 then do; 
temp = substrn(cause~of~death,l,index-1) 1 )  
'OLANZAPINE' I  I  
substrn(cause~of~death,index+ll,length(cause~of~death)); 
count = count + 1; 
end ; 
else temp = cause-of-death; 
cause-of-death = temp; 
index = find(cause-of-death, 'CINTRIBUTING', 'i'); 
if index ne 0 then do; 
temp = substrn(cause-of-death,l,index-1) ( I  
'CONTRIBUTING' I  I  
substrn(cause~of~death,index+l2,length(cause~of~death) ) ;  
count = count + 1; 
end ; 
else temp = cause-of-death; 
cause-of-death = temp; 
index = find(cause-of-death, 'AUTOMOBILE', 'i'); 
if index ne 0 then do; 
temp = substrn(cause~of~death,l,index-1) ( 1  
'CAR' I I 
substrn(cause~of~death,index+l0,length(cause~of~death)); 
count = count + 1; 
end ; 
else temp = cause-of-death; 
cause-of-death = temp; 
index = find(cause-of-death, 'AUTO ' ,  'i'); 
if index ne 0 then do; 
temp = substrn(cause~of~death,l,index-1) ( 1  
'CAR' I I 
substrn(cause~of~death,index+5,length(cause~of~death) ) ;  
count = count + 1; 
end ; 
else temp = cause-of-death; 
cause-of-death = temp; 
index = find(cause-of-death, 'DEPHENHYDRAMINE', 'it); 
if index ne 0 then do; 
temp = substrn(cause~of~death,l,index-1) ( I  
'DIPHENHYDRAMINE' I  I  
substrn(cause~of~death,index+l5,length(cause~of~death) ; 
count = count + 1; 
end ; 
else temp = cause-of-death; 
cause-of-death = temp; 
index = find(cause-of-death, 'DIPENHYDRAMINE', 'i'); 
if index ne 0 then do; 
temp = substrn(cause-of-death,l,index-1) I ( 
'DIPHENHYDRAMINE' 1 I 
substrn(cause~of~death,index+l4,length(cause~of~death)); 
count = count + 1; 
end ; 
else temp = cause-of-death; 
cause-of-death = temp; 
index = find(cause-of-death, 'BENADRYL', 'i'); 
if index ne 0 then do; 
temp = substrn(cause~of~death,l,index-1) I  (
'DIPHENHYDRAMINE' I I 
substrn(cause~of~death,index+8,length(cause~o£~death) 1 ;  
count = count + 1; 
end ; 
else temp = cause-of-death; 
cause-of-death = temp; 
index = find(cause-of-death, 'DIPHENYDRAMINE', 'i'); 
if index ne 0 then do; 
temp = substrn(cause~of~death,l,index-1) I  I  
'DIPHENHYDRAMINE' I  I  
substrn(cause~of~death,index+l4,length(cause~of~death)); 
count = count + 1; 
end ; 
else temp = cause-of-death; 
cause-of-death = temp; 
index = find(cause-of-death, 'DIPHENYHDRAMINE', 'i'); 
if index ne 0 then do; 
temp = substrn(cause~of~death,l,index-1) I  I  
'DIPHENHYDRAMINE' 1 1  
substrn(cause~of~death,index+l5,length(cause~o£~death)); 
count = count + 1; 
end ; 
else temp = cause-of-death; 
cause-of-death = temp; 
index = find(cause-of-death, 'COCANE', 'i'); 
if index ne 0 then do; 
temp = substrn(cause~of~death,llindex-1) I I
'COCAINE' 1 )  
substrn(cause~of~death,index+6,length(cause~of~death)); 
count = count + 1; 
end ; 
else temp = cause-of-death; 
cause-of-death = temp; 
index = find(cause-of-death, 'CICAINE', 'it); 
if index ne 0 then do; 
temp = substrn(cause~of~death,l,index-1) 1 )  
'COCAINE' 1 ( 
substrn(cause~of~death,index+7,length(cause~of~death) ) ;  
count = count + 1; 
end ; 
else temp = cause-of-death; 
cause-of-death = temp; 
index = find(cause-of-death, 'COCAIN ' ,  'i'); 
if index ne 0 then do; 
temp = substrn(cause~of~death,l,index-1) I I  
'COCAINE' I  I  
substrn(cause~of~death,index+7,length(cause~of~death)); 
count = count + 1; 
end ; 
else temp = cause-of-death; 
cause-of-death = temp; 
index = find(cause-of-death, 'COCIANE', 'it); 
if index ne 0 then do; 
temp = substrn(cause~of~death,l,index-1) I I
'COCAINE' I ( 
substrn(cause~of~death,index+7,length(cause~of~death)); 
count = count + 1; 
end ; 
else temp = cause-of-death; 
cause-of-death = temp; 
index = find(cause-of-death, 'HEARD', 'it); 
if index ne 0 then do; 
temp = substrn(cause~of~death,l,index-1) 1 I
'HEART' I I 
substrn(cause~of~death,index+5,length(cause~of~death) ) ;  
count = count + 1; 
end ; 
else temp = cause-of-death; 
cause-of-death = temp; 
index = find(cause-of-death, 'SYSTEMMIC', 'i'); 
if index ne 0 then do; 
temp = substrn(cause~of~death,l,index-1) I I
'SYSTEMIC' ( 1 
substrn(cause~of~death,index+9,length(cause~of~death)); 
count = count + 1; 
end ; 
else temp = cause-of-death; 
cause-of-death = temp; 
index = find(cause-of-death, 'HEROINE', 'i'); 
if index ne 0 then do; 
temp = substrn(cause~of~death,l,index-1) I ( 
'HEROIN' I I 
substrn(cause~of~death,index+7,length(cause~of~death) 1 ;  
count = count + 1; 
end ; 
else temp = cause-of-death; 
cause-of-death = temp; 
index = find(cause-of-death, 'OXCODONE', 'i'); 
if index ne 0 then do; 
temp = substrn(cause~of~death,l,index-1) I I 
'OXYCODONE' I I 
substrn(cause~of~death,index+8,length(cause~of~death)); 
count = count + 1; 
end; 
else temp = cause-of-death; 
cause-of-death = temp; 
index = find(cause-of-death, 'EXYCODONE', 'i'); 
if index ne 0 then do; 
temp = substrn(cause-of-death,l,index-1) I I 
'OXYCODONE'  I I 
substrn(cause~of~death,index+9,length(cause~of~death)); 
count = count + 1; 
end ; 
else temp = cause-of-death; 
cause-of-death = temp; 
index = find(cause-of-death, ' P X Y C O D O N E ' ,  'i'); 
if index ne 0 then do; 
temp = substrn(cause~of~death,l,index-1) I I 
'OXYCODONE'  I I 
substrn(cause~of~death,index+9,length(cause~of~death)); 
count = count + 1; 
end ; 
else temp = cause-of-death; 
cause-of-death = temp; 
index = find(cause-of-death, ' O X Y C O N T I N ' ,  'i'); 
if index ne 0 then do; 
temp = substrn(cause~of~death,l,index-1) I I 
'OXYCODONE'  I ( 
substrn(cause~of~death,index+9,length(cause~of~death)); 
count = count + 1; 
end ; 
else temp = cause-of-death; 
cause-of-death = temp; 
index = find(cause-of-death, ' O C Y C O D O N E ' ,  'it); 
if index ne 0 then do; 
temp = substrn(cause~of~death,l,index-1) 1 )  
'OXYCODONE'  I I 
substrn (cause-of-death, index+9, length (cause-of-death) ) ; 
count = count + 1; 
end ; 
else temp = cause-of-death; 
cause-of-death = temp; 
index = find(cause-of-death, ' A L P R O Z O L A M ' ,  'i'); 
if index ne 0 then do; 
temp = substrn(cause~of~death,l,index-1) I I 
'ALPRAZOLAM'  I I 
substrn(cause~of~death,index+l0,length(cause~of~death)); 
count = count + 1; 
end; 
else temp = cause-of-death; 
cause-of-death = temp; 
index = find(cause-of-death, ' O X Y C O C O N E ' ,  'i'); 
if index ne 0 then do; 
temp = substrn(cause~of~death,l,index-1) I I 
'OXYCODONE'  1 )  
substrn(cause~of~death,index+9,length(cause~of~death) ) ;  
count = count + 1; 
end ; 
else temp = cause-of-death; 
cause-of-death = temp; 
index = find(cause-of-death, 'OXYCONDONE',  'it); 
if index ne 0 then do; 
temp = substrn(cause~of~death,l,index-1) I ( 
'OXYCODONE' ( I 
substrn(cause~of~death,index+l0,length(cause~of~death)); 
count = count + 1; 
end; 
else temp = cause-of-death; 
cause-of-death = temp; 
index = find(cause-of-death, 'OXYODONE' ,  'i'); 
if index ne 0 then do; 
temp = substrn(cause~o£~death,l,index-1) I I 
'OXYCODONE' I I 
substrn(cause~of~death,index+8,length(cause~of~death)); 
count = count + 1; 
end ; 
else temp = cause-of-death; 
cause-of-death = temp; 
index = find(cause-of-death, 'HYDROCONE' ,  'i'); 
if index ne 0 then do; 
temp = substrn (cause-of-death, 1, index-1) I I 
'HYDROCODONE' 1 ( 
substrn(cause~of~death,index+9,length(cause~of~death)); 
count = count + 1; 
end ; 
else temp = cause-of-death; 
cause-of-death = temp; 
index = find(cause-of-death, 'HYRDOCODONE',  'it); 
if index ne 0 then do; 
temp = substrn(cause~of~death,l,index-1) 1 )  
'HYDROCODONE' I I 
substrn(cause~of~death,index+ll,length(cause~of~death)); 
count = count + 1; 
end ; 
else temp = cause-of-death; 
cause-of-death = temp; 
index = find(cause-of-death, 'HYDROCDONE' ,  'i'); 
if index ne 0 then do; 
temp = substrn(cause~of~death,l,index-1)  
'HYDROCODONE' I I 
substrn(cause~of~death,index+l0,length(cause~o£~death)); 
count = count + 1; 
end ; 
else temp = cause-of-death; 
cause-of-death = temp; 
index = find(cause-of-death, 'HYDOCODONE' ,  'i'); 
if index ne 0 then do; 
temp = substrn(cause~of~death,l,index-1) 1 )  
'HYDROCODONE' I I 
substrn(cause~of~death,index+l0,length(cause~of~death)); 
count = count + 1; 
end ; 
else temp = cause-of-death; 
cause-of-death = temp; 
index = find(cause-of-death, 'HYDROCOONE' ,  'i'); 
if index ne 0 then do; 
temp = substrn(cause~of~death,l,index-1) ( I 
'HYDROCODONE' I I 
substrn(cause~of~death,index+l0,length(cause~of~death) ) ;  
count = count + 1; 
end ; 
else temp = cause-of-death; 
cause-of-death = temp; 
index = find(cause-of-de-ath, 'HYROCODONE' ,  'i'); 
if index ne 0 then do; 
temp = substrn(cause~of~death,l,index-1) I I
'HYDROCODONE' 1 )  
substrn (cause-of-death, index+lO, length (cahse-of-death) ) ; 
count = count + 1; 
end ; 
else temp = cause-of-death; 
cause-of-death = temp; 
index = find(cause-of-death, 'MYODROCODONE', 'i'); 
if index ne 0 then do; 
temp = substrn(cause~of~death,l,index-1) ( I
'HYDROCODONE' 1 I 
substrn(cause~of~death,index+l2,length(cause~of~death)); 
count = count + 1; 
end ; 
else temp = cause-of-death; 
cause-of-death = temp; 
index = find(cause-of-death, 'METHADON ' ,  'i'); 
if index ne 0 then do; 
temp = substrn(cause~of~death,l,index-1) ( I 
'METHADONE' I I 
substrn(cause~of~death,index+9,length(cause~of~death)); 
count = count + 1; 
end ; 
else temp = cause-of-death; 
cause-of-death = temp; 
index = find(cause-of-death, ' C O C A I N E E ' ,  'i'); 
if index ne 0 then do; 
temp = substrn(cause~of~death,l,index-1) I I  
'COCAINE' 1 )  
substrn(cause-of-death, index+8, length (cause-of-death) ) ; 
count = count + 1; 
end ; 
else temp = cause-of-death; 
cause-of-death = temp; 
index = find(cause-of-death, 'MENTADONE', 'it); 
if index ne 0 then do; 
temp = substrn(cause~of~death,l,index-1) ( 1
'METHADONE' 1 )  
substrn(cause~of~death,index+9,length(cause~of~death)); 
count = count + 1; 
end ; 
else temp = cause-of-death; 
cause-of-death = temp; 
index = find(cause-of-death, 'METHADNE', 'i'); 
if index ne 0 then do; 
temp = substrn(cause~of~death,l,index-1) I I  
'METHADONE' I  I  
substrn(cause~of~death,index+8,length(cause~of~death) 1 ;  
count = count + 1; 
end ; 
else temp = cause-of-death; 
cause-of-death = temp; 
index = find(cause-of-death, 'METHODONE', 'it); 
if index ne 0 then do; 
temp = substrn(cause~of~death,l,index-1) 1 )  
'METHADONE' 1 I  
substrn(cause~of~death,index+9,length(cause~of~death) ) ;  
count = count + 1; 
end ; 
else temp = cause-of-death; 
cause-of-death = temp; 
index = find(cause-of-death, 'METHADDONE', 'i'); 
if index ne 0 then do; 
temp = substrn(cause-of-death,l,index-1) I I  
'METHADONE' I  I  
substrn(cause~of~death,index+l0,length(cause~of~death) 1 ;  
count = count + 1; 
end ; 
else temp = cause-of-death; 
cause-of-death = temp; 
index = find(cause-of-death, 'MEHTADONE', 'it); 
if index ne 0 then do; 
temp = substrn(cause~of~death,l,index-1) I I  
'METHADONE' I  I  
substrn(cause~of~death,index+9,length(cause~of~death)); 
count = count + 1; 
end ; 
else temp = cause-of-death; 
cause-of-death = temp; 
index = find(cause-of-death, 'COODEINE', 'i'); 
if index ne 0 then do; 
temp = substrn(cause~of~death,l,index-1) I I 
'CODEINE' I  I  
substrn(cause~of~death,index+8,length(cause~of~death)); 
count = count + 1; 
end ; 
else temp = cause-of-death; 
cause-of-death = temp; 
index = find(cause-of-death, 'ALCOHOL', 'i'); 
if index ne 0 then do; 
temp = substrn(cause~of~death,l,index-1) I  I
'ETHANOL' I  I  
substrn(cause~of~death,index+7,length(cause~of~death) 1 ;  
count = count + 1; 
end ; 
else temp = cause-of-dea-th; 
cause-of-death = temp; 
index = find(cause-of-death, 'POISONINGN', 'it); 
if index ne 0 then do; 
temp = substrn(cause~of~death,l,index-1) I  I  
'POISONING' I  I  
substrn(cause~of~death,index+l0,length(cause~of~death)); 
count = count + 1; 
end ; 
else temp = cause-of-death; 
cause-of-death = temp; 
index = find(cause-of-death, 'EHTANOL', 'it); 
if index ne 0 then do; 
temp = substrn(cause~of~death,l,index-1) I I 
'ETHANOL' I  I  
substrn(cause~of~death,index+7,length(cause~o£~death)); 
count = count + 1; 
end ; 
else temp = cause-of-death; 
cause-of-death = temp; 
index = find(cause-of-death, 'POISONING', 'it); 
if index ne 0 then do; 
temp = substrn(cause~of~death,l,index-1) I  I
'POISONING' 1 )  
substrn(cause~of~death,index+9,length(cause~of~death)); 
count = count + 1; 
end ; 
else temp = cause-of-death; 
cause-of-death = temp; 
index = find(cause-of-death, 'SBBSTANCE', 'i'); 
if index ne 0 then do; 
temp = substrn(cause~~of~death,1,index-1) I I 
'SUBSTANCE' I ( 
substrn(cause~of~death,index+9,length(cause~of~death)); 
count = count + 1; 
end ; 
else temp = cause-of-death; 
cause-of-death = temp; 
index = find(cause-of-death, 'MORPH ' ,  'i'); 
if index ne 0 then do; 
temp = substrn(cause~of~death,l,index-1) I I 
'MORPHINE' I I 
substrn(cause~of~death,index+6,length(cause~of~death)); 
count = count + 1; 
end ; 
else temp = cause-of-death; 
cause-of-death = temp; 
index = find(cause-of-death, 'DEXTROMETH ' ,  'it); 
if index ne 0 then do; 
temp = substrn(cause~o£~death,l,index-1) I I
'DEXTROMETHORPHAN' 1 )  
substrn(cause~of~death,index+ll,length(cause~of~death) 1 ;  
count = count + 1; 
end ; 
else temp = cause-of-death; 
cause-of-death = temp; 
index = find(cause-of-death, 'COC ' ,  'i'); 
if index ne 0 then do; 
temp = substrn(cause~of~death,l,index-1) I ( 
'COCAINE' I ( 
substrn(cause~of~death,index+4,length(cause~o£~death)); 
count = count + 1; 
end; 
else temp = cause-of-death; 
cause-of-death = temp; 
index = find(cause-of-death, 'ALPRAZOLM', 'i'); 
if index ne 0 then do; 
temp = substrn(cause~of~death,l,index-1) I I
'ALPRAZOLAM' ( I 
substrn(cause~of~death,index+9,length(cause~of~death)); 
count = count + 1; 
end ; 
else temp = cause-of-death; 
cause-of-death = temp; 
index = find(cause-of-death, 'ALPAZOLAM', 'i'); 
if index ne 0 then do; 
temp = substrn(cause~of~death,l,index-1) I  I  
'ALPRAZOLAM' I  I  
substrn(cause~of~death,index+9,length(cause~of~death)); 
count = count + 1; 
end ; 
else temp = cause-of-death; 
cause-of-death = temp; 
index = find(cause-of-death, 'ALPRAXOLAM', 'i'); 
if index ne 0 then do; 
temp = substrn(cause~of~death,l,index-1) I  I 
'ALPRAZOLAM' 1 )  
substrn(cause~of~death,index+l0,length(cause~of~death)); 
count = count + 1; 
end ; 
else temp = cause-of-death; 
cause-of-death = temp; 
index = find(cause-of-death, 'APRAZOLAM', 'i'); 
if index ne 0 then do; 
temp = substrn(cause~of~death,l,index-1) 1 ( 
'ALPRAZOLAM' I  I  
substrn(cause~of~death,index+9,length(cause~of~death) ) ;  
count = count + 1; 
end ; 
else temp = cause-of-death; 
cause-of-death = temp; 
index = find(cause-of-death, 'ALPROAZOLAM', 'i'); 
if index ne 0 then do; 
temp = substrn(cause~of~death,l,index-1) 1 )  
'ALPRAZOLAM' 1 I  
substrn(cause~of~death,index+ll,length(cause~of~death)); 
count = count + 1; 
end ; 
else temp = cause-of-death; 
cause-of-death = temp; 
index = find(cause-of-death, 'ALPRAZOLEM', 'it); 
if index ne 0 then do; 
temp = substrn(cause~of~death,l,index-1) I I  
'ALPRAZOLAM' I I 
substrn(cause~of~death,index+l0,length(cause~of~death) ) ;  
count = count + 1; 
end ; 
else temp = cause-of-death; 
cause-of-death = temp; 
index = find(cause-of-death, 'ALPRA ' ,  'i'); 
if index ne 0 then do; 
temp = substrn(cause~of~death,l,index-1) 1 )  
'ALPRAZOLAM' I I 
substrn(cause~of~death,index+6,length(cause~of~death)); 
count = count + 1; 
end ; 
else temp = cause-of-death; 
cause-of-death = temp; 
index = find(cause-of-death, 'ALPAZOLAM', 'i'); 
if index ne 0 then do; 
temp = substrn(cause~of~death,l,index-1) I I
'ALPRAZOLAM' 1 I 
substrn(cause~of~death,index+9,length(cause~o£~death) 1 ;  
count = count + 1; 
end ; 
else temp = cause-of-death; 
cause-of-death = temp; 
index = find(cause-of-death, 'CODIENE', 'i'); 
if index ne 0 then do; 
temp = substrn(cause~of~death,l,index-1) I I
'CODEINE' I I 
substrn(cause~of~death,index+7,length(cause~o£~death) ) ;  
count = count + 1; 
end ; 
else temp = cause-of-death; 
cause-of-death = temp; 
index = find(cause-of-death, 'CODEIN ' ,  'i'); 
if index ne 0 then do; 
temp = substrn(cause~of~death,l,index-1) I I
'CODEINE' I I 
substrn(cause~of~death,index+7,length(cause~of~death)) ; 
count = count + 1; 
end ; 
else temp = cause-of-death; 
cause-of-death = temp; 
index = find(cause-of-death, 'PROP ' ,  'it); 
if index ne 0 then do; 
temp = substrn(cause~of~death,l,index-1) ( I 
'PROPOXYPHENE' I I 
substrn(cause~of~death,index+5,length(cause~of~death)); 
count = count + 1; 
end ; 
else temp = cause-of-death; 
cause-of-death = temp; 
index = find(cause-of-death, 'PROPOXYHENE', 'i'); 
if index ne 0 then do; 
temp = substrn(cause~of~death,l,index-1) I I
'PROPOXYPHENE' I I 
substrn(cause~of~death,index+ll,length(cause~of~death)); 
count = count + 1; 
end ; 
else temp = cause-of-death; 
cause-of-death = temp; 
index = find(cause-of-death, 'PROPOX ' ,  'i'); 
if index ne 0 then do; 
temp = substrn(cause~of~death,l,index-1) I I 
'PROPOXYPHENE' I ( 
substrn(cause~of~death,index+7,length(cause~o£~death) ) ;  
count = count + 1; 
end ; 
else temp = cause-of-death; 
cause-of-death = temp; 
index = find(cause-of-death, 'PROPOX,', 'i'); 
if index ne 0 then do; 
temp = substrn(cause-of-death,l,index-1) I I 
'PROPOXYPHENE' I I 
substrn(cause~of~death,index+7,length(cause~of~death)); 
count = count + 1; 
end ; 
else temp = cause-of-death; 
cause-of-death = temp; 
index = find(cause-of-death, 'CITALOPROM', 'it); 
if index ne 0 then do; 
temp = substrn(cause~of~death,l,index-1) ( 1  
'CITALOPRAM' I I 
substrn(cause~of~death,index+l0,length(cause~of~death)); 
count = count + 1; 
end ; 
else temp = cause-of-death; 
cause-of-death = temp; 
index = find(cause-of-death, 'CIALOPRAM', 'i'); 
if index ne 0 then do; 
temp = substrn(cause-of-death,l,index-1) ( I 
'CITALOPRAM' 1 I 
substrn(cause~of~death,index+9,length(cause~of~death) 1 ;  
count = count + 1; 
end ; 
else temp = cause-of-death; 
cause-of-death = temp; 
index = find(cause-of-death, 'DRUB', 'i'); 
if index ne 0 then do; 
temp = substrn(cause-of-death,l,index-1) 1 )  
'DRUG' I I 
substrn(cause~of~death,index+4,length(cause~of~death) 1 ;  
count = count + 1; 
end ; 
else temp = cause-of-death; 
cause-of-death = temp; 
"Changinng all variations to poisoning; 
index = find(cause-of-death, 'TOXICITY', 'i'); 
if index ne 0 then temp = substrn(cause~of~death,l,index-1) I I
'POISONING' ( 1  
substrn(cause~of~death,index+8,length(cause~of~death) 1 ;  
else temp = cause-of-death; 
cause-of-death = temp; 
index = find(cause-of-death, 'INTOXICATION', ' i f ) ;  
if index ne 0 then temp = substrn(cause~of~death,l,index-1) ( 1 
'POISONING' \ ( 
substrn(cause~of~death,index+l2,length(cause~of~death~ 1 ;  
else temp = cause-of-death; 
cause-of-death = temp; 
index = find(cause-of-death, 'OVERDOSE', 'i'); 
if index ne 0 then temp = substrn(cause~of~death,l,index-1) ( 1  
'POISONING' ( 1  
substrn(cause~of~death,index+ll,length(cause~of~death~ 1 ;  
else temp = cause-of-death; 
cause-of-death = temp; 
if drug-s- = 'DIPHENYLAMINE' then drug-s- = 'DIPHENHYDRAMINE'; 
retain count; 
drop temp; 
drop index; 
run ; 
proc print data=thesis.metissues; 
var drug unit bac presence; 
run ; 
proc freq data=thesis.metissues; 
tables bac; 
run ; 
*sort to be in correct order to next data statement; 
proc sort data=thesis.metissues; 
by case-number drug descending bac; 
run ; 
/*Creation of new variable arrays*/ 
data thesis.mefina1; 
set thesis.metissues; 
by case-number drug descending bac; 
array names {139} $100. acetaminophen-n acetone-n acetylmorphine-n 
alprazolam-n amitriptyline-n amoxapine-n amphetamine-n 
benzoylecgonine-n benztropine-n brompheniramine-n bupropion-n 
busiprone-n butabarbital-n butalbital-n caffeine-n 
carbamazepine-n carbondioxide-n carbonmonoxide-n 
carisoprodol-n chlordiazepoxide-n chlorodifluoromethane-n 
chlorpheniramine-n chlorpromazine-n citalopram-n 
clomipramine-n clonzepam-n clozapine-n cocaethlyene-n 
cocaine-n codeine-n cyanide-n cyclobenzaprine-n 
desalkyflurazepam-n desipramine-n dextromethorphan-n 
diazepam-n difluoroethane-n dihydrocodeine-n diltiazem-n 
diphenhydramine-n doxepin-n doxylamine-n ephedrine-n 
ethanol-n ethyleneglycol-n fenfluramine-n fentanyl-n 
fluoxetine-n fluvoxamine-n gabapentin-n 
gamrnahydroxybutyrate-n guaifenesin-n hydrocodone-n 
hydromorphone-n hydroxyzine-n ibuprofen-n imipramine-n 
insulin-n isopropanol-n ketamine-n lithium-n lorazepam-n 
lysergicaciddiethylamide-n mda-n mdma-n meclizine-n 
meperidine-n meprobamate-n metaxalone-n methadone-n 
methamphetamine-n methanol-n methocarbamol-n methotrexate-n 
methylphenidate-n midazolam-n mirtazapine-n molidone-n 
morphine-n naproxen-n nefazodone-n nicotine-n nitricacid-n 
norchlorcyclizine-n nordiazepam-n nordoxepin-n 
norfluoxetine-n normeperidine-n norpropoxyphene-n 
nortriptylene-n olanzapine-n orphenadrine-n oxazepam-n 
oxycodone-n oxymorphone-n pancuroniumbromide-n paraquat-n 
paroxetine-n pentazocine-n pentobarbital-n pentoxifylline-n 
phencyclidine-n phenobarbital-n phentermine-n 
phenyltoloxamine-n phenytoin-n primidone-n promethazine-n 
propane-n propoxyphene-n propranolol-n propyleneglycol-n 
quetiapine-n quinine-n ritalinicacid-n salicylate-n 
salicylicacid-n secobarbital-n sertraline-n temazepam-n 
tetrafluroethane-n tetrahydrocannabinol-n thccarboxylicacid-n 
theophylline-n thiopental-n thioridazine-n toluene-n 
tramadol-n tranylcypromine-n trazodone-n triazolam-n 
tricyclic-n trifluoperazine-n trihexyphenidyl-n 
trimipramine-n valproic-n venlafaxine-n verapamil-n 
zolpidem-n ('acetaminophen', 'acetone', 'acetylmorphine', 
'alprazolam', 'amitriptyline', 'amoxapine', 'amphetamine', 
'benzoylecgonine', 'benztropine', 'brompheniramine', 
'bupropion', 'busiprone', 'butabarbital', 'butalbital', 
'caffeine', 'carbamazepine', 'carbon dioxide', 'carbon 
monoxide', 'carisoprodol', 'chlordiazepoxide', 
'chlorodifluoromethane', 'chlorpheniramine', 
'chlorpromazine', 'citalopram', 'clomipramine', 'clonzepam', 
'clozapine', 'cocaethlyene', 'cocaine', 'codeine', 'cyanide', 
'cyclobenzaprine', 'desalkyflurazepam', 'desipramine', 
'dextromethorphan', 'diazepam', 'difluoroethane', 
'dihydrocodeine', 'diltiazem', 'diphenhydramine', 'doxepin', 
'doxylamine', 'ephedrine', 'ethanol', 'ethyleneglycol', 
'fenfluramine', 'fentanyl', 'fluoxetine', 'fluvoxamine', 
'gabapentin', 'gammahydroxybutyrate', 'guaifenesin', 
'hydrocodone', 'hydromorphone', 'hydroxyzine', 'ibuprofen', 
'imipramine', 'insulin', 'isopropanol', 'ketamine', 
'lithium', 'lorazepam', 'lysergicaciddiethylamide', 'mda', 
'mdrna', 'meclizine', 'meperidine', 'meprobamate', 
'metaxalone', 'methadone', 'methamphetamine', 'methanol', 
'methocarbamol', 'methotrexate', 'methylphenidate' ,
'midazolam', 'mirtazapine', 'molidone', 'morphine', 
'naproxen', 'nefazodone', 'nicotine', 'nitricacid', 
'norchlorcyclizine', 'nordiazepam', 'nordoxepin', 
'norfluoxetine', 'normeperidine', 'norpropoxyphene', 
'nortriptylene', 'olanzapine', 'orphenadrine', 'oxazepam', 
'oxycodone', 'oxymorphone', 'pancuroniurnbromide', 'paraquat', 
'paroxetine', 'pentazocine', 'pentobarbital', 
'pentoxifylline', 'phencyclidine', 'phenobarbital', 
'phentermine', 'phenyltoloxamine', 'phenytoin', 'primidone', 
'promethazine', 'propane', 'propoxyphene', 'propranolol', 
'propyleneglycol', 'quetiapine', 'quinine', 'ritalinicacid', 
'salicylate', 'salicylicacid', 'secobarbital', 'sertraline' ,
'temazepam', 'tetrafluroethane', 'tetrahydrocannabinol', 
'thccarboxylicacid', 'theophylline', 'thiopental', 
'thioridazine' , 'toluene', 'tramadol', 'tranylcypromine', 
'trazodone', 'triazolam', 'tricyclic', 'trifluoperazine', 
'trihexyphenidyl', 'trimipramine', 'valproic', 'venlafaxine', 
'verapamil', 'zolpidem'); 
array drugs {I391 acetaminophen acetone acetylmorphine alprazolam 
amitriptyline amoxapine amphetamine benzoylecgonine 
benztropine brompheniramine bupropion busiprone butabarbital 
butalbital caffeine carbamazepine carbondioxide 
carbonmonoxide carisoprodol chlordiazepoxide 
chlorodifluoromethane chlorpheniramine chlorpromazine 
citalopram clomipramine clonzepam clozapine cocaethlyene 
cocaine codeine cyanide cyclobenzaprine desalkyflurazepam 
desipramine dextromethorphan diazepam difluoroethane 
dihydrocodeine diltiazem diphenhydramine doxepin doxylamine 
ephedrine ethanol ethyleneglycol fenfluramine fentanyl 
fluoxetine fluvoxamine gabapentin gammahydroxybutyrate 
guaifenesin hydrocodone hydromorphone hydroxyzine ibuprofen 
imipramine insulin isopropanol ketamine lithium lorazepam 
lysergicaciddiethylamide mda mdma meclizine meperidine 
meprobamate metaxalone methadone methamphetamine methanol 
methocarbamol methotrexate methylphenidate midazolam 
mirtazapine molidone morphine naproxen nefazodone nicotine 
nitricacid norchlorcyclizine nordiazepam nordoxepin 
norfluoxetine normeperidine norpropoxyphene nortriptylene 
olanzapine orphenadrine oxazepam oxycodone oxymorphone 
pancuroniurnbromide paraquat paroxetine pentazocine 
pentobarbital pentoxifylline phencyclidine phenobarbital 
phentermine phenyltoloxamine phenytoin primidone promethazine 
propane propoxyphene propranolol propyleneglycol quetiapine 
quinine ritalinicacid salicylate salicylicacid secobarbital 
sertraline temazepam tetrafluroethane tetrahydrocannabinol 
thccarboxylicacid theophylline thiopental thioridazine 
toluene tramadol tranylcypromine trazodone triazolam 
tricyclic trifluoperazine trihexyphenidyl trimipramine 
valproic venlafaxine verapamil zolpidem; 
array amounts {I391 acetaminophen-c acetone-c acetylmorphine-c 
alprazolam-c amitriptyline-c arnoxapine-c amphetamine-c 
benzoylecgonine-c benztropine-c brompheniramine-c bupropion-c 
busiprone-c butabarbital-c butalbital-c caffeine-c 
carbamazepine-c carbondioxide-c carbonmonoxide-c 
carisoprodol-c chlordiazepoxide-c chlorodifluoromethane-c 
chlorpheniramine-c chlorpromazine-c citalopram-c 
clomipramine-c clonzepam-c clozapine-c cocaethlyene-c 
cocaine-c codeine-c cyanide-c cyclobenzaprine-c 
desalkyflurazepam-c desipramine-c dextromethorphan-c 
diazepam-c difluoroethane-c dihydrocodeine-c diltiazem-c 
diphenhydramine-c doxepin-c doxylamine-c ephedrine-c 
ethanol-c ethyleneglycol-c fenfluramine-c fentanyl-c 
fluoxetine-c fluvoxamine-c gabapentin-c 
gammahydroxybutyrate-c guaifenesin-c hydrocodone-c 
hydromorphone-c hydroxyzine-c ibuprofen-c imipramine-c 
insulin-c isopropanol-c ketamine-c lithium-c lorazepam-c 
lysergicaciddiethylamide-c mda-c mdma-c meclizine-c 
meperidine-c meprobamate-c metaxalone-c methadone-c 
methamphetamine-c methanol-c methocarbamol-c rnethotrexate-c 
methylphenidate-c midazolam-c mirtazapine-c molidone-c 
morphine-c naproxen-c nefazodone-c nicotine-c nitricacid-c 
norchlorcyclizine~c nordiazepam-c nordoxepin-c 
norfluoxetine-c normeperidine-c norpropoxyphene-c 
nortriptylene-c olanzapine-c orphenadrine-c oxazepam-c 
oxycodone-c oxymorphone-c pancuroniumbromide-c paraquat-c 
paroxetine-c pentazocine-c pentobarbital-c pentoxifylline-c 
phencyclidine-c phenobarbital-c phentermine-c 
phenyltoloxamine-c phenytoin-c primidone-c prornethazine-c 
propane-c propoxyphene-c propranolol-c propyleneglycol-c 
quetiapine-c quinine-c ritalinicacid-c salicylate-c 
salicylicacid-c secobarbital-c sertraline-c temazepam-c 
tetrafluroethane-c tetrahydrocannabinol-c thccarboxylicacid-c 
theophylline-c thiopental-c thioridazine-c toluene-c 
tramadol-c tranylcypromine-c trazodone-c triazolam-c 
tricyclic-c trifluoperazine-c trihexyphenidyl-c 
trimipramine-c valproic-c venlafaxine-c verapamil-c 
zolpidem-c; 
array levels (1391 $9. acetaminophen-1 acetone-1 acetylmorphine-1 
alprazolam-1 amitriptyline-1 amoxapine-1 amphetamine-1 
benzoylecgonine-1 benztropine-1 brompheniramine-1 bupropion-1 
busiprone-1 butabarbital-1 butalbital-1 caffeine-1 
carbamazepine-1 carbondioxide-1 carbonmonoxide-1 
carisoprodol-1 chlordiazepoxide-1 chlorodifluoromethane-1 
chlorpheniramine-1 chlorpromazine-1 citalopram-1 
clomipramine-1 clonzepam-1 clozapine-1 cocaethlyene-1 
cocaine-1 codeine-1 cyanide-1 cyclobenzaprine-1 
desalkyflurazepam-1 desipramine-1 dextromethorphan-1 
diazepam-1 difluoroethane-1 dihydrocodeine-1 diltiazem-1 
diphenhydramine-1 doxepin-1 doxylamine-1 ephedrine-1 
ethanol-1 ethyleneglycol-1 fenfluramine-1 fentanyl-1 
fluoxetine-1 fluvoxamine-1 gabapentin-1 
a r r a y  p r e s s  (139) $31.  ace taminophens  a c e t o n e s  ace ty lmorph ineg  
a l p r a z o l a m g  a m i t r i p t y l i n e s  amoxapines  amphetamines 
benzoylecgonineq  b e n z t r o p i n e g  brompheniramine-p buprop ionq  
b u s i p r o n e g  b u t a b a r b i t a l s  b u t a l b i t a l s  c a f f e i n e 2  
ca rbamazep ine j  ca rbond iox ideg  carbonmonoxide-p 
c a r i s o p r o d o l s  c h l o r d i a z e p o x i d e s  ch lorodi f luoromethaneg  
chlorpheniramine-p ch lorpromazineg  c i t a l o p r a m g  
c l o m i p r a m i n e j  c lonzepamg c l o z a p i n e g  c o c a e t h l y e n e g  
c o c a i n e j  c o d e i n e 2  c y a n i d e s  cyc lobenzapr ineg  
desalkyflurazepam-p d e s i p r a m i n e g  dextromethorphang 
d i a z e p a m s  d i f l u o r o e t h a n e s  d ihydrocode ineg  
d i l t i a z e m s  diphenhydramines d o x e p i n s  doxy lamines  
e p h e d r i n e 2  e t h a n o l g  e t h y l e n e g l y c o l g  f e n f l u r a m i n e 2  
f e n t a n y l g  f l u o x e t i n e s  fluvoxamine_p g a b a p e n t i n g  
gammahydroxybutyrates g u a i f e n e s i n g  hydrocodones  
hydromorphoneg hydroxyz ineg  i b u p r o f e n 2  imip ramines  
i n s u l i n 2  isopropanol-p ke t a rn ines  l i t h i u m 2  1orazeparn-p 
lysergicaciddiethylamideg m d a g  mdmag m e c l i z i n e s  
m e p e r i d i n e s  meprobamate2 me taxa lone2  methadones  
methamphetamine3 m e t h a n o l 2  methocarbamolg m e t h o t r e x a t e g  
me thy lphen ida t eg  midazolamg m i r t a z a p i n e s  mo l idoneg  
m o r p h i n e s  nap roxenq  ne fazodoneg  n i c o t i n e 3  n i t r i c a c i d j  
n o r c h l o r c y c l i z i n e g  nord iazepams no rdoxep ing  
no r f luoxe t ine -p  no rmeper id ineg  norpropoxyphene-p 
n o r t r i p t y l e n e - p  o l a n z a p i n e g  o r p h e n a d r i n e s  oxazepams 
oxycodones  oxymorphoneg pancuroniumbromide_p p a r a q u a t g  
p a r o x e t i n e s  p e n t a z o c i n e g  p e n t o b a r b i t a l g  p e n t o x i f y l l i n e g  
p h e n c y c l i d i n e g  p h e n o b a r b i t a l 3  phen te rmineg  
phenyltoloxamine-p phenytoins primidoneq promethazines 
propanes propoxyphenes propranololq propyleneglycol~ 
quetiapines quinines ritalinicacids salicylateq 
salicylicacidq secobarbitals sertralines temazepams 
tetrafluroethaneq tetrahydrocannabinols thccarboxylicacid_p 
theophylline_p thiopentalq thioridazines toluenes 
tramadola tranylcypromines trazodoneq triazolamq 
tricyclicq trifluoperazinej trihexyphenidyls 
trimipramines valproicq venlafaxineq verapamils 
zolpidemq; 
if first.case-number then do; 
do i = 1 to 139 by 1; 
drugs{i) = .; 
amounts{i) = .; 
levels{i} = "; 
press{i} = "; 
*number-of-drugs keeps track of the number of drugs detected (not just 
tested for) ; 
number-of-drugs = 0; 
end ; 
end ; 
do i =1 to 139 by 1; 
if drug=upcase(names{i}) then do; 
drugs{i) = 1; 
press{i) = presence; 
levels(i) = unit; 
indexl = find(drug-level, ' M I ,  'i') ; 
index2 = find(drug-level, 'P', 'i') ; 
index3 = find (drug-level, ' / ' , ' i ' ) ; 
if indexl ne 0 then do; 
amounts{i)=input(substrn( 
drug-level,l,indexl-1) ,4.) ; 
end ; 
else if index2 ne 0 then do; 
amounts{i) = .; 
end; 
else if index3 ne 0 then do; 
amounts{i)=input(substrn( 
drug-level,l,index3-1),4.) ; 
end ; 
else do; 
amounts{i) = input(drug-level, 8.); 
end ; 
if amounts{i) ne 0 & press{i} ne 'not detected' 
then number-of-drugs = number-of-drugs+l; 
end ; 
end ; 
if 1ast.case-number then output; 
retain case-number acetaminophen acetone acetylmorphine 
alprazolam amitriptyline amoxapine amphetamine 
benzoylecgonine benztropine brompheniramine bupropion 
busiprone butabarbital butalbital caffeine carbamazepine 
carbondioxide carbonmonoxide carisoprodol chlordiazepoxide 
chlorodifluoromethane chlorpheniramine chlorpromazine 
citalopram clomipramine clonzepam clozapine cocaethlyene 
cocaine codeine cyanide cyclobenzaprine desalkyflurazepam 
desipramine dextromethorphan diazepam difluoroethane 
dihydrocodeine diltiazem diphenhydramine doxepin doxylamine 
ephedrine ethanol ethyleneglycol fenfluramine fentanyl 
fluoxetine fluvoxamine gabapentin gammahydroxybutyrate 
guaifenesin hydrocodone hydromorphone hydroxyzine ibuprofen 
imipramine insulin isopropanol ketamine lithium lorazepam 
lysergicaciddiethylamide mda mdma meclizine meperidine 
meprobamate metaxalone methadone methamphetamine methanol 
methocarbamol methotrexate methylphenidate midazolam 
mirtazapine molidone morphine naproxen nefazodone nicotine 
nitricacid norchlorcyclizine nordiazepam nordoxepin 
norfluoxetine normeperidine norpropoxyphene nortriptylene 
olanzapine orphenadrine oxazepam oxycodone oxymorphone 
pancuroniumbromide paraquat paroxetine pentazocine 
pentobarbital pentoxifylline phencyclidine phenobarbital 
phentermine phenyltoloxamine phenytoin primidone promethazine 
propane propoxyphene propranolol propyleneglycol quetiapine 
quinine ritalinicacid salicylate salicylicacid secobarbital 
sertraline temazepam tetrafluroethane tetrahydrocannabinol 
thccarboxylicacid theophylline thiopental thioridazine 
toluene tramadol tranylcypromine trazodone triazolam 
tricyclic trifluoperazine trihexyphenidyl trimipramine 
valproic venlafaxine verapamil zolpidem acetaminophen-c 
acetone-c acetylmorphine-c alprazolam-c amitriptyline-c 
amoxapine-c amphetamine-c benzoylecgonine-c benztropine-c 
brompheniramine-c bupropion-c busiprone-c butabarbital-c 
butalbital-c caffeine-c carbamazepine-c carbondioxide-c 
carbonmonoxide-c carisoprodol-c chlordiazepoxide-c 
chlorodifluoromethane~c chlorpheniramine-c chlorpromazine-c 
citalopram-c clomipramine-c clonzepam-c clozapine-c 
cocaethlyene-c cocaine-c codeine-c cyanide-c 
cyclobenzaprine-c desalkyflurazepam-c desipramine-c 
dextromethorphan-c diazepam-c difluoroethane-c 
dihydrocodeine-c diltiazem-c diphenhydramine-c doxepin-c 
doxylamine-c ephedrine-c ethanol-c ethyleneglycol-c 
fenfluramine-c fentanyl-c fluoxetine-c fluvoxamine-c 
gabapentin-c gammahydroxybutyrate-c guaifenesin-c 
hydrocodone-c hydromorphone-c hydroxyzine-c ibuprofen-c 
imipramine-c insulin-c isopropanol-c ketamine-c lithium-c 
lorazepam-c ly~ergicaciddiethylamide~c mda-c mdma-c 
meclizine-c meperidine-c meprobamate-c metaxalone-c 
methadone-c methamphetamine-c methanol-c methocarbamol-c 
methotrexate-c methylphenidate-c midazolam-c mirtazapine-c 
molidone-c morphine-c naproxen-c nefazodone-c nicotine-c 
nitricacid-c norchlorcyclizine-c nordiazepam-c nordoxepin-c 
norfluoxetine-c normeperidine-c norpropoxyphene-c 
nortriptylene-c olanzapine-c orphenadrine-c oxazepam-c 
oxycodone-c oxymorphone-c pancuroniumbromide-c paraquat-c 
paroxetine-c pentazocine-c pentobarbital-c pentoxifylline-c 
phencyclidine-c phenobarbital-c phentermine-c 
phenyltoloxamine-c phenytoin-c primidone-c promethazine-c 
propane-c propoxyphene-c propranolol-c propyleneglycol-c 
quetiapine-c quinine-c ritalinicacid-c salicylate-c 
salicylicacid-c secobarbital-c sertraline-c temazepam-c 
tetrafluroethane-c tetrahydrocannabinol-c thccarboxylicacid-c 
theophylline-c thiopental-c thioridazine-c toluene-c 
tramadol-c tranylcypromine-c trazodone-c triazolam-c 
tricyclic-c trifluoperazine-c trihexyphenidyl-c 
trimipramine-c valproic-c venlafaxine-c verapamil-c 
zolpidem-c acetaminophenj acetones acetylmorphines 
alprazolams amitriptylines amoxapines amphetamine3 
benzoylecgonines benztropinej brompheniramineg bupropiong 
busipronej butabarbitals butalbitalj caffeine9 
carbamazepinej carbondioxideq carbonmonoxidej 
carisoprodolg chlordiazepoxide_p chlorodifluoromethaneg 
chlorpheniraminej chlorpromazineq citalopramg 
clomipraminej clonzepamg clozapineq cocaethlyeneq 
cocaine2 codeine2 cyanides cyclobenzaprineq 
desalkyflurazepam_p desipramine9 dextromethorphanj 
diazepams difluoroethanes dihydrocodeines diltiazems 
diphenhydraminej doxeping doxylaminej ephedrine2 
ethanolq ethyleneglycols fenfluramine_p fentanylj 
fluoxetines fluvoxamineg gabapentinj 
gammahydroxybutyratej guaifenesins hydrocodonej 
hydromorphoneg hydroxyzineq ibuprofenq imipraminej 
insulin2 isopropanolg ketamines lithiurns lorazepamj 
lysergicaciddiethylamidej mdas mdmaj meclizineq 
meperidines meprobamates metaxaloneq methadones 
methamphetamines methanol9 methocarbamolq methotrexatej 
methylphenidatej midazolamq mirtazapinej molidonej 
morphines naproxens nefazodoneq nicotine2 nitricacidj 
norchlorcyclizineq nordiazepamg nordoxepinj 
norfluoxetinej normeperidineg norpropoxyphenej 
nortriptyleneq olanzapines orphenadrineg oxazepamx 
oxycodones oxymorphone_p pancuroniumbromideq paraquat3 
paroxetineq pentazocineq pentobarbitals pentoxifyllines 
phencyclidine> phenobarbital9 phentermineq 
phenyltoloxamine-p phenytoinq primidonej promethazinej 
propanes propoxyphenes propranololj propyleneglycolq 
quetiapines quinine3 ritalinicacidg salicylatej 
sa1icylicacid-p secobarbitalj sertralinej temazepamj 
tetrafluroethanej tetrahydrocannabinolq thccarboxylicacid~ 
theophyllines thiopentals thioridazines toluenes 
tramado19 tranylcypromines trazodones triazolams 
tricyclics trifluoperazines trihexyphenidyls 
trimipramines valproics venlafaxines verapamilx 
zolpidems acetaminophen-1 acetone-1 acetylmorphine-1 
alprazolam-1 amitriptyline-1 amoxapine-1 amphetamine-1 
benzoylecgonine-1 benztropine-1 brompheniramine-1 
bupropion-1 busiprone-1 butabarbital-1 butalbital-1 
caffeine-1 carbamazepine-1 carbondioxide-1 carbonmonoxide-1 
carisoprodol-1 chlordiazepoxide-1 chlorodifluoromethane-1 
cocaine-1 codeine-1 cyanide-1 cyclobenzaprine-1- 
desalkyflurazepam-1 desipramine-1 dextromethorphan-1 
diazepam-1 difluoroethane-1 dihydrocodeine-1 
diltiazem-1 diphenhydramine-1 doxepin-1 doxylamine-1 
ephedrine-1 ethanol-1 ethyleneglycol-1 fenfluramine-1 
fentanyl-1 fluoxetine-1 fluvoxamine-1 gabapentin-1 
gammahydroxybutyrate-1 guaifenesin-1 hydrocodone-1 
hydromorphone-1 hydroxyzine-1 ibuprofen-1 imipramine-1 
insulin-1 isopropanol-1 ketamine-1 lithium-1 lorazepam-1 
lysergicaciddiethylamide-1 mda-1 mdma-1 meclizine-1 
meperidine-1 meprobamate-1 metaxalone-1 methadone-1 
methamphetamine-1 methanol-1 methocarbamol-1 methotrexate-1 
methylphenidate-1 midazolam-1 mirtazapine-1 molidone-1 
morphine-1 naproxen-1 nefazodone-1 nicotine-1 nitricacid-1 
norchlorcyclizine-1 nordiazepam-1 nordoxepin-1 
norfluoxetine-1 normeperidine-1 norpropoxyphene-1 
nortriptylene-1 olanzapine-1 orphenadrine-1 oxazepam-1 
oxycodone-1 oxymorphone-1 pancuroniumbromide-1 paraquat-1 
paroxetine-1 pentazocine-1 pentobarbital-1 pentoxifylline-1 
phencyclidine-1 phenobarbital-1 phentermine-1 
phenyltoloxamine-1 phenytoin-1 primidone-1 promethazine-1 
propane-1 propoxyphene-1 propranolol-1 propyleneglycol-1 
quetiapine-1 quinine-1 ritalinicacid-1 salicylate-1 
salicylicacid-1 secobarbital-1 sertraline-1 temazepam-1 
tetrafluroethane-1 tetrahydrocannabinol-1 thccarboxylicacid-1 
theophylline-1 thiopental-1 thioridazine-1 toluene-1 
tramadol-1 tranylcypromine-1 trazodone-1 triazolam-1 
tricyclic-1 trifluoperazine-1 trihexyphenidyl-1 
trimipramine-1 valproic-1 venlafaxine-1 verapamil-1 
zolpidem-1 number-of-drugs; 
drop acetaminophen-n acetone-n a.cetylmorphine-n alprazolam-n 
amitriptyline-n amoxapine-n amphetamine-n benzoylecgonine-n 
benztropine-n brompheniramine-n bupropion-n busiprone-n 
butabarbital-n butalbital-n caffeine-n carbamazepine-n 
carbondioxide-n carbonmonoxide-n carisoprodol-n 
chlordiazepoxide-n chlorodifluorornethane~n chlorpheniramine-n 
chlorpromazine-n citalopram-n clomipramine-n clonzepam-n 
clozapine-n cocaethlyene-n cocaine-n codeine-n cyanide-n 
cyclobenzaprine-n desalkyflurazepam-n desipramine-n 
dextromethorphan-n diazepam-n difluoroethane-n 
dihydrocodeine-n diltiazem-n diphenhydramine-n doxepin-n 
doxylamine-n ephedrine-n ethanol-n ethyleneglycol-n 
fenfluramine-n fentanyl-n fluoxetine-n fluvoxamine-n 
gabapentin-n gammahydroxybutyrate-n guaifenesin-n 
hydrocodone-n hydromorphone-n hydroxyzine-n ibuprofen-n 
imipramine-n insulin-n isopropanol-n ketamine-n lithium-n 
lorazepam-n lysergicaciddiethylamide-n mda-n mdma-n 
meclizine-n meperidine-n meprobamate-n metaxalone-n 
methadone-n methamphetamine-n methanol-n methocarbamol-n 
methotrexate-n methylphenidate-n midazolam-n mirtazapine-n 
molidone-n morphine-n naproxen-n nefazodone-n nicotine-n 
nitricacid-n norchlorcyclizine-n nordiazepam-n nordoxepin-n 
norfluoxetine-n normeperidine-n norpropoxyphene-n 
nortriptylene-n olanzapine-n orphenadrine-n oxazepam-n 
oxycodone-n oxymorphone-n pancuroniumbromide-n paraquat-n 
paroxetine-n pentazocine-n pentobarbital-n pentoxifylline-n 
phencyclidine-n phenobarbital-n phentermine-n 
phenyltoloxamine-n phenytoin-n primidone-n promethazine-n 
propane-n propoxyphene-n propranolol-n propyleneglycol-n 
quetiapine-n quinine-n ritalinicacid-n salicylate-n 
salicylicacid-n secobarbital-n sertraline-n ternazepam-n 
tetrafluroethane-n tetrahydrocannabinol-n thccarboxylicacid-n 
theophylline-n thiopental-n thioridazine-n toluene-n 
tramadol-n tranylcypromine-n trazodone-n triazolam-n 
tricyclic-n trifluoperazine-n trihexyphenidyl-n 
trimipramine-n valproic-n venlafaxine-n verapamil-n 
zolpidem-n i; 
run ; 
data thesis.mefinal1; 
set thesis.mefina1; 
if upcase(tox-) ne IN'; 
run ; 
proc freq data=thesis.mefinall; 
tables fatalnew; 
run ; 
/*Checking a drug to see if the above code workedx/ 
proc print data=thesis.mefinall; 
var case-number doxepin doxepin-c doxepin-1 doxepins; 
run ; 
*DUI DATASETS; 
PROC IMPORT OUT= thesis.DUIDrug1 
DATAFILE= "E:\Thesis Files\DUIoriginalDrug.jrnp" 
DBMS=JMP REPLACE; 
RUN: 
PROC IMPORT OUT= thesis.DUIDescrip1 
DATAFILE= "E:\Thesis Files\DUIoriginal~escrip.jmp" 
DBMS=JMP REPLACE; 
RUN; 
/*Looking for duplicates in descriptive information - 
keeping the most recent observation*/ 
data thesis.DUIDescrip2; 
set thesis.DUIDescrip1; 
by fslabnum; 
*last = 1ast.fslabnum; 
if 1ast.fslabnum then output; 
run ; 
/*Sort in order to merge two datasets*/ 
proc sort data=thesis.DUIDrugl; 
by FSLabNum; 
run ; 
proc sort data=thesi~.DUIDescrip2; 
by FSLabNum datesubmitted; 
run ; 
/*Merge the descriptive and the drug sets into one*/ 
data thesis.DUI1; 
merge thesis.DUIDescrip2 thesis.DUIDrug1; 
by FSLabNum; 
run ; 
/*Calculating age, using current date as the last possible 
date if no other date is available to calculate age*/ 
data thesis.DUIclean1; 
set thesis.DUI1; 
attrib currentdate format=MMDDYYlO.; 
currentdate = 01/01/2005; 
if dateofbirth ne . & datesubmitted ne . then 
age-all = yrdif(dateofbirth, datesubmitted, 'ACT/ACT1); 
else if dateofbirth ne . & date-case-completed ne . then 
age-all = yrdif(dateofbirth, date-case-completed, 
'ACT/ACT1); 
else if dateofbirth ne . then age-all = yrdif(dateofbirth, 
currentdate, 'ACT/ACT1); 
else age-all = .; 
age = floor(age-all); 
drop age-all dateofbirth datesubmitted submissionnum 
date-case-completed; 
run ; 
data thesis.DUIclea1-12; 
set thesis.DUIclean1; 
*Fixing drug names to simplify; 
if drug = '1,l-difluoroethane' then drug = 'Difluoroethane'; 
if drug = '6-Acetyl Morphine' then drug = 'AcetylMorphinel; 
if drug = 'Blood Alcohol' then drug = 'Ethanol'; 
if drug = 'Gamma-Hydroxybutyrate/Lactonel then drug = 
'Gamma-Hydroxybutyrate' ;
if drug = 'N-Desalkyl Flurazepam' then drug = 
'Desalkyflurazepam'; 
run ; 
data thesis.DUIclean4; 
set thesis.DUIclean2; 
*Create new database variable; 
database = 'dui'; 
if database = 'dui' then bac = 'BLOOD'; 
*Format variables to match other dataset; 
drug = upcase(drug); 
attrib case-number format=$lO.; 
case-number = fslabnum; 
*Create units of measurement - all in blood; 
if drug = 'ETHANOL' then unit = 'Grams%'; 
else unit = 'mg/Lg; 
*Set illegal ages to missing; 
if age < 14 then age = .; 
drop fslabnurn; 
run ; 
proc f req data=thesis.DUIclean4; 
tables presence; 
run ; 
data thesis.DUIclean5; 
set thesis.DUIclean4; 
*Edit the concentrations to reflect a more accurate amount 
based on the presence variable; 
if presence = 'less than' ( presence = 'present less than' then 
amount = amount*.5; 
else if presence = 'greater than' then amount = amount*1.15; 
else if presence = 'present' I presence = 'quantitated' I 
presence = 'not detected' I presence = ' ' then 
amount=amount; 
else amount = .; 
run ; 
proc sort data=thesis.DUIclean5; 
by case-number drug descending bac; 
run ; 
data thesis.DUIfina1; 
set thesis.DUIclean5; 
by case-number drug descending bac; 
array names 11391 $100. acetaminophen-n acetone-n acetylmorphine-n 
alprazolam-n amitriptyline-n amoxapine-n amphetamine-n 
benzoylecgonine-n benztropine-n brompheniramine-n bupropion-n 
busiprone-n butabarbital-n butalbital-n caffeine-n 
carbamazepine-n carbondioxide-n carbonmonoxide-n 
carisoprodol-n chlordiazepoxide-n chlorodifluoromethane-n 
chlorpheniramine-n chlorpromazine-n citalopram-n 
clomipramine-n clonzepam-n clozapine-n cocaethlyene-n 
cocaine-n codeine-n cyanide-n cyclobenzaprine-n 
desalkyflurazepam-n desipramine-n dextromethorphan-n 
diazepam-n difluoroethane-n dihydrocodeine-n diltiazem-n 
diphenhydramine-n doxepin-n doxylamine-n ephedrine-n 
ethanol-n ethyleneglycol-n fenfluramine-n fentanyl-n 
fluoxetine-n fluvoxamine-n gabapentin-n 
gammahydroxybutyrate-n guaifenesin-n hydrocodone-n 
hydromorphone-n hydroxyzine-n ibuprofen-n imipramine-n 
insulin-n isopropanol-n ketamine-n lithium-n lorazepam-n 
lysergicaciddiethylamide-n mda-n mdma-n meclizine-n 
meperidine-n meprobamate-n metaxalone-n methadone-n 
methamphetamine-n methanol-n methoca.rbamo1-n methotrexate-n 
methylphenidate-n midazolam-n mirtazapine-n molidone-n 
morphine-n naproxen-n nefazodone-n nicotine-n nitricacid-n 
norchlorcyclizine~n nordiazepam-n nordoxepin-n 
norfluoxetine-n normeperidine-n norpropoxyphene-n 
nortriptylene-n olanzapine-n orphenadrine-n oxazepam-n 
oxycodone-n oxymorphone-n pancuroniumbromide-n paraquat-n 
paroxetine-n pentazocine-n pentobarbital-n pentoxifylline-n 
phencyclidine-n phenobarbital-n phentermine-n 
phenyltoloxamine-n phenytoin-n primidone-n promethazine-n 
propane-n propoxyphene-n propranolol-n propyleneglycol-n 
quetiapine-n quinine-n ritalinicacid-n salicylate-n 
salicylicacid-n secobarbital-n sertraline-n temazepam-n 
tetrafluroethane-n tetrahydrocannabinol-n thccarboxylicacid-n 
theophylline-n thiopental-n thioridazine-n toluene-n 
tramadol-n tranylcypromine-n trazodone-n triazolam-n 
tricyclic-n trifluoperazine-n trihexyphenidyl-n 
trimipramine-n valproic-n venlafaxine-n verapamil-n 
zolpidem-n ('acetaminophen', 'acetone', 'acetylmorphine', 
'alprazolam', 'amitriptyline', 'amoxapine', 'amphetamine', 
'benzoylecgonine', 'benztropine', 'brompheniramine', 
'bupropion' , 'busiprone' , 'butabarbital', 'butalbital', 
'caffeine', 'carbamazepine', 'carbon dioxide', 'carbon 
monoxide', 'carisoprodol', 'chlordiazepoxide', 
'chlorodifluoromethane', 'chlorpheniramine', 
'chlorpromazine', 'citalopram', 'clomipramine', 'clonzepam', 
'clozapine', 'cocaethlyene', 'cocaine', 'codeine', 'cyanide', 
'cyclobenzaprine', 'desalkyflurazepam', 'desipramine', 
'dextromethorphan', 'diazepam', 'difluoroethane', 
'dihydrocodeine', 'diltiazem', 'diphenhydramine', 'doxepin', 
'doxylamine', 'ephedrine', 'ethanol', 'ethyleneglycol', 
'fenfluramine', 'fentanyl', 'fluoxetine', 'fluvoxamine', 
'gabapentin' , 'gamrnahydroxybutyrate', 'guaifenesin', 
'hydrocodone', 'hydromorphone', 'hydroxyzine', 'ibuprofen', 
'imipramine', 'insulin', 'isopropanol', 'ketamine', 
'lithium', 'lorazepam', 'lysergicaciddiethylamide', 'mda', 
'mdma', 'meclizine', 'meperidine', 'meprobamate', 
'metaxalone', 'methadone', 'methamphetamine', 'methanol', 
'methocarbamol', 'methotrexate', 'methylphenidate', 
'midazolam', 'mirtazapine', 'molidone', 'morphine', 
'naproxen', 'nefazodone', 'nicotine', 'nitricacid', 
'norchlorcyclizine', 'nordiazepam', 'nordoxepin', 
'norfluoxetine', 'normeperidine', 'norpropoxyphene', 
'nortriptylene', 'olanzapine', 'orphenadrine', 'oxazepam', 
'oxycodone', 'oxymorphone', 'pancuroniumbromide', 
'paraquat', 'paroxetine', 'pentazocine', 'pentobarbital', 
'pentoxifylline', 'phencyclidine', 'phenobarbital', 
'phentermine', 'phenyltoloxamine', 'phenytoin' ,
'primidone', 'promethazine', 'propane', 'propoxyphene', 
'propranololl, 'propyleneglycol', 'quetiapine', 'quinine', 
'ritalinicacid', 'salicylate', 'salicylicacid' ,
'secobarbital', 'sertraline', 'temazepam', 
'tetrafluroethane', 'tetrahydrocannabinol', 
'thccarboxylicacid', 'theophylline', 'thiopental', 
'thioridazine', 'toluene', 'tramadol', 'tranylcypromine', 
'trazodone', 'triazolam', 'tricyclic', 'trifluoperazine', 
'trihexyphenidyl', 'trimipramine', 'valproic', 'venlafaxine', 
'verapamil', 'zolpidem'); 
array drugs {I391 acetaminophen acetone acetylmorphine alprazolam 
amitriptyline amoxapine amphetamine benzoylecgonine 
benztropine brompheniramine bupropion busiprone butabarbital 
butalbital caffeine carbamazepine carbondioxide 
carbonmonoxide carisoprodol chlordiazepoxide 
chlorodifluoromethane chlorpheniramine chlorpromazine 
citalopram clomipramine clonzepam clozapine cocaethlyene 
cocaine codeine cyanide cyclobenzaprine desalkyflurazepam 
desipramine dextromethorphan diazepam difluoroethane 
dihydrocodeine diltiazem diphenhydramine doxepin doxylamine 
ephedrine ethanol ethyleneglycol fenfluramine fentanyl 
fluoxetine fluvoxamine gabapentin gammahydroxybutyrate 
guaifenesin hydrocodone hydromorphone hydroxyzine ibuprofen 
imipramine insulin isopropanol ketamine lithium lorazepam 
lysergicaciddiethylamide mda mdma meclizine meperidine 
meprobamate metaxalone methadone methamphetamine methanol 
methocarbamol methotrexate methylphenidate midazolam 
mirtazapine molidone morphine naproxen nefazodone nicotine 
nitricacid norchlorcyclizine nordiazepam nordoxepin 
norfluoxetine normeperidine norpropoxyphene nortriptylene 
olanzapine orphenadrine oxazepam oxycodone oxymorphone 
pancuroniumbromide paraquat paroxetine pentazocine 
pentobarbital pentoxifylline phencyclidine phenobarbital 
phentermine phenyltoloxamine phenytoin primidone promethazine 
propane propoxyphene propranolol propyleneglycol quetiapine 
quinine ritalinicacid salicylate salicylicacid secobarbital 
sertraline temazepam tetrafluroethane tetrahydrocannabinol 
thccarboxylicacid theophylline thiopental thioridazine 
toluene tramadol tranylcypromine trazodone triazolam 
tricyclic trifluoperazine trihexyphenidyl trimipramine 
valproic venlafaxine verapamil zolpidem; 
array amounts (1391 acetaminophen-c acetone-c acetylmorphine-c 
alprazolam-c amitriptyline-c amoxapine-c amphetamine-c 
benzoylecgonine-c benztropine-c brompheniramine-c bupropion-c 
busiprone-c butabarbital-c butalbital-c caffeine-c 
carbamazepine-c carbondioxide-c carbonmonoxide-c 
carisoprodol-c chlordiazepoxide-c chlorodifluoromethane-c 
chlorpheniramine-c chlorpromazine-c citalopram-c 
clomipramine-c clonzepam-c clozapine-c cocaethlyene-c 
cocaine-c codeine-c cyanide-c cyclobenzaprine-c 
desalkyflurazepam-c desipramine-c dextromethorphan-c 
diazepam-c difluoroethane-c dihydrocodeine-c diltiazem-c 
diphenhydramine-c doxepin-c doxylamine-c ephedrine-c 
ethanol-c ethyleneglycol-c fenfluramine-c fentanyl-c 
fluoxetine-c fluvoxamine-c gabapentin-c 
gammahydroxybutyrate-c guaifenesin-c hydrocodone-c 
hydromorphone-c hydroxyzine-c ibuprofen-c imipramine-c 
insulin-c isopropanol-c ketamine-c lithium-c lorazepam-c 
lysergicaciddiethylamide-c mda-c mdrna-c meclizine-c 
meperidine-c meprobamate-c metaxalone-c methadone-c 
methamphetamine-c methanol-c methocarbamol-c methotrexate-c 
methylphenidate-c midazolam-c mirtazapine-c molidone-c 
morphine-c naproxen-c nefazodone-c nicotine-c nitricacid-c 
norchlorcyclizine-c nordiazepam-c nordoxepin-c 
norfluoxetine-c normeperidine-c norpropoxyphene-c 
nortriptylene-c olanzapine-c orphenadrine-c oxazepam-c 
oxycodone-c oxymorphone-c pancuroniurnbromide-c paraquat-c 
paroxetine-c pentazocine-c pentobarbital-c pentoxifylline-c 
phencyclidine-c phenobarbital-c phentermine-c 
phenyltoloxamine-c phenytoin-c primidone-c promethazine-c 
propane-c propoxyphene-c propranolol-c propyleneglycol-c 
quetiapine-c quinine-c ritalinicacid-c salicylate-c 
salicylicacid-c secobarbital-c sertraline-c temazepam-c 
tetrafluroethane-c tetrahydrocannabinol-c thccarboxylicacid-c 
theophylline-c thiopental-c thioridazine-c toluene-c 
tramadol-c tranylcypromine-c trazodone-c triazolam-c 
tricyclic-c trifluoperazine-c trihexyphenidyl-c 
trimipramine-c valproic-c venlafaxine-c verapamil-c 
zolpidem-c; 
array levels {I391 $14. acetaminophen-1 acetone-1 acetylmorphine-1 
alprazolam-1 amitriptyline-1 amoxapine-1 amphetamine-1 
benzoylecgonine-1 benztropine-1 brompheniramine-1 bupropion-1 
busiprone-1 butabarbital-1 butalbital-1 caffeine-1 
carbamazepine-1 carbondioxide-1 carbonmonoxide-1 
carisoprodol-1 chlordiazepoxide-1 chlorodifluoromethane-1 
chlorpheniramine-1 chlorpromazine-1 citalopram-1 
clomipramine-1 clonzepam-1 clozapine-1 cocaethlyene-1 
a r r a y  p ress  {139} $31. acetaminophenq a c e t o n e s  acetylmorphineq 
a lp razo lamq a m i t r i p t y l i n e q  amoxapineq amphetamines 
benzoylecgonineq b e n z t r o p i n e j  brompheniramineq bupropionq 
b u s i p r o n e x  b u t a b a r b i t a l s  b u t a l b i t a l j  c a f f e i n e 3  
carbamazepineg carbondioxideq carbonmonoxide_p 
car isoprodol-p  chlordiazepoxideq c h l o r o d i f l u o r o m e t h a n e ~  
chlorpheniramine-p chlorpromazineq c i t a l o p r a m q  
c l o m i p r a m i n e ~  clonzepams c l o z a p i n e q  cocae th lyene3  
c o c a i n e 3  c o d e i n e 3  c y a n i d e q  cyc lobenzapr ines  
desalkyflurazepamq d e s i p r a m i n e j  dextromethorphang 
diazepam3 d i f l u o r o e t h a n e q  dihydrocodeineq d i l t i a z e m q  
diphenhydramineq doxep inq  doxylamineq ephedr ineq  
e t h a n o l 3  e thy leneg lyco lq  f e n f l u r a m i n e j  f e n t a n y l q  
f l u o x e t i n e j  f luvoxamines gabapen t inq  
gammahydroxybutyrateq g u a i f e n e s i n q  hydrocodone-p 
hydromorphones hydroxyzineq i b u p r o f e n j  i m i p r a m i n e ~  
i n s u l i n q  i s o p r o p a n o l j  k e t a m i n e s  l i t h i u m q  lorazepamq 
lysergicaciddiethylamideq mdaq mdmaq m e c l i z i n e q  
m e p e r i d i n e s  meprobamateq metaxalone3 methadones 
methamphetamineq methanolq  methocarbamolq m e t h o t r e x a t e j  
methylphenidateq midazolamq m i r t a z a p i n e s  molidoneq 
morphine3 naproxenx nefazodone-p n i c o t i n e 2  n i t r i c a c i d j  
norchlorcyclizine_p nordiazepams nordoxepinj 
norfluoxetines normeperidinej norpropoxyphenej 
nortriptylenes olanzapinej orphenadrines oxazepamj 
oxycodones oxymorphonej pancuroniumbromide_p paraquat2 
paroxetinej pentazocines pentobarbitalq pentoxifyllineq 
phencyclidineq phenobarbital3 phenterminej 
phenyltoloxamine-p phenytoinj primidones promethazinej 
propanes propoxyphenes propranololj propyleneglycolj 
quetiapinej quinines ritalinicacidj salicylatej 
salicylicacid-p secobarbitalj sertralinej temazepamj 
tetrafluroethanej tetrahydrocannabinols thccarboxylicacidj 
theophyllines thiopentalj thioridazines toluenes 
tramado12 tranylcyprominej trazodonej triazolams 
tricyclics trifluoperazinej trihexyphenidylj 
trimipramines valproicj venlafaxines verapamilj 
zolpidemj; 
if first.case-number then do; 
do i = 1 to 139 by 1; 
drugsri} = .; 
amounts{i} = .; 
levels.Ii} = " ; 
press{i} = "; 
number-of-drugs = 0; 
end ; 
end ; 
do i =1 to 139 by 1; 
if drug=upcase(names{i}) then do; 
drugs{i}=l; 
amounts{i}=amount; 
levels{i} = unit; 
pressIi} = presence; 
if amounts{i} ne 0 & pressCi) ne 'not detected' 
then number-of-drugs = number-of-drugs+l; 
end ; 
end ; 
if 1ast.case-number then output; 
retain case-number acetaminophen acetone acetylmorphine 
alprazolam amitriptyline amoxapine amphetamine 
benzoylecgonine benztropine brompheniramine bupropion 
busiprone butabarbital butalbital caffeine carbamazepine 
carbondioxide carbonmonoxide carisoprodol chlordiazepoxide 
chlorodifluoromethane chlorpheniramine chlorpromazine 
citalopram clomipramine clonzepam clozapine cocaethlyene 
cocaine codeine cyanide cyclobenzaprine desalkyflurazepam 
desipramine dextromethorphan diazepam difluoroethane 
dihydrocodeine diltiazem diphenhydramine doxepin doxylamine 
ephedrine ethanol ethyleneglycol fenfluramine fentanyl 
fluoxetine fluvoxamine gabapentin gammahydroxybutyrate 
guaifenesin hydrocodone hydromorphone hydroxyzine ibuprofen 
imipramine insulin isopropanol ketamine lithium lorazepam 
lysergicaciddiethylamide mda mdma meclizine meperidine 
meprobamate metaxalone methadone methamphetamine methanol 
methocarbamol methotrexate methylphenidate midazolam 
mirtazapine molidone morphine naproxen nefazodone nicotine 
nitricacid norchlorcyclizine nordiazepam nordoxepin 
norfluoxetine normeperidine norpropoxyphene nortriptylene 
olanzapine orphenadrine oxazepam oxycodone oxymorphone 
pancuroniumbromide paraquat paroxetine pentazocine 
pentobarbital pentoxifylline phencyclidine phenobarbital 
phentermine phenyltoloxamine phenytoin primidone promethazine 
propane propoxyphene propranolol propyleneglycol quetiapine 
quinine ritalinicacid salicylate salicylicacid secobarbital 
sertraline temazepam tetrafluroethane tetrahydrocannabinol 
thccarboxylicacid theophylline thiopental thioridazine 
toluene tramadol tranylcypromine trazodone triazolam 
tricyclic trifluoperazine trihexyphenidyl trimipramine 
valproic venlafaxine verapamil zolpidem acetaminophen-c 
acetone-c acetylmorphine-c alprazolam-c amitriptyline-c 
amoxapine-c amphetamine-c benzoylecgonine-c benztropine-c 
brompheniramine-c bupropion-c busiprone-c butabarbital-c 
butalbital-c caffeine-c carbamazepine-c carbondioxide-c 
carbonmonoxide-c carisoprodol-c chlordiazepoxide-c 
chlorodifluoromethane~c chlorpheniramine-c chlorpromazine-c 
citalopram-c clomipramine-c clonzepam-c clozapine-c 
cocaethlyene-c cocaine-c codeine-c cyanide-c 
cyclobenzaprine-c desalkyflurazepam-c desipramine-c 
dextromethorphan-c diazepam-c difluoroethane-c 
dihydrocodeine-c diltiazem-c diphenhydramine-c doxepin-c 
doxylamine-c ephedrine-c ethanol-c ethyleneglycol-c 
fenfluramine-c fentanyl-c fluoxetine-c fluvoxamine-c 
gabapentin-c gammahydroxybutyrate-c guaifenesin-c 
hydrocodone-c hydromorphone-c hydroxyzine-c ibuprofen-c 
imipramine-c insulin-c isopropanol-c ketamine-c lithium-c 
lorazepam-c lysergicaciddiethylamide-c mda-c mdma-c 
meclizine-c meperidine-c meprobamate-c metaxalone-c 
methadone-c methamphetamine-c methanol-c methocarbamol-c 
methotrexate-c methylphenidate-c midazolam-c mirtazapine-c 
molidone-c morphine-c naproxen-c nefazodone-c nicotine-c 
nitricacid-c norchlorcyclizine-c nordiazepam-c nordoxepin-c 
norfluoxetine-c normeperidine-c norpropoxyphene-c 
nortriptylene-c olanzapine-c orphenadrine-c oxazepam-c 
oxycodone-c oxymorphone-c pancuroniumbromide-c paraquat-c 
paroxetine-c pentazocine-c pentobarbital-c pentoxifylline-c 
phencyclidine-c phenobarbital-c phentermine-c 
phenyltoloxamine-c phenytoin-c primidone-c promethazine-c 
propane-c propoxyphene-c propranolol-c propyleneglycol-c 
quetiapine-c quinine-c ritalinicacid-c salicylate-c 
salicylicacid-c secobarbital-c sertraline-c temazepam-c 
tetrafluroethane-c tetrahydrocannabinol-c thccarboxylicacid-c 
theophylline-c thiopental-c thioridazine-c toluene-c 
tramadol-c tranylcypromine-c trazodone-c triazolam-c 
t r icycl ic-c  t r i f luoperazine-c trihexyphenidyl-c 
trimipramine-c valproic-c venlafaxine-c verapamil-c 
zolpidem-c acetaminophenq a c e t o n e s  acetylmorphineq 
a l p r a z o l a m s  a m i t r i p t y l i n e s  amoxapinej  amphetamines 
benzoylecgoninej  b e n z t r o p i n e j  brompheniraminej bupropionq 
b u s i p r o n e g  b u t a b a r b i t a l j  b u t a l b i t a l s  c a f f e i n e j  
carbamazepineq c a r b o n d i o x i d e j  carbonmonoxides 
c a r i s o p r o d o l q  chlordiazepoxide-p c h l o r o d i f l u o r o m e t h a n e ~  
chlorpheniramineq chlorpromazines  c i t a l o p r a m s  
clomipramine-p c lonzepamj  clozapine-p c o c a e t h l y e n e s  
c o c a i n e j  c o d e i n e 3  c y a n i d e s  cyclobenzapr ineg 
desa lkyf lurazepams des ip ramine3  dextromethorphan_p 
diazepams d i f l u o r o e t h a n e q  dihydrocodeineg d i l t i a z e m s  
diphenhydramines d o x e p i n s  doxylamines e p h e d r i n e 3  
e t h a n o l 9  e t h y l e n e g l y c o l s  f en f lu ramineq  f e n t a n y l j  
f l u o x e t i n e q  fluvoxamineq g a b a p e n t i n s  
gammahydroxybutyratej g u a i f e n e s i n s  hydrocodones 
hydromorphonej hydroxyzines  i b u p r o f e n 3  i m i p r a m i n e j  
i n s u l i n g  i s o p r o p a n o l j  k e t a m i n e j  l i t h i u m 3  l o r a z e p a m j  
lysergicaciddiethylamidej mdaq mdmas m e c l i z i n e s  
meper id ineq meprobamatej metaxalone* methadones 
methamphetamine3 methanol2  methocarbamolq metho t rexa teq  
methylphenidates  midazolamq m i r t a z a p i n e s  mol idones  
morphine2 n a p r o x e n j  nefazodoneq n i c o t i n e 9  n i t r i c a c i d g  
n o r c h l o r c y c l i z i n e q  nordiazepams n o r d o x e p i n j  
n o r f l u o x e t i n e q  normeper id ines  norpropoxyphenes 
n o r t r i p t y l e n e q  o l a n z a p i n e j  o r p h e n a d r i n e j  oxazepams 
oxycodonej  oxymorphones pancuroniumbromide_p p a r a q u a t 2  
p a r o x e t i n e s  p e n t a z o c i n e j  p e n t o b a r b i t a l s  p e n t o x i f y l l i n e g  
phencyc l id ineq  p h e n o b a r b i t a l 3  phentermineq 
phenyl to loxaminej  p h e n y t o i n s  p r imidones  promethazineq 
p r o p a n e s  propoxyphenej  p r o p r a n o l o l j  p r o p y l e n e g l y c o l j  
q u e t i a p i n e s  q u i n i n e s  r i t a l i n i c a c i d j  s a l i c y l a t e g  
s a l i c y l i c a c i d j  s e c o b a r b i t a l q  s e r t r a l i n e q  temazepamq 
t e t r a f l u r o e t h a n e s  te t rahydrocannabinol2  thcca rboxy l i cac idq  
t h e o p h y l l i n e q  t h i o p e n t a l s  t h i o r i d a z i n e s  toluene* 
t r amadolq  t ranylcypromines  t r a z o d o n e s  t r i a z o l a m s  
t r i c y c l i c ~  t r i f l u o p e r a z i n e q  t r i h e x y p h e n i d y l j  
t r i m i p r a m i n e j  v a l p r o i c q  v e n l a f a x i n e s  v e r a p a m i l s  
zo lp idems  acetaminophen-1 acetone-1 acetylmorphine-1 
alprazolam-1 amitr iptyl ine-1 amoxapine-1 amphetamine-1 
benzoylecgonine-1 benztropine-1 brompheniramine-1 bupropion-1 
busiprone-1 butabarbital-1 buta lb i ta l -1  caffeine-1 
carbamazepine-1 carbondioxide-1 carbonmonoxide-1 
carisoprodol-1 chlordiazepoxide-1 chlorodifluoromethane-1 
chlorpheniramine-1 chlorpromazine-1 citalopram-1 
clomipramine-1 clonzepam-1 clozapine-1 cocaethlyene-1 
cocaine-1 codeine-1 cyanide-1 cyclobenzaprine-1 
desalkyflurazepam-1 desipramine-1 dextromethorphan-1 
diazepam-1 difluoroethane-1 dihydrocodeine-1 diltiazem-1 
diphenhydramine-1 doxepin-1 doxylamine-1 ephedrine-1 
ethanol-1 ethyleneglycol-1 fenfluramine-1 fentanyl-1 
fluoxetine-1 fluvoxamine-1 gabapentin-1 
garnmahydroxybutyrate-1 guaifenesin-1 hydrocodone-1 
hydromorphone-1 hydroxyzine-1 ibuprofen-1 imipramine-1 
insulin-1 isopropanol-1 ketamine-1 lithim1 lorazepam-1 
lysergicaciddiethylamide-1 mda-1 mdma-1 meclizine-1 
meperidine-1 meprobamate-1 metaxalone-1 methadone-1 
methamphetamine-1 methanol-1 methocarbamol-1 methotrexate-1 
methylphenidate-1 midazolam-1 mirtazapine-1 molidone-1 
morphine-1 naproxen-1 nefazodone-1 nicotine-1 nitricacid-1 
norchlorcyclizine-1 nordiazepam-1 nordoxepin-1 
norfluoxetine-1 normeperidine-1 norpropoxyphene-1 
nortriptylene-1 olanzapine-1 orphenadrine-1 oxazepam-1 
oxycodone-1 oxymorphone-1 pancuroniumbromide-1 paraquat-1 
paroxetine-1 pentazocine-1 pentobarbital-1 pentoxifylline-1 
phencyclidine-1 phenobarbital-1 phentermine-1 
phenyltoloxamine-1 phenytoin-1 primidone-1 promethazine-1 
propane-1 propoxyphene-1 propranolol-1 propyleneglycol-1 
petiapine-1 quinine-1 ritalinicacid-1 salicylate-1 
salicylicacid-1 secobarbital-1 sertraline-1 temazepam-1 
tetrafluroethane-1 tetrahydrocannabinol-1 thccarboxylicacid-1 
theophylline-1 thiopental-1 thioridazine-1 toluene-1 
tramadol-1 tranylcypromine-1 trazodone-1 triazolam-1 
tricyclic-1 trifluoperazine-1 trihexyphenidyl-1 
trimipramine-1 valproic-1 venlafaxine-1 verapamil-1 
zolpidem-1 number-of-drugs; 
drop acetaminophen-n acetone-n acetylmorphine-n alprazolam-n 
amitriptyline-n amoxapine-n amphetamine-n benzoylecgonine-n 
benztropine-n brompheniramine-n bupropion-n busiprone-n 
butabarbital-n butalbital-n caffeine-n carbamazepine-n 
carbondioxide-n carbonmonoxide-n carisoprodol-n 
chlordiazepoxide-n chlorodifluoromethane-n chlorphenirarnine-n 
chlorpromazine-n citalopram-n clomipramine-n clonzepam-n 
clozapine-n cocaethlyene-n cocaine-n codeine-n cyanide-n 
cyclobenzaprine-n desalkyflurazepam-n desipramine-n 
dextromethorphan-n diazepam-n difluoroethane-n 
dihydrocodeine-n diltiazem-n diphenhydramine-n doxepin-n 
doxylamine-n ephedrine-n ethanol-n ethyleneglycol-n 
fenfluramine-n fentanyl-n fluoxetine-n fluvoxamine-n 
gabapentin-n gammahydroxybutyrate-n guaifenesin-n 
hydrocodone-n hydromorphone-n hydroxyzine-n ibuprofen-n 
imipramine-n insulin-n isopropanol-n ketamine-n lithium-n 
lorazepam-n lysergicaciddiethylamide-n mda-n mdma-n 
meclizine-n meperidine-n meprobamate-n metaxalone-n 
methadone-n methamphetamine-n methanol-n methocarbamol-n 
methotrexate-n methylphenidate-n midazolam-n mirtazapine-n 
molidone-n morphine-n naproxen-n nefazodone-n nicotine-n 
nitricacid-n norchlorcyclizine-n nordiazepam-n nordoxepin-n 
norfluoxetine-n normeperidine-n norpropoxyphene-n 
nortriptylene-n olanzapine-n orphenadrine-n oxazepam-n 
oxycodone-n oxymorphone-n pancuroniumbromide-n paraquat-n 
paroxetine-n pentazocine-n pentobarbital-n pentoxifylline-n 
phencyclidine-n phenobarbital-n phentermine-n 
phenyltoloxamine-n phenytoin-n primidone-n promethazine-n 
propane-n propoxyphene-n propranolol-n propyleneglycol-n 
quetiapine-n quinine-n ritalinicacid-n salicylate-n 
salicylicacid-n secobarbital-n sertraline-n temazepam-n 
tetrafluroethane-n tetrahydrocannabinol-n thccarboxylicacid-n 
theophylline-n thiopental-n thioridazine-n toluene-n 
tramadol-n tranylcypromine-n trazodone-n triazolam-n 
tricyclic-n trifluoperazine-n trihexyphenidyl-n 
trimipramine-n valproic-n venlafaxine-n verapamil-n 
zolpidem-n i; 
run ; 
proc freq data=thesis.DUIfinal; 
tables age; 
run ; 
/*Merge two datasets togetherk/ 
data thesis.combined; 
set thesis.Mefinal1 thesis.DUIfina1; 
indexfatal = find(fatalnew, 'POISONING', 'i'); 
drop tox- presence amount drug-level drug unit; 
run ; 
*Can either be a drug death or in the dui dataset; 
data thesis.final1; 
set thesis.cornbined; 
if indexfatal ne 0 I database = 'dui'; 
drop drug-s- index1 index2 index3; 
run ; 
data thesis.diphenhydramine2; 
set thesis.final1; 
if diphenhydramine = 1 & diphenhydramine-c ne 0 & 
diphenhydramineg ne 'not detected'; 
if (number-of-drugs = 1 & diphenhydramine = 1) then group = 
' single ' ; 
else if number-of-drugs = 2 & (diphenhydramine = 1 & ethanol = 1) 
then group = 'with alcohol'; 
else if number-of-drugs >=2 then group = 'et al'; 
run ; 
data thesis.diphenhydraminedata; 
set thesis.diphenhydramine2; *or diphenhydraminel; 
if bac = 'BLOOD' I bac = 'aBLOOD(P0ST)' I 
bac = 'bBLOOD(PRE) ' ;  
run ; 
data thesis.diphenhydraminefina1; 
set thesis.diphenhydraminedata; 
if case-number ne 'C0133260' & case-number ne 'C0133349' & 
case-number ne 'C0136742' & case-number ne 'NV045033' & 
case-number ne 'NV046032' & case-number ne 'NV046331' & 
case-number ne 'NV046619' & case-number ne 'NV047201' & 
case-number ne 'NV047229' & case-number ne 'NV050545' & 
case-number ne 'NV050657' & case-number ne 'NV050687' & 
case-number ne 'NV051115' & case-number ne 'T0058619' & 
case-number ne 'T0059266' & case-number ne 'T0063020' & 
case-number ne 'W0067678' & case-number ne 'W0067902' & 
case-number ne 'W0068316' & case-number ne 'W0068326'; 
run ; 
data thesis.diphenfina1; 
set thesis.diphenhydraminefina1; 
if group = 'single' then newgroup = 1; 
if group = 'with a' I group = let al' then newgroup = 2; 
logdiphen = log(diphenhydramine-c); 
run ; 
proc glm data=thesis.diphenfinal; 
class newgroup database; 
model logdiphen = newgroup database newgroup*database; 
run ; 
data thesis.cocaine2; 
set thesis.final1; 
if (cocaine = 1 1 benzoylecgonine = 1) & cocaine-c ne 0 & 
cocaine-c ne . & cocaine2 ne 'not detected'; 
if (number-of-drugs = 1 & cocaine = 1) I (number-of-drugs = 2 
& (cocaine = 1 & benzoylecgonine = 1)) then group = 
' single ' ; 
else if (number-of-drugs = 2 & (cocaine = 1 & ethanol = 1)) ) 
(number-of-drugs = 3 & (cocaine = 1 & benzoylecgonine = 1 
& ethanol = 1)) then group = 'with alcohol'; 
else if number-of-drugs >=2 then group = 'et al'; 
run ; 
data thesis.cocainedata; 
set thesis.cocaine2; 
if bac = 'BLOOD' I bac = 'aBLOOD(P0ST) ' I 
bac = 'bBLOOD(PRE) ' ;  
run ; 
data thesis.cocainefina1; 
set thesis.cocainedata; 
if case-number ne 'C0131292' & case-number ne 'C0131309' & 
case-number ne 'C0132494' & case-number ne 'C0133717' & 
case-number ne 'C0133871' & case-number ne 'C0135112' & 
case-number ne 'NV045054' & case-number ne 'NV045197' & 
case-number ne 
case-number ne 
case-number ne 
case-number ne 
case-number ne 
case-number ne 
case-number ne 
case-number ne 
case-number ne 
case-number ne 
case-number ne 
case-number ne 
case-number ne 
case-number ne 
case-number ne 
case-number ne 
case-number ne 
case-number ne 
case-number ne 
case-number ne 
case-number ne 
case-number ne 
case-number ne 
case-number ne 
case-number ne 
case-number ne 
case-number ne 
case-number ne 
case-number ne 
case-number ne 
case-number ne 
case-number ne 
case-number ne 
case-number ne 
case-number ne 
run ; 
'NV045270' & case-number ne 
'NV045619' & case-number ne 
'NV046009' & case-number ne 
'NV046329' & case-number ne 
'NV046632' & case-number ne 
'NV047201' & case-number ne 
'NV047622' & case-number ne 
'NV047878' & case-number ne 
'NV047935' & case-number ne 
'NV048238' & case-number ne 
'NV048292' & case-number ne 
'NV048603' & case-number ne 
'NV048882' & case-number ne 
'NV049148' & case-number ne 
'NV050361' & case-number ne 
'NV0503901 & case-number ne 
'NV050687' & case-number ne 
'NV051034' & case-number ne 
'NV051257' & case-number ne 
'T0063321' & case-number ne 
'W0065652' & case-number ne 
'W0066710' & case-number ne 
'~0067005' & case-number ne 
'W0067044' & case-number ne 
'W0067497' & case-number ne 
'W0067734' & case-number ne 
'W0067820' & case-number ne 
'W0068023' & case-number ne 
'W0068343' & case-number ne 
'W0068443' & case-number ne 
'W0068708' & case-number ne 
'W0068837' & case-number ne 
'W0068937' & case-number ne 
'W0069006' & case-number ne 
'W0069408' ; 
data thesis.cocfina1; 
set thesis.cocainefina1; 
logcocaine = log(cocaine-c); 
run ; 
proc glm data=thesis.cocfinal; 
class group database; 
model logcocaine = group database group*database; 
run ; 
data thesis.oxycodone2; 
set thesis.final1; 
if oxycodone = 1 & oxycodonej ne 'not detected' & 
oxycodone-c ne 0 & oxycodone-c ne .; 
if (number-of-drugs = 1 & oxycodone = 1) then group = 
'single' ; 
else if number-of-drugs = 2 & (oxycodone = 1 & ethanol = 1) 
then group = 'with alcohol'; 
else if number-of-drugs >=2 then group = 'et al'; 
run ; 
data thesis.oxycodonedata; 
set thesis.oxycodone2; 
if bac = 'BLOOD' 1 bac = 'aBLOOD(P0ST) ' I 
bac = 'bBLOOD(PRE) ' ;  
run ; 
data thesis.oxycodonefina1; 
set thesis.oxycodonedata; 
if case-number ne 'T0060024' & case-number ne 'T0060223' & 
case-number ne 'T00639301 & case-number ne 'T0063935' & 
case-number ne 'T00639801 & case-number ne 'T0064036' & 
case-number ne 'T0064217' & case-number ne 'W0063194' & 
case-number ne 'W0063955' & case-number ne 'W0064128' & 
case-number ne 'W0064135' & case-number ne 'W0064844' & 
case-number ne 'W0064884' & case-number ne 'W0064912' & 
case-number ne 'W0064992' & case-number ne 'W0065793' & 
case-number ne 'W0067575' & case-number ne 'W0067766' & 
case-number ne 'W0069583'; 
run ; 
data thesis.oxyfina1; 
set thesis.oxycodonefina1; 
logoxy = log(oxycodone-c); 
run ; 
proc glm data=thesis.oxyfinal; 
class group database; 
model logoxy = group database group*database; 
run ; 
data thesis.hydro2; 
set thesis.final1; 
if hydrocodone = 1 & hydrocodone_p ne 'not detected' & 
hydrocodone-c ne 0 & hydrocodone-c ne .; 
if (number-of-drugs = 1 & hydrocodone = 1) then group = 
' single ' ; 
else if number-of-drugs = 2 & (hydrocodone = 1 & 
ethanol = 1) then group = 'with alcohol'; 
else if number-of-drugs >=2 then group = let all; 
run ; 
data thesis.hydrodata; 
set thesis.hydro2; 
if bac = 'BLOOD' I bac = 'aBLOOD(P0ST) ' I 
bac = 'bBLOOD(PRE)'; 
data thesis.hydrocodonefina1; 
set thesis.hydrodata; 
if case-number ne 'C0134397' & case-number ne 'C0134883' & 
case-number ne "20136093' & case-number ne 'T0059266' & 
case-number ne 'T0061306' & case-number ne 'T0063871' & 
case-number ne 'T0063980' & case-number ne 'T0064217' & 
case-number ne 'W0064613' & case-number ne 'W0064705' & 
case-number ne 'W0065937' & case-number ne 'W0066627' & 
case-number ne 'W0066632' & case-number ne 'W0067364' & 
case-number ne 'W0067426' & case-number ne 'W0067766' & 
case-number ne 'W0067977' & case-number ne 'W0068235' & 
case-number ne 'W0068326' & case-number ne 'W0068348' & 
case-number ne 'W0068382' & case-number ne 'W0068421' & 
case-number ne 'W0068708' & case-number ne 'W0068797' & 
case-number ne 'W0068849' & case-number ne 'W0068999' & 
case-number ne 'W0069082' & case-number ne 'W0069583'; 
run ; 
data thesis.hydrofina1; 
set thesis.hydrocodonefina1; 
if group = 'single' then newgroup = 1; 
if group = 'with a' I group = let all then newgroup = 2; 
else group = .; 
loghydro = log(hydrocodone-c); 
run ; 
proc glm data=thesis.hydrofinal; 
class newgroup database; 
model loghydro = newgroup database newgroup*database; 
run ; 
data thesis.meth2; 
set thesis.final1; 
if methadone = 1 & methadones ne 'not detected' & 
methadone-c ne 0 & methadone-c ne .; 
if (number-of-drugs = 1 & methadone = 1) then group = 'single'; 
else if number-of-drugs = 2 & (methadone = 1 & ethanol = 1) 
then group = 'with alcohol'; 
else if number-of-drugs >=2 then group = 'et al'; 
run ; 
data thesis.methdata; 
set thesis.meth2; 
if bac = 'BLOOD' I bac = 'aBLOOD(P0ST) ' I 
bac = 'bBLOOD(PRE)'; 
run ; 
data thesis.methadonefina1; 
set thesis.methdata; 
if case-number ne 'NV046574' & case-number ne 'T0059478' & 
case-number ne 'T0062596' & case-number ne 'T0063441' & 
case-number ne 'T0063548' & case-number ne 'T0063555' & 
case-number ne 'W0064013' & case-number ne 'W0064530' & 
case-number ne 'W0065458' & case-number ne 'W0065525' & 
case-number ne 'W0065559' & case-number ne 'W0067039' & 
case-number ne 'W0067338' & case-number ne 'W0068276'; 
run ; 
data thesis.methfina1; 
set thesis.methadonefina1; 
logmeth = log(methadone-c); 
run ; 
proc glm data=thesis.methfinal; 
class group database; 
model logmeth = group database group*database; 
run ; 
proc g l m  data=thesis.methfinal; 
class group database; 
model logmeth = group database; 
run ; 
data thesis.morphine2; 
set thesis.final1; 
if morphine = 1 & morphines ne 'not detected' & 
morphine-c ne 0 & morphine-c ne .; 
if number-of-drugs = 1 & morphine = 1 then group = 'single'; 
else if number-of-drugs = 2 & (morphine = 1 & ethanol = 1) 
then group = 'with alcohol'; 
else if number-of-drugs >=2 then group = 'et all; 
run ; 
data thesis.morphinedata; 
set thesis.morphine2; 
if bac = 'BLOOD' I bac = 'aBLOOD(P0ST)' ( 
bac = 'bBLOOD(PRE) ' ;  
run ; 
data thesis.morphinefina1; 
set thesis.morphinedata; 
run ; 
data thesis.morphfina1; 
set thesis.morphinefina1; 
logmorph = log(morphine-c); 
run ; 
proc g l m  data=thesis.morphfinal; 
class group database; 
model logmorph = group database group*database; 
run ; 
proc glm data=thesis.morphfinal; 
class group database; 
model logrnorph = group database; 
run ; 
APPENDIX E 
Table of Variable Fields 
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